header|cdr_h1|h1_bestgerm|h1_germdist|fw_h1|h1f_bestgerm|h1f_germdist|cdr_h2|h2_bestgerm|h2_germdist|fw_h2|h2f_bestgerm|h2f_germdist
>abagovomab_VH|YTFTNYWMQ|IGHV1-2|3|QVKLQESGAELARPGASVKLSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|7|GAIYPGDGNTRYT|IGHV5-51|4|WVKQRPGQGLDWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|4
>abciximab_VH|YTFTNYWMH|IGHV1-2|2|EVQLQQSGTVLARPGASVKMSCEASG|IGHV7-4-1|8|GAIYPGNSDTSYI|IGHV5-51|4|WVKQRPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|3
>abelacimab_VH|FTFSTAAMS|IGHV3-15|2|QVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|1|SGISGSGSSTYYA|IGHV3-23/IGHV3-23D|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>abiprubart_VH|YTFTNYWMH|IGHV1-2|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GYINPSNDYTKYN|IGHV1-3|6|WVRQAPGQRLEWI|IGHV1-3|1
>abituzumab_VH|YTFSSFWMH|IGHV3-74|2|QVQLQQSGGELAKPGASVKVSCKASG|IGHV7-4-1|3|GYINPRSGYTEYN|IGHV1-2|5|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>abrezekimab_VH|FSLTNYHVQ|IGHV1-58|5|QVTLKESGPVLVKPTETLTLTCTVSG|IGHV2-26|0|GVMWSDGDTSFN|IGHV3-53/IGHV3-66|8|WIRQPPGKALEWL|IGHV2-26/IGHV2-5/IGHV2-70|0
>abrilumab_VH|YTLSDLSIH|IGHV1-24|3|QVQLVQSGAEVKKPGASVKVSCKVSG|IGHV1-24|0|GGFDPQDGETIYA|IGHV1-24|1|WVRQAPGKGLEWM|IGHV1-24|0
>acapatamab_VH|FTFSDYYMY|IGHV3-11|1|QVQLVESGGGLVKPGESLRLSCAASG|IGHV3-11|1|AIISDGGYYTYYS|IGHV3-23/IGHV3-23D|7|WVRQAPGKCLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>acapatamab_VH_1|FTFNKYAMN|IGHV3-21/IGHV3-48|3|EVQLVESGGGLVQPGGSLKLSCAASG|IGHV3-73|0|ARIRSKYNNYATYYA|IGHV3-73|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>acasunlimab_VH|STFSTYAMS|IGHV3-23/IGHV3-23D|2|EVQLLEPGGGLVQPGGSLRLSCEASG|IGHV3-23/IGHV3-23D|2|SGFSGSGGFTFYA|IGHV3-23/IGHV3-23D|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>acasunlimab_VH_1|FSLNDYWMS|IGHV3-11|4|EVQLVESGGGLVQPGRSLRLSCTASG|IGHV3-49|0|GYIDVGGSLYYA|IGHV3-53/IGHV3-66|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>acimtamig_VH|YTFTSYYMH|IGHV1-46|0|QVQLVQSGAEVKKPGESLKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|2|GIINPSGGSTSYA|IGHV1-46|0|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>acimtamig_VH_1|YTFTTYTIH|IGHV1-18|3|QVQLQQSGAELARPGASVKMSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|5|GYINPSSGYSKYN|IGHV1-2|6|WVRQRPGHDLEWI|IGHV4-4|3
>acrixolimab_VH|FTFLRYAMH|IGHV3-30/IGHV3-30-3/IGHV3-64|2|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AVISYDGRYKYYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>actoxumab_VH|FSFSNYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|2|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|ALIWYDGSNEDYT|IGHV3-33|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>adalimumab_VH|FTFDDYAMH|IGHV3-9|0|EVQLVESGGGLVQPGRSLRLSCAASG|IGHV3-9|0|SAITWNSGHIDYA|IGHV3-9|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>adebrelimab_VH|YTFTSYWMH|IGHV1-3|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GRIGPNSGFTSYN|IGHV1-2|4|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>adecatumumab_VH|FTFSSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|0|EVQLLESGGGVVQPGRSLRLSCAASG|IGHV3-23/IGHV3-23D|2|AVISYDGSNKYYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>adintrevimab_VH|FTFSSYYMN|IGHV3-21/IGHV3-48|1|EVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|0|SSISEDGYSTYYP|IGHV3-43|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>aducanumab_VH|FAFSSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|1|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AVIWFDGTKKYYT|IGHV3-33|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>afasevikumab_VH|FTFDDYAMH|IGHV3-9|0|EVQLVESGGGLVQPGRSLRLSCAASG|IGHV3-9|0|SGINWSSGGIGYA|IGHV3-9|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>alacizumab_VH|FTFSSYGMS|IGHV3-23/IGHV3-23D|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ATITSGGSYTYYV|IGHV3-NL1|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>alemtuzumab_VH|FTFTDFYMN|IGHV1-69-2|3|QVQLQESGPGLVRPSQTLSLTCTVSG|IGHV4-30-4/IGHV4-31|1|GFIRDKAKGYTTEYN|IGHV3-49|4|WVRQPPGRGLEWI|IGHV4-4|1
>alextatug_VH|FTFSKAWMS|IGHV3-15|1|EVQLVESGGALVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|1|GRIKSVTDGETTDYA|IGHV3-15|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>alirocumab_VH|FTFNNYAMN|IGHV3-21/IGHV3-48|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|STISGSGGTTNYA|IGHV3-23/IGHV3-23D|3|WVRQAPGKGLDWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>alnuctamab_VH|FTFSDNAMG|IGHV3-11|3|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SAISGPGSSTYYA|IGHV3-23/IGHV3-23D|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>alnuctamab_VH_1|FTFSTYAMN|IGHV3-21/IGHV3-48|2|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SRIRSKYNNYATYYA|IGHV3-73|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>alomfilimab_VH|VTFDDYGMS|IGHV3-20|1|EVQLVESGGGVVRPGGSLRLSCVASG|IGHV3-20|1|SGINWNGGDTDYS|IGHV3-20|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>alsevalimab_VH|GSIKSGSYYWG|IGHV4-39|2|QLQLQESGPGLVKPSETLSLTCTVSG|IGHV4-39|0|GNIYYSGSTYYN|IGHV4-28/IGHV4-30-4/IGHV4-31|1|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>amatuximab_VH|YSFTGYTMN|IGHV1-2|3|QVQLQQSGPELEKPGASVKISCKASG|IGHV7-4-1|4|GLITPYNGASSYN|IGHV1-45|6|WVKQSHGKSLEWI|IGHV4-4|4
>amivantamab_VH|FTFSTYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|1|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AVIWDDGSYKYYG|IGHV3-33|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>amivantamab_VH_1|YTFTSYGIS|IGHV1-18|0|QVQLVQSGAEVKKPGASVKVSCETSG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|2|GWISAYNGYTNYA|IGHV1-18|1|WVRQAPGHGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>amlitelimab_VH|FTFSNYAMN|IGHV3-21/IGHV3-48|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|STISGSGGATRYA|IGHV3-23/IGHV3-23D|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>amubarvimab_VH|ITVSSNYMN|IGHV3-53/IGHV3-66|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SLIYSGGSTYYA|IGHV3-53/IGHV3-66|1|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>anbenitamab_VH|FTFTDYTMD|IGHV3-43|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ADVNPNSGGSIYN|IGHV1-2|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>anbenitamab_VH_1|FNIKDTYIH|IGHV1-69-2|6|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ARIYPTNGYTRYA|IGHV1-2|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>andecaliximab_VH|FSLLSYGVH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|4|QVQLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|0|GVIWTGGTTNYN|IGHV4-34|5|WVRQPPGKGLEWL|IGHV4-4|1
>anetumab_VH|YSFTSYWIG|IGHV5-51|0|QVELVQSGAEVKKPGESLKISCKGSG|IGHV5-51|2|GIIDPGDSRTRYS|IGHV5-51|2|WVRQAPGKGLEWM|IGHV1-24|0
>anifrolumab_VH|YIFTNYWIA|IGHV5-10-1|3|EVQLVQSGAEVKKPGESLKISCKGSG|IGHV5-51|0|GIIYPGDSDIRYS|IGHV5-51|1|WVRQMPGKGLESM|IGHV5-10-1/IGHV5-51|1
>anivovetmab_VH|FSLSSYHVH|IGHV3-13|4|QVQLKESGPGLVAPSQTLSLTCTVSG|IGHV4-30-4/IGHV4-31|2|GVMWNDGDTSYN|IGHV4-28/IGHV4-30-4/IGHV4-31|7|WVRQPPGKGLEWL|IGHV4-4|1
>anrukinzumab_VH|FTFISYAMS|IGHV3-23/IGHV3-23D|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ASISSGGNTYYP|IGHV3-53/IGHV3-66|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>anselamimab_VH|FSLSSYGVS|IGHV3-23/IGHV3-23D|4|QVQLKESGPGLVAPSQSLSITCTVSG|IGHV4-30-4/IGHV4-31|4|GVIWGDGSTNYH|IGHV4-34|5|WVRQPPGKGLEWL|IGHV4-4|1
>ansuvimab_VH|FALRMYDMH|IGHV3-13|4|EVQLVESGGGLIQPGGSLRLSCAASG|IGHV3-53|0|SAVGPSGDTTYA|IGHV3-13|5|WVRQTIDKRLEWV|IGHV3-13|4
>anumigilimab_VH|FTFSLYWMG|IGHV3-7|2|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SSISSSGGVTPYA|IGHV3-23/IGHV3-23D|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>anvatabart_VH|FNIKDTYIH|IGHV1-69-2|6|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ARIYPTNGYTRYA|IGHV1-2|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>anzurstobart_VH|YTFRGYGIS|IGHV1-18|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWISAYGGETNYA|IGHV1-18|2|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>apamistamab_VH|FDFSRYWMS|IGHV3-7|2|EVKLLESGGGLVQPGGSLKLSCAASG|IGHV3-23/IGHV3-23D|2|GEINPTSSTINFT|IGHV1-2|7|WVRQAPGKGLEWI|IGHV1-24|1
>apitegromab_VH|FTFSSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|0|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AVISYDGSNKYYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>aprutumab_VH|FTFSSYAMS|IGHV3-23/IGHV3-23D|0|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SAISGSGTSTYYA|IGHV3-23/IGHV3-23D|1|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>arcitumomab_VH|FTFTDYYMN|IGHV1-69-2|2|EVKLVESGGGLVQPGGSLRLSCATSG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|2|GFIGNKANGYTTEYS|IGHV3-49|5|WVRQPPGKALEWL|IGHV2-26/IGHV2-5/IGHV2-70|1
>ascrinvacumab_VH|GSISSGEYYWN|IGHV4-30-4|2|QVQLQESGPGLVKPSQTLSLTCTVSG|IGHV4-30-4/IGHV4-31|0|GYIYYSGSTYYN|IGHV4-28/IGHV4-30-4/IGHV4-31|0|WIRQHPGKGLEWI|IGHV4-31|0
>aselizumab_VH|FTFSTYAMS|IGHV3-23/IGHV3-23D|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ASISTGGSTYYP|IGHV3-13|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>astegolimab_VH|YSFTNYWIG|IGHV5-51|1|EVQLVQSGAEVKKPGESLKISCKGSG|IGHV5-51|0|GIIYPGNSDTRFS|IGHV5-51|2|WVRQMPGKGLEWM|IGHV5-10-1/IGHV5-51|0
>atezolizumab_VH|FTFSDSWIH|IGHV3-73|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AWISPYGGSTYYA|IGHV3-23/IGHV3-23D|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>atibuclimab_VH|YSITSDSAWN|IGHV4-28|5|DVQLQQSGPGLVKPSQSLSLTCTVTG|IGHV4-30-4/IGHV4-31|4|GYISYSGSTSYN|IGHV4-28/IGHV4-30-4/IGHV4-31|2|WIRQFPGNRLEWM|IGHV1-3|3
>atidortoxumab_VH|YSISSGMGWG|IGHV4-38-2|2|EVQLQESGPGLVRPSETLSLTCAVSG|IGHV4-38-2|2|GSIDQRGSTYYN|IGHV4-38-2|3|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>atinumab_VH|FTFSNYWMS|IGHV3-15|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ATIKQDGSQKNYV|IGHV3-7|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>atisnolerbart_VH|YTFISYNIF|IGHV1-18|3|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWMNPFRNNAGYA|IGHV1-8|4|WVRQATGQGLDWM|IGHV1-8|1
>atoltivimab_VH|FTFNNYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|2|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AVIWHDGSDKYYA|IGHV3-33|2|WVRQAPGMGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>avdoralimab_VH|FTFSSYVMH|IGHV3-13|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SAIDTGGGTYYA|IGHV3-13|4|WVRQATGKGLEWV|IGHV3-13|0
>avelumab_VH|FTFSSYIMM|IGHV3-13|2|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SSIYPSGGITFYA|IGHV1-46|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>avizakimab_VH|YTFTDYWMH|IGHV1-69-2|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GTIDPSDQYTIYS|IGHV5-10-1|3|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>axatilimab_VH|FSLTTYGMGVG|IGHV2-5|3|EVTLKESGPALVKPTQTLTLTCTFSG|IGHV2-70|2|ANIWWDDDKYYN|IGHV2-70|3|WIRQPPGKALEWL|IGHV2-26/IGHV2-5/IGHV2-70|0
>azintuxizumab_VH|FTFSDYYMA|IGHV3-11|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ASINYDGSSTYYV|IGHV3-30/IGHV3-30-3/IGHV3-30-5|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>bafisontamab_VH|GSVSSGDYYWT|IGHV4-30-4|2|QVQLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|0|GHIYYSGNTNYN|IGHV4-59/IGHV4-61|2|WIRQSPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|1
>bafisontamab_VH_1|YTFTSYGFS|IGHV1-18|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWISASNGNTYYA|IGHV1-18|2|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>balstilimab_VH|FTFSSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|0|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AVIWYDGSNKYYA|IGHV3-33|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>bamlanivimab_VH|GTFSNYAIS|IGHV1-69/IGHV1-69D|1|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GRIIPILGIANYA|IGHV1-69/IGHV1-69D|3|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>bapineuzumab_VH|FTFSNYGMS|IGHV3-11|2|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|ASIRSGGGRTYYS|IGHV3-64|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>bapotulimab_VH|GTFSSYAIS|IGHV1-69/IGHV1-69D|0|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GGIIPILGIANYA|IGHV1-69/IGHV1-69D|2|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>barecetamab_VH|FTFSDYDMS|IGHV3-11|1|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|STIDLDSGSIYYA|IGHV3-43|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>barzolvolimab_VH|YTFTDYYIN|IGHV1-69-2|2|QVQLVQSGAEVKKPGASVKLSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|ARIYPGSGNTYYN|IGHV1-2|6|WVRQAPGKGLEWI|IGHV1-24|1
>basiliximab_VH|YSFTRYWMH|IGHV1-2|3|QVQLQQSGTVLARPGASVKMSCKASG|IGHV7-4-1|6|GAIYPGNSDTSYN|IGHV5-51|4|WIKQRPGQGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|3
>batoclimab_VH|GSLSSSFSYWV|IGHV4-39|4|QLLLQESGPGLVKPSETLSLTCTVSG|IGHV4-39|1|GTIYYSGNTYYN|IGHV4-28/IGHV4-30-4/IGHV4-31|2|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>bavituximab_VH|YSFTGYNMN|IGHV1-2|3|EVQLQQSGPELEKPGASVKLSCKASG|IGHV7-4-1|5|GHIDPYYGDTSYN|IGHV1-46|6|WVKQSHGKSLEWI|IGHV4-4|4
>bavunalimab_VH|FTFDDAWMS|IGHV3-15|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AEISTKANNHATYYA|IGHV3-73|7|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>bavunalimab_VH_1|FTFSSYTMH|IGHV3-13|1|EVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|0|SFISYDGNYKYYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>bebtelovimab_VH|FSLSISGVGVG|IGHV2-5|1|QITLKESGPTLVKPTQTLTLTCTFSG|IGHV2-5|0|ALIYWDDDKRYS|IGHV2-5|1|WLRQPPGKALEWL|IGHV2-26/IGHV2-5/IGHV2-70|1
>becotatug_VH|FSLSNYDVH|IGHV3-13|4|QVQLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|0|GVIWSGGNTDYN|IGHV3-53/IGHV3-66|5|WVRQAPGKGLEWL|IGHV1-24|1
>bedinvetmab_VH|FTFSSHGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|1|EVQLVESGGDLVKPGGSLRLSCVASG|IGHV3-15/IGHV3-21|2|AVINSGGSSTYYT|IGHV3-NL1|3|WVRQSPGKGLQWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|2
>befovacimab_VH|FTFSSYGMD|IGHV3-30-5/IGHV3-33/IGHV3-NL1|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SSIRGSRGSTYYA|IGHV3-23/IGHV3-23D|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>begelomab_VH|YTFRSYDIN|IGHV1-8|1|QVQLQQSGAELVKPGASVKLSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|4|GWIFPGDGSTKYN|IGHV1-3|5|WVRQRPEQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|3
>belantamab_VH|GTFSNYWMH|IGHV3-74|2|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GATYRGHSDTYYN|IGHV5-51|6|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>belimumab_VH|GTFNNNAIN|IGHV1-69/IGHV1-69D|4|QVQLQQSGAEVKKPGSSVRVSCKASG|IGHV1-69/IGHV1-69D|2|GGIIPMFGTAKYS|IGHV1-69/IGHV1-69D|3|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>belrestotug_VH|YTFTSYYMH|IGHV1-46|0|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GVIGPSGASTSYA|IGHV1-46|3|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>beludavimab_VH|YPFTSYGIS|IGHV1-18|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWISTYQGNTNYA|IGHV1-18|2|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>bemarituzumab_VH|YIFTTYNVH|IGHV1-2|4|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GSIYPDNGDTSYN|IGHV1-45|6|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>bempikibart_VH|FTFDDHAMH|IGHV3-9|1|EVQLVESGGGLVQPGRSLRLSCAASG|IGHV3-9|0|SGISWNSRGIGYA|IGHV3-9|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>benmelstobart_VH|FSLSTYGVH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|4|QITLKESGPTLVKPTQTLTLTCTVSG|IGHV2-5|1|GVIWRGVTTDYN|IGHV3-53/IGHV3-66|7|WIRQPPGKALEWL|IGHV2-26/IGHV2-5/IGHV2-70|0
>benralizumab_VH|YTFTSYVIH|IGHV1-18|2|EVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GYINPYNDGTKYN|IGHV1-2|6|WVRQRPGQGLAWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>bentracimab_VH|GTFDSYSIH|IGHV1-69/IGHV1-69D|3|QVQLQESGAEVKKPGSSVRVSCKASG|IGHV1-69/IGHV1-69D|3|GGIIPAFGTLSSA|IGHV1-69/IGHV1-69D|4|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>benufutamab_VH|FNIKDTFIH|IGHV3-43|6|EVQLQQSGAEVVKPGASVKLSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|4|GRIDPANTNTKYD|IGHV1-3|6|WVKQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>bepranemab_VH|FSLTSNDIA|IGHV1-8|5|EVQLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|1|GTIWTDGSTNYN|IGHV4-34|4|WIRQPPGKGLEWM|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|1
>berlimatoxumab_VH|GSISSGSYYWD|IGHV4-30-4|2|ELQLQESGPGLVKPSETLSLTCTVSG|IGHV4-39|1|GNIYKSGSTYYN|IGHV4-28/IGHV4-30-4/IGHV4-31|2|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>bermekimab_VH|FTFSMFGVH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|3|QVQLVESGGGVVQPGRSLRLSCTASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|1|AAVSYDGSNKYYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>bersanlimab_VH|FTFSNAWMS|IGHV3-15|0|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|AFIWYDGSNKYYA|IGHV3-33|1|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>betifisolimab_VH|YIFTTYWMH|IGHV1-2|3|QVQLVQSGAEVKKPGASVKLSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GMIQPNSGGTKYN|IGHV1-2|4|WVKQRPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|3
>bevacizumab_VH|YTFTNYGMN|IGHV7-4-1|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GWINTYTGEPTYA|IGHV7-4-1|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>bexmarilimab_VH|FSLSTSGMGIG|IGHV2-5|2|QVTLKESGPTLVKPTQTLTLTCSFSG|IGHV2-5|2|AHIWWDDDKRYN|IGHV2-5|4|WIRQPPGKALEWL|IGHV2-26/IGHV2-5/IGHV2-70|0
>bezetabart_VH|FNFSDYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|2|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AVIWYDGSISYYA|IGHV3-33|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>bezlotoxumab_VH|YSFTSYWIG|IGHV5-51|0|EVQLVQSGAEVKKSGESLKISCKGSG|IGHV5-51|1|GIFYPGDSSTRYS|IGHV5-51|2|WVRQMPGKGLEWM|IGHV5-10-1/IGHV5-51|0
>bifikafusp_VH|FTFSSFSMS|IGHV3-21/IGHV3-48|2|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SSISGSSGTTYYA|IGHV3-23/IGHV3-23D|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>bimagrumab_VH|YTFTSSYIN|IGHV1-8|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GTINPVSGSTSYA|IGHV1-46|3|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>bimekizumab_VH|FTFSDYNMA|IGHV3-11|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ATITYEGRNTYYR|IGHV3-30/IGHV3-30-3/IGHV3-30-5|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>bintrafusp_VH|FTFSSYIMM|IGHV3-13|2|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SSIYPSGGITFYA|IGHV1-46|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>birtamimab_VH|FTFNTYAMY|IGHV3-23/IGHV3-23D|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ARIRSKSNNYAIYYA|IGHV3-73|5|WIRQAPGKGLEWV|IGHV3-11|0
>bleselumab_VH|GSISSPGYYGG|IGHV4-31|3|QLQLQESGPGLLKPSETLSLTCTVSG|IGHV4-39|1|GSIYKSGSTYHN|IGHV4-38-2|2|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>blinatumomab_VH|YAFSSYWMN|IGHV3-21/IGHV3-48|3|QVQLQQSGAELVRPGSSVKISCKASG|IGHV1-69/IGHV1-69D|5|GQIWPGDGDTNYN|IGHV5-51|5|WVKQRPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|3
>blinatumomab_VH_1|YTFTRYTMH|IGHV1-2|2|DIKLQSGAELARPGASVKMSCKTSG|||GYINPSRGYTNYN|IGHV1-2|5|WVKQRPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|3
>blontuvetmab_VH|YTFTDYEVH|IGHV1-69-2|2|QVQLQQSRAELVRPGASVTLSCKPSG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|8|GAIDPETGGTADN|IGHV1-2|7|WVKQTPVHGLEWI|IGHV4-4|4
>blosozumab_VH|FPIKDTFQH|IGHV3-43|6|QVQLVQSGAEVKKPGASVKVSCKVSG|IGHV1-24|0|GWSDPEIGDTEYA|IGHV1-24|5|WVRQAPGKGLEWM|IGHV1-24|0
>bococizumab_VH|YTFTSYYMH|IGHV1-46|0|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GEISPFGGRTNYN|IGHV1-45|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>boserolimab_VH|YTFTNYGMN|IGHV7-4-1|2|EIQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|2|GWINTNTGEPTYA|IGHV7-4-1|1|WVKQAPGQGLKWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>botensilimab_VH|FTFSSYSMN|IGHV3-21/IGHV3-48|0|EVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|0|SSISSSSSYIYYA|IGHV3-21|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>brazikumab_VH|FTFSSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|0|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AVIWYDGSNEYYA|IGHV3-33|1|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>bremzalerbart_VH|GSITNYFWT|IGHV4-59|4|QVQLQESGPGLVKPSETLSLTCSVSG|IGHV4-38-2|1|GYIYYSGGTNYN|IGHV4-59/IGHV4-61|1|WIRQSPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|1
>brenetafusp_VH|YSFTGYTMN|IGHV1-2|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ALINPYKGVSTYN|IGHV1-2|8|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>brentuximab_VH|YTFTDYYIT|IGHV1-69-2|2|QIQLQQSGPEVVKPGASVKISCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|5|GWIYPGSGNTKYN|IGHV1-3|4|WVKQKPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|3
>briakinumab_VH|FTFSSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|0|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AFIRYDGSNKYYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>briquilimab_VH|YTFTSYNMH|IGHV1-3|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GVIYSGNGDTSYN|IGHV1-3|6|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>brodalumab_VH|YTFTRYGIS|IGHV1-18|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWISTYSGNTNYA|IGHV1-18|2|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>brolucizumab_VH|FSLTDYYYMT|IGHV4-38-2|7|EVQLVESGGGLVQPGGSLRLSCTASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|GFIDPDDDPYYA|IGHV2-70|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>brontictuzumab_VH|YTLRGYWIE|IGHV1-18|5|QVQLVQSGAEVKKPGASVKISCKVSG|IGHV1-24|1|GQILPGTGRTNYN|IGHV1-2|6|WVRQAPGKGLEWI|IGHV1-24|1
>budigalimab_VH|YTFTHYGMN|IGHV7-4-1|2|EIQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|2|GWVNTYTGEPTYA|IGHV7-4-1|3|WVRQAPGQGLEWV|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>budoprutug_VH|YTFTSNWMH|IGHV1-3|2|QVQLEQPGAEVVKPGASVKVSCKTSG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|4|GEIDPSDSYTNYN|IGHV5-10-1|2|WVKQTPGKGLEWI|IGHV4-4|2
>burfiralimab_VH|YTFTGYNMN|IGHV1-2|2|EVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GNIDPYYGSDTYA|IGHV1-46|6|WVRQAPGKGLEWM|IGHV1-24|0
>burosumab_VH|YTFTNHYMH|IGHV1-2|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GIINPISGSTSNA|IGHV1-46|3|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>cabiralizumab_VH|YTFTDNYMI|IGHV1-69-2|2|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GDINPYNGGTTFN|IGHV1-2|6|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>cabotamig_VH|FTFSSYAMS|IGHV3-23/IGHV3-23D|0|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AVIDSNGGSTYYP|IGHV3-64|4|WVRQTPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>cabotamig_VH_1|YSFTGYTMN|IGHV1-2|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ALINPYKGVSTYN|IGHV1-2|8|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>cadonilimab_VH|YSFTGYTMN|IGHV1-2|3|QVQLVESGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GLINPYNNITNYA|IGHV1-18|5|WVRQAPGQCLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>cadonilimab_VH_1|YSFTGYTMN|IGHV1-2|3|QVVLVESGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|2|GLINPYNNITNYA|IGHV1-18|5|WVRQAPGQCLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>calpurbatug_VH|DSNRPSYWS|IGHV4-34|5|QVQLVESGPGLVKPSETLSLTCRVSG|IGHV4-38-2|2|GYVYDSGVTIYN|IGHV4-28/IGHV4-30-4/IGHV4-31|4|WIRQAPGKAMEWI|IGHV2-26/IGHV2-5/IGHV2-70|3
>camidanlumab_VH|GTFSRYIIN|IGHV1-69/IGHV1-69D|3|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GRIIPILGVENYA|IGHV1-69/IGHV1-69D|4|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>camoteskimab_VH|GSISADGYYWS|IGHV4-31|2|QVQLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|0|GSLYYSGSTYYN|IGHV4-39|1|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>camrelizumab_VH|FTFSSYMMS|IGHV3-23/IGHV3-23D|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ATISGGGANTYYP|IGHV3-23/IGHV3-23D|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>canakinumab_VH|FTFSVYGMN|IGHV3-21/IGHV3-48|2|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AIIWYDGDNQYYA|IGHV3-33|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>canrivitug_VH|GSISSHYWS|IGHV4-59|1|QVQLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|0|GYIYYSGSSNYN|IGHV4-59/IGHV4-61|1|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>cantuzumab_VH|YTFTYYGMN|IGHV7-4-1|2|QVQLVQSGAEVKKPGETVKISCKASD|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|4|GWIDTTTGEPTYA|IGHV7-4-1|3|WVKQAPGQGLKWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>caplacizumab_VH|RTFSYNPMG|IGHV3-11|5|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AAISRTGGSTYYP|IGHV3-23/IGHV3-23D|4|WFRQAPGKGRELV|IGHV3-49|2
>carlumab_VH|GTFSSYGIS|IGHV1-69/IGHV1-69D|1|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GGIIPIFGTANYA|IGHV1-69/IGHV1-69D|0|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>carotuximab_VH|FTFSDAWMD|IGHV3-15|2|EVKLEESGGGLVQPGGSMKLSCAASG|IGHV3-73|3|AEIRSKASNHATYYA|IGHV3-73|6|WVRQSPEKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|2
>casdozokitug_VH|FTFRSYGMN|IGHV3-21/IGHV3-48|2|EVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|0|SGISSSGSYIYYA|IGHV3-11|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>cemavafusp_VH|YTFTEYTMH|IGHV1-2|2|EVQLQQSGPELVKPGASVKISCKTSG|IGHV1-69-2|6|GGINPNNGGTWYN|IGHV1-2|4|WVKQRHGKSLEWI|IGHV4-4|4
>cemiplimab_VH|FTFSNFGMT|IGHV3-15|3|EVQLLESGGVLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|1|SGISGGGRDTYFA|IGHV3-23/IGHV3-23D|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>cendakimab_VH|FSLSTSDMGVD|IGHV2-5|3|EVTLRESGPGLVKPTQTLTLTCTLYG|IGHV2-70|4|AHIWWDDVKRYN|IGHV2-5|5|WIRQPPGKGLEWL|IGHV2-26/IGHV2-5/IGHV2-70|1
>cepeprubart_VH|FTFSSFGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|1|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AYISSASSTIYYA|IGHV3-48|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>cergutuzumab_VH|YTFTEFGMN|IGHV7-4-1|3|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWINTKTGEATYV|IGHV7-4-1|4|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>certolizumab_VH|YVFTDYGMN|IGHV1-69-2|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GWINTYIGEPIYA|IGHV7-4-1|4|WVRQAPGKGLEWM|IGHV1-24|0
>cetrelimab_VH|GTFSSYAIS|IGHV1-69/IGHV1-69D|0|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GGIIPIFDTANYA|IGHV1-69/IGHV1-69D|1|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>cetuximab_VH|FSLTNYGVH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|5|QVQLKQSGPGLVQPSQSLSITCTVSG|IGHV4-30-4/IGHV4-31|5|GVIWSGGNTDYN|IGHV3-53/IGHV3-66|5|WVRQSPGKGLEWL|IGHV1-24|2
>cevostamab_VH|FSLTRFGVH|IGHV1-24|6|EVQLVESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|2|GVIWRGGSTDYN|IGHV3-53/IGHV3-66|5|WVRQPPGKGLEWL|IGHV4-4|1
>cevostamab_VH_1|FTFTSYYIH|IGHV1-46|2|EVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GWIYPENDNTKYN|IGHV1-3|5|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>cibisatamab_VH|YTFTEFGMN|IGHV7-4-1|3|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWINTKTGEATYV|IGHV7-4-1|4|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>cibisatamab_VH_1|YTFTEFGMN|IGHV7-4-1|3|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWINTKTGEATYV|IGHV7-4-1|4|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>ciduvectamig_VH|FTFSSYSMS|IGHV3-21/IGHV3-48|1|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SVISGSGGFTDYA|IGHV3-23/IGHV3-23D|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>ciduvectamig_VH_1|DSVFNNNAAWS|IGHV6-1|4|QVQLQQSGPRLVRPSQTLSLTCAISG|IGHV6-1|2|GRTYYRSKWLYDYA|IGHV6-1|2|WIRQSPSRGLEWL|IGHV6-1|0
>cifurtilimab_VH|YSFTGYYIH|IGHV1-2|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ARVIPNAGGTSYN|IGHV1-2|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>cilgavimab_VH|FTFRDVWMS|IGHV3-11|3|EVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|0|GRIKSKIDGGTTDYA|IGHV3-15|1|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>cinpanemab_VH|FDFEKAWMS|IGHV3-15|3|EVQLVESGGGLVEPGGSLRLSCAVSG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|2|ARIKSTADGGTTSYA|IGHV3-15|4|WVRQAPGQGLQWV|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>cinrebafusp_VH|FNIKDTYIH|IGHV1-69-2|6|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ARIYPTNGYTRYA|IGHV1-2|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>cirevetmab_VH|YTFISSWMN|IGHV7-4-1|3|EVQLVQSGAEVKKPGASVKVSCKTSG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|2|GQIYPGDGDTNYN|IGHV5-51|4|WVRQAPGAGLDWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>citatuzumab_VH|YTFTNYGMN|IGHV7-4-1|2|EVQLVQSGPGLVQPGGSVRISCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|4|GWINTYTGESTYA|IGHV7-4-1|3|WVKQAPGKGLEWM|IGHV1-24|1
>cixutumumab_VH|GTFSSYAIS|IGHV1-69/IGHV1-69D|0|EVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|1|GGIIPIFGTANYA|IGHV1-69/IGHV1-69D|0|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>clazakizumab_VH|FSLSNYYVT|IGHV3-11|5|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GIIYGSDETAYA|IGHV4-28/IGHV4-30-4/IGHV4-31|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>clervonafusp_VH|FTFSNYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|1|EVQLQESGGGVVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|2|SYISSGSSTIYYA|IGHV3-48|1|WIRQAPGKGLEWV|IGHV3-11|0
>clesrovimab_VH|FSFDDSAMS|IGHV3-20|3|EVQLVESGGGLVRPGRSLRLSCTVSG|IGHV3-49|2|SFIKSKTYGGTKEYA|IGHV3-15|5|WVRQAPGKGLEWI|IGHV1-24|1
>clivatuzumab_VH|YTFPSYVLH|IGHV1-3|3|QVQLQQSGAEVKKPGASVKVSCEASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|2|GYINPYNDGTQYN|IGHV1-2|6|WVKQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>cobolimab_VH|FTFSSYDMS|IGHV3-13|1|VQLLESGGGLVQPGGSLRLSCAAASG|IGHV3-20|17|STISGGGTYTYYQ|IGHV3-23/IGHV3-23D|5|WVRQAPGKGLDWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>codrituzumab_VH|YTFTDYEMH|IGHV1-69-2|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GALDPKTGDTAYS|IGHV1-24|7|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>cofetuzumab_VH|YTFTDYAVH|IGHV1-3|2|QVQLVQSGPEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GVISTYNDYTYNN|IGHV1-18|7|WVRQAPGKRLEWI|IGHV1-24|2
>coltuximab_VH|YTFTSNWMH|IGHV1-3|2|QVQLVQPGAEVVKPGASVKLSCKTSG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|4|GEIDPSDSYTNYN|IGHV5-10-1|2|WVKQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>conatumumab_VH|GSISSGDYFWS|IGHV4-30-4|1|QVQLQESGPGLVKPSQTLSLTCTVSG|IGHV4-30-4/IGHV4-31|0|GHIHNSGTTYYN|IGHV4-28/IGHV4-30-4/IGHV4-31|4|WIRQLPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|1
>concizumab_VH|FTFSNYAMS|IGHV3-23/IGHV3-23D|1|EVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|0|ATISRSGSYSYFP|IGHV3-11|7|WVRQTPEKRLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|3
>coprelotamab_VH|FNIKDTYIH|IGHV1-69-2|6|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ARIYPTNGYTRYA|IGHV1-2|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>coramitug_VH|FTFSSYTMS|IGHV3-23/IGHV3-23D|1|EVQLVESGGGLVQPGGSLKLSCAASG|IGHV3-73|0|AEINNSGDTTYYP|IGHV1-46|7|WVRQTPEKRLELV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|4
>cosfroviximab_VH|FSLSTSGVGVG|IGHV2-5|0|DVKLLESGGGLVQPGGSLKLSCAASG|IGHV3-23/IGHV3-23D|3|ALIWWDDDKYYN|IGHV2-70|2|WFRQPSGKGLEWL|IGHV2-26/IGHV2-5/IGHV2-70|3
>cosibelimab_VH|GTFSRSAIS|IGHV1-69/IGHV1-69D|2|EVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|1|GVIIPAFGEANYA|IGHV1-69/IGHV1-69D|3|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>crefmirlimab_VH|FNIKDTYIH|IGHV1-69-2|6|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GRIDPANDNTLYA|IGHV1-45|5|FVRQAPGKGLEWI|IGHV1-24|2
>crenezumab_VH|FTFSSYGMS|IGHV3-23/IGHV3-23D|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ASINSNGGSTYYP|IGHV3-64|4|WVRQAPGKGLELV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>crexavibart_VH|FTVSNNYMS|IGHV3-53/IGHV3-66|1|EVQLVESGGGLIQPGGSLRLSCAASG|IGHV3-53|0|SVIYSGGSTYYA|IGHV3-53/IGHV3-66|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>crizanlizumab_VH|YTFTSYDIN|IGHV1-8|0|QVQLVQSGAEVKKPGASVKVSCKVSG|IGHV1-24|0|GWIYPGDGSIKYN|IGHV1-3|6|WVRQAPGKGLEWM|IGHV1-24|0
>crotedumab_VH|FTFSNYLMN|IGHV3-21/IGHV3-48|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ANIQEDGIEKYYV|IGHV3-7|3|WVRQAPGKGLEWL|IGHV1-24|1
>crovalimab_VH|FTVHSSYYMA|IGHV4-38-2|7|QVQLVESGGGLVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|1|GAIFTGSGAEYKA|IGHV1-58|7|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>cudarolimab_VH|FTFSSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|0|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AVISYDGSNKYYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>cusatuzumab_VH|FTFSVYYMN|IGHV3-11|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SDINNEGGTTYYA|IGHV3-20|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>dacetuzumab_VH|YSFTGYYIH|IGHV1-2|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ARVIPNAGGTSYN|IGHV1-2|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>daclizumab_VH|YTFTSYRMH|IGHV1-3|1|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GYINPSTGYTEYN|IGHV1-46|5|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>dafsolimab_VH|YTFTSYTMH|IGHV1-3|1|QVQLQQSGAELARPGASVKMSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|5|GYINPSSGYTNYI|IGHV1-2|4|WVKQRPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|3
>dalnicastobart_VH|YTFTGYYMH|IGHV1-2|0|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWINPDSGGTNYA|IGHV1-2|2|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>dalotuzumab_VH|YSITGGYLWN|IGHV4-38-2|4|QVQLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|0|GYISYDGTNNYK|IGHV4-59/IGHV4-61|5|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>dalutrafusp_VH|YAFSSSWIN|IGHV1-8|4|EVQLVQSGAEVKKPGESLKISCKASG|IGHV5-51|1|GRIYPRAGDTNYA|IGHV1-2|4|WVRQMPGKGLEWM|IGHV5-10-1/IGHV5-51|0
>danburstotug_VH|GTFSSYAYS|IGHV1-69/IGHV1-69D|1|QMQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-45|1|GGIIPSFGTANYA|IGHV1-69/IGHV1-69D|1|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>danvilostomig_VH|FTFSSYTMH|IGHV3-13|1|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|TFISYDGNNKYYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>danvilostomig_VH_1|FSLSSYAMS|IGHV3-23/IGHV3-23D|2|EVQLVESGGGLVQPGGSLRLSCTASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|GYIGDTTGIAYA|IGHV4-28/IGHV4-30-4/IGHV4-31|8|WVRQAPGKGLEYI|IGHV3-64|1
>dapirolizumab_VH|FSSTNYHVH|IGHV1-2|6|EVQLVESGGGLVQPGGSLRLSCAVSG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|GVIWGDGDTSYN|IGHV4-28/IGHV4-30-4/IGHV4-31|6|WVRQAPGKGLEWM|IGHV1-24|0
>daratumumab_VH|FTFNSFAMS|IGHV3-23/IGHV3-23D|2|EVQLLESGGGLVQPGGSLRLSCAVSG|IGHV3-23/IGHV3-23D|1|SAISGSGGGTYYA|IGHV3-23/IGHV3-23D|1|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>dargistotug_VH|YTFTSYPMN|IGHV7-4-1|1|QVQLVQSGSELKKPGASVKVSCKASG|IGHV7-4-1|0|GWINTNTGNPTYA|IGHV7-4-1|0|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>datopotamab_VH|YTFTTAGMQ|IGHV1-18|4|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWINTHSGVPKYA|IGHV7-4-1|4|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>davutamig_VH|FTFDDYAMH|IGHV3-9|0|EVQLVESGGGLVQPGTSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|SGITWNSYNIDYA|IGHV3-9|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>davutamig_VH_1|FIVTTNYMT|IGHV3-53/IGHV3-66|4|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SLIYSSGHTYYA|IGHV3-53/IGHV3-66|3|WLRQAPGKGLEWV|IGHV3-11|1
>daxdilimab_VH|YTFTSYGIS|IGHV1-18|0|QVQLQQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GWISAYNGNTNYA|IGHV1-18|0|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>dazukibart_VH|YTFSRYWMH|IGHV3-74|2|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GHIDPSDSYTYYN|IGHV5-10-1|3|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>dectrekumab_VH|FTFSSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|0|EVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|1|AIIWYDGSNKYYA|IGHV3-33|1|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>delpacibart_VH|YTFTNYWMH|IGHV1-2|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GEINPINGRSNYA|IGHV1-2|5|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>demcizumab_VH|YSFTAYYIH|IGHV1-2|3|QVQLVQSGAEVKKPGASVKISCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GYISSYNGATNYN|IGHV1-18|4|WVKQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>demupitamab_VH|GSVSSGDYYWT|IGHV4-30-4|2|QVQLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|0|GHIYYSGNTNYN|IGHV4-59/IGHV4-61|2|WIRQSPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|1
>denecimig_VH|FTFHDYAMH|IGHV3-9|1|EVQLVESGGGLVQPGRSLRLSCAASG|IGHV3-9|0|SGISWRGDIGGYV|IGHV3-20|6|WVRQVPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>denecimig_VH_1|YSFSTSWIV|IGHV5-10-1|4|EVQLVQSGAEVKKPGESLRISCKGSG|IGHV5-10-1|0|GMIDPSDSFTSYS|IGHV5-10-1|3|WVRQMPGKGLEWM|IGHV5-10-1/IGHV5-51|0
>denintuzumab_VH|GSISTSGMGVG|IGHV2-5|3|QVQLQESGPGLVKPSQTLSLTCTVSG|IGHV4-30-4/IGHV4-31|0|GHIWWDDDKRYN|IGHV2-5|5|WIRQHPGKGLEWI|IGHV4-31|0
>denosumab_VH|FTFSSYAMS|IGHV3-23/IGHV3-23D|0|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SGITGSGGSTYYA|IGHV3-23/IGHV3-23D|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>depatuxizumab_VH|YSISSDFAWN|IGHV4-28|4|QVQLQESGPGLVKPSQTLSLTCTVSG|IGHV4-30-4/IGHV4-31|0|GYISYSGNTRYQ|IGHV4-28/IGHV4-30-4/IGHV4-31|4|WIRQPPGKGLEWM|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|1
>depemokimab_VH|FSLTGSSVH|IGHV1-24|5|QVTLRESGPALVKPTQTLTLTCTVSG|IGHV2-70|1|GVIWASGGTDYN|IGHV4-28/IGHV4-30-4/IGHV4-31|5|WVRQPPGKGLEWL|IGHV4-4|1
>derlotuximab_VH|FSLTDYGVR|IGHV3-20|5|QVQLKESGPGLVAPSQSLSITCTVSG|IGHV4-30-4/IGHV4-31|4|GVIWGGGSTYYN|IGHV3-53/IGHV3-66|4|WIRQPPGKGLEWL|IGHV2-26/IGHV2-5/IGHV2-70|1
>devextinetug_VH|FSFADYYIY|IGHV3-11|4|EIQLQQSGPELGKPGASVKVSCRASG|IGHV7-4-1|6|GYIDPFNGGDTYN|IGHV1-45|6|WVKQSHGKSLELI|IGHV4-4|5
>dezamizumab_VH|FTFATYNMH|IGHV3-13|3|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GYIYPGDGNANYN|IGHV1-45|6|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>dilpacimab_VH|FTFSNFPMA|IGHV3-15|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ATISSSDGTTYYR|IGHV3-11|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>dilpacimab_VH_1|YTFTNYGMN|IGHV7-4-1|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GWINTYTGEPTYA|IGHV7-4-1|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>dinutuximab_VH|SSFTGYNMN|IGHV1-2|4|EVQLLQSGPELEKPGASVMISCKASG|IGHV7-4-1|6|GAIDPYYGGTSYN|IGHV1-2|6|WVRQNIGKSLEWI|IGHV4-4|3
>diridavumab_VH|GPFRSYAIS|IGHV1-69/IGHV1-69D|2|EVQLVESGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|2|GGIIPIFGTTKYA|IGHV1-69/IGHV1-69D|2|WVRQAPGQGPEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>disitamab_VH|YTFTDYYIH|IGHV1-69-2|1|EVQLVQSGAEVKKPGATVKISCKVSG|IGHV1-69-2|0|GRVNPDHGDSYYN|IGHV1-2|7|WVQQAPGKGLEWM|IGHV1-69-2|0
>divozilimab_VH|YTFTSYNMH|IGHV1-3|1|EVQLVQPGAEVVKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|3|GAIYPGNGDTSYN|IGHV5-51|5|WVRQAPGRGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>docaravimab_VH|FSLTGHGVN|IGHV1-58|6|QVQLKESGPGLLAPSQSLSITCTVSG|IGHV4-30-4/IGHV4-31|5|GIIWADGTTNYN|IGHV4-34|5|WVRQPPGKGLEWL|IGHV4-4|1
>domagrozumab_VH|FTFSSYAMS|IGHV3-23/IGHV3-23D|0|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|STISSGGSYTSYP|IGHV3-74|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>domvanalimab_VH|FTFSNFGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AFISSGSSSIYYA|IGHV3-21|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>donanemab_VH|YDFTRYYIN|IGHV1-8|3|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GWINPGSGNTKYN|IGHV1-3|3|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>donzakimig1_VH|FSLSSYAMI|IGHV3-23/IGHV3-23D|3|EVQLVESGGGLVQPGGSLRLSCAVSG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|GIIDIEGSTYYA|IGHV3-53/IGHV3-66|5|WVRQAPGKGLEWI|IGHV1-24|1
>donzakimig1_VH_1|IDLSNYAIN|IGHV1-69/IGHV1-69D|5|EVQLLESGGGLVQPGGSLRLSCAVSG|IGHV3-23/IGHV3-23D|1|GIIWASGTTFYA|IGHV4-28/IGHV4-30-4/IGHV4-31|6|WVRQAPGKCLEWI|IGHV1-24|2
>donzakimig2_VH|YSFTSYYIH|IGHV1-46|2|EVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|1|GRIGPGSGDINYN|IGHV1-2|5|WVRQAPGQCLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>dostarlimab_VH|FTFSSYDMS|IGHV3-13|1|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|STISGGGSYTYYQ|IGHV3-23/IGHV3-23D|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>dovanvetmab_VH|YSFTSYTIH|IGHV5-10-1|2|QVLLVQSGAEVRTPGASVKIFCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|5|GNINPTSGYTENN|IGHV1-2|6|WLRQAPAQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>dresbuxelimab_VH|YSFTGYTMN|IGHV1-2|3|QVQLVQSGAEVVKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GLINPYNAGTSYN|IGHV1-2|6|WVRQAPGQNLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>drozitumab_VH|FTFDDYAMS|IGHV3-20|1|EVQLVQSGGGVERPGGSLRLSCAASG|IGHV3-20|2|SGINWQGGSTGYA|IGHV3-20|1|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>duligotuzumab_VH|FTLSGDWIH|IGHV3-73|4|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GEISAAGGYTDYA|IGHV1-18|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>dupilumab_VH|FTFRDYAMT|IGHV3-49|2|EVQLVESGGGLEQPGGSLRLSCAGSG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|2|SSISGSGGNTYYA|IGHV3-23/IGHV3-23D|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>durvalumab_VH|FTFSRYWMS|IGHV3-7|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ANIKQDGSEKYYV|IGHV3-7|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>dusigitumab_VH|YTFTSYDIN|IGHV1-8|0|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWMNPNSGNTGYA|IGHV1-8|0|WVRQATGQGLEWM|IGHV1-8|0
>duvakitug_VH|YTFTSYDIN|IGHV1-8|0|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWLNPNSGYTGYA|IGHV1-8|2|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>duvortuxizumab_VH|FSLSTSGMGVG|IGHV2-5|1|QVTLRESGPALVKPTQTLTLTCTFSG|IGHV2-70|0|AHIWWDDDKRYN|IGHV2-5|4|WIRQPPGKALEWL|IGHV2-26/IGHV2-5/IGHV2-70|0
>duvortuxizumab_VH_1|FTFSTYAMN|IGHV3-21/IGHV3-48|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GRIRSKYNNYATYYA|IGHV3-73|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>ebdarokimab_VH|YTFTSYWIG|IGHV5-51|1|EVQLVQSGAEVKKPGESLKISCQSSG|IGHV5-51|2|GIMSPVDSDIRYN|IGHV5-51|5|WVRQMPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>eblasakimab_VH|YSFTSYWIG|IGHV5-51|0|EVQLVQSGAEVKKPGESLKISCKGSG|IGHV5-51|0|GVIYPGDSYTRYS|IGHV5-51|2|WVRQMPGKGLEWM|IGHV5-10-1/IGHV5-51|0
>ebronucimab_VH|FTFSSYSMN|IGHV3-21/IGHV3-48|0|EVQLVESGGGLVQPGRSLRLSCAASG|IGHV3-9|0|SGISSSSSYISYA|IGHV3-21|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>eciskafusp_VH|FSFSSYTMS|IGHV3-23/IGHV3-23D|2|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|ATISGGGRDIYYP|IGHV3-11|7|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>ecleralimab_VH|FTFSDYWMH|IGHV3-74|1|EVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|0|GHIKSKTDAGTTDYA|IGHV3-15|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>ecromeximab_VH|FAFSHYAMS|IGHV3-23/IGHV3-23D|2|EVTLVESGGDFVKPGGSLKVSCAASG|IGHV3-15/IGHV3-21|5|AYISSGGSGTYYS|IGHV3-11|5|WVRQTPAKRLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|3
>eculizumab_VH|YIFSNYWIQ|IGHV5-10-1|4|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GEILPGSGSTEYT|IGHV1-2|6|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>edrecolomab_VH|YAFTNYLIE|IGHV1-18|4|QVQLQQSGAELVRPGTSVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|5|GVINPGSGGTNYN|IGHV1-2|3|WVKQRPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|3
>efalizumab_VH|YSFTGHWMN|IGHV1-2|4|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GMIHPSDSETRYN|IGHV5-10-1|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>efungumab_VH|CIISSYWIS|IGHV1-69/IGHV1-69D|4|EVQLVESGAEVKKPGESLRISCKGSG|IGHV5-10-1|1|GKIDPGDSYINYS|IGHV5-10-1|3|WVRQMPGKGLEWM|IGHV5-10-1/IGHV5-51|0
>eglatoprutug_VH|YTFTSYNMH|IGHV1-3|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GVIYSGNGDTSYA|IGHV3-NL1|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>eldelumab_VH|FTFSNNGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|2|QMQLVESGGGVVQPGRSLRLSCTASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|2|AVIWFDGMNKFYV|IGHV3-33|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>elezanumab_VH|YTFTSHGIS|IGHV1-18|1|EVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GWISPYSGNTNYA|IGHV1-18|2|WVRQAPGQGLDWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>elgemtumab_VH|FTFSSYAMS|IGHV3-23/IGHV3-23D|0|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SAINSQGKSTYYA|IGHV3-64|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>elipovimab_VH|ASISDSYWS|IGHV4-59|3|QMQLQESGPGLVKPSETLSLTCSVSG|IGHV4-38-2|2|GYVHKSGDTNYN|IGHV4-59/IGHV4-61|4|WIRRSPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|2
>elotuzumab_VH|FDFSRYWMS|IGHV3-7|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GEINPDSSTINYA|IGHV1-2|5|WVRQAPGKGLEWI|IGHV1-24|1
>elranatamab_VH|FTFSSYPMS|IGHV3-23/IGHV3-23D|1|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SAIGGSGGSLPYA|IGHV3-23/IGHV3-23D|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>elranatamab_VH_1|FTFSDYYMT|IGHV3-11|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AFIRNRARGYTSDHN|IGHV3-49|9|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>eltrekibart_VH|YEFTSYWIH|IGHV5-10-1|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GNISPNSGSANYN|IGHV1-2|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>eluvixtamab_VH|YTFTNYGMN|IGHV7-4-1|2|QVQLVQSGAEVKKPGESVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GWINTYTGEPTYA|IGHV7-4-1|2|WVKQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>eluvixtamab_VH_1|FTFNKYAMN|IGHV3-21/IGHV3-48|3|EVQLVESGGGLVQPGGSLKLSCAASG|IGHV3-73|0|ARIRSKYNNYATYYA|IGHV3-73|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>emactuzumab_VH|YTFTSYDIS|IGHV1-18|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GVIWTDGGTNYA|IGHV3-53/IGHV3-66|6|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>emapalumab_VH|FTFSSYAMS|IGHV3-23/IGHV3-23D|0|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SAISGSGGSTYYA|IGHV3-23/IGHV3-23D|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>emerfetamab_VH|YTFTNYGMN|IGHV7-4-1|2|QVQLVQSGAEVKKPGESVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GWINTYTGEPTYA|IGHV7-4-1|2|WVKQAPGQCLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>emerfetamab_VH_1|FTFNKYAMN|IGHV3-21/IGHV3-48|3|EVQLVESGGGLVQPGGSLKLSCAASG|IGHV3-73|0|ARIRSKYNNYATYYA|IGHV3-73|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>emfizatamab1_VL|FTISTNAMS|IGHV3-23/IGHV3-23D|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GVITGRDITYYA|IGHV3-53/IGHV3-66|6|WVRQAPGKGLEWI|IGHV1-24|1
>emfizatamab1_VL_1|YSFSSSWIG|IGHV5-51|2|EVQLVQSGAEVKKPGESLKISCKGSG|IGHV5-51|0|GIIYPDDSDTRYS|IGHV5-51|1|WVRQAPGKGLEWM|IGHV1-24|0
>emfizatamab2_VL|FSFSSGYDMC|IGHV4-38-2|5|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|ACIAAGSAGITYDA|IGHV6-1|12|WVRQAPGKGLEWI|IGHV1-24|1
>emfizatamab2_VL_1|FTISSYHMQ|IGHV3-13|3|SRSLVESGGGLVQPGGSLRLSCTASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|4|GTISSGGNVYYA|IGHV3-53/IGHV3-66|5|WVRQAPGKGLEYI|IGHV3-64|1
>emibetuzumab_VH|YTFTDYYMH|IGHV1-69-2|0|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GRVNPNRRGTTYN|IGHV1-2|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>emicizumab_VH|YTFTDNNMD|IGHV1-69-2|3|QVQLVQSGSELKKPGASVKVSCKASG|IGHV7-4-1|0|GDINTRSGGSIYN|IGHV1-2|6|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>emicizumab_VH_1|FTFSYYDIQ|IGHV3-13|3|QVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-11|1|SSISPSGQSTYYR|IGHV3-23/IGHV3-23D|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>emirodatamab_VH|FSLNNARMGVS|IGHV2-26|1|QVTLKESGPTLVKPTETLTLTCTLSG|IGHV2-26|2|AHIFSNDEKSYS|IGHV2-26|0|WIRQPPGKCLEWL|IGHV2-26/IGHV2-5/IGHV2-70|1
>emirodatamab_VH_1|FTFNKYAMN|IGHV3-21/IGHV3-48|3|EVQLVESGGGLVQPGGSLKLSCAASG|IGHV3-73|0|ARIRSKYNNYATYYA|IGHV3-73|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>empasiprubart_VH|YTFTDYNMD|IGHV1-69-2|2|EVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GDINPNYESTGYN|IGHV1-2|6|WVRQATGQGLEWI|IGHV1-8|1
>enapotamab_VH|FTFSSYAMN|IGHV3-21/IGHV3-48|1|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|STTSGSGASTYYA|IGHV3-23/IGHV3-23D|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>enavatuzumab_VH|FTFSSYWMS|IGHV3-7|0|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AEIRLKSDNYATHYA|IGHV3-73|7|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>encelimab_VH|FSIKDDYIH|IGHV1-69-2|6|EVQLVQSGAEVKKPGATVKISCKASG|IGHV1-69-2|1|GWIDAMNDDSQYS|IGHV1-3|6|WVQQAPGKGLEWM|IGHV1-69-2|0
>enfortumab_VH|FTFSSYNMN|IGHV3-21/IGHV3-48|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SYISSSSSTIYYA|IGHV3-48|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>englumafusp_VH|YTFTDYIMH|IGHV1-69-2|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GYINPYNDGSKYT|IGHV1-2|7|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>enibarcimab_VH|YTFSRYWIE|IGHV1-18|4|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GEILPGSGSTNYN|IGHV1-2|5|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>enlonstobart_VH|LTFSSSGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|2|QVQLVESGGGVVQPGRSLRLTCKASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|2|AVIWYDGSKRYYA|IGHV3-33|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>enoblituzumab_VH|FTFSSFGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AYISSDSSAIYYA|IGHV3-48|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>enokizumab_VH|GTFSYYWIE|IGHV1-69/IGHV1-69D|3|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GEILPGSGTTNPN|IGHV1-2|6|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>enoticumab_VH|FTFSSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|0|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|SFLWYDGTNKNYV|IGHV3-33|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>enristomig_VH|GIFAIKPIS|IGHV1-69/IGHV1-69D|5|EVQLLESGGGEVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|1|STTTSSGATNYA|IGHV3-53/IGHV3-66|6|WYRQAPGKQREWV|IGHV3-11|3
>enristomig_VH_1|FSFSINAMG|IGHV3-23/IGHV3-23D|4|EVQLLESGGGEVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|1|AAIESGRNTVYA|IGHV3-53/IGHV3-66|6|WYRQAPGKRREFV|IGHV3-11|4
>ensituximab_VH|FSLSKFGVN|IGHV3-21/IGHV3-48|6|QVQLKESGPDLVAPSQSLSITCTVSG|IGHV4-30-4/IGHV4-31|5|GVIWGDGSTSYN|IGHV4-28/IGHV4-30-4/IGHV4-31|5|WVRQPPGKGLEWL|IGHV4-4|1
>enuzovimab_VH|FIVSSNYMS|IGHV3-53/IGHV3-66|1|EVQLVESGGGLIQPGGSLRLSCAASG|IGHV3-53|0|SIIYSGGSTFYA|IGHV3-53/IGHV3-66|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>envafolimab_VH|KMSSRRCMA|IGHV3-11|7|QVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-11|1|AKLLTTSGSTYLA|IGHV3-23/IGHV3-23D|8|WFRQAPGKERERV|IGHV3-49|3
>epacmarstobart_VH|YTFTSYWIT|IGHV1-18|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GDIYPGSGSTNHI|IGHV1-2|6|WVKQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>epcoritamab_VH|FTFNTYAMN|IGHV3-21/IGHV3-48|3|EVKLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|ARIRSKYNNYATYYA|IGHV3-73|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>epcoritamab_VH_1|FTFHDYAMH|IGHV3-9|1|EVQLVESGGGLVQPDRSLRLSCAASG|IGHV3-9|1|STISWNSGTIGYA|IGHV3-9|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>epratuzumab_VH|YTFTSYWLH|IGHV1-3|2|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GYINPRNDYTEYN|IGHV1-2|7|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>eptinezumab_VH|IDLSGYYMN|IGHV1-2|5|EVQLVESGGGLVQPGGSLRLSCAVSG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|GVIGINGATYYA|IGHV3-53/IGHV3-66|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>eramkafusp_VH|YTFTSYNMH|IGHV1-3|1|QVQLQQPGAELVKPGASVKMSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|5|GAIYPGNGDTSYN|IGHV5-51|5|WVKQTPGRGLEWI|IGHV4-4|3
>erenumab_VH|FTFSSFGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|1|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AVISFDGSIKYS|IGHV2-70|7|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>erfonrilimab_VH|KMSSRRCMA|IGHV3-11|7|QVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-11|1|AKLLTTSGSTYLA|IGHV3-23/IGHV3-23D|8|WFRQAPGKERERV|IGHV3-49|3
>erfonrilimab_VH_1|YIYSAYCMG|IGHV1-2|6|QVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-11|1|AAIYIGGGSTYYA|IGHV3-23/IGHV3-23D|4|WFRQAPGKGLEGV|IGHV3-49|1
>erlizumab_VH|YTFTEYTMH|IGHV1-2|2|EVQLVESGGGLVQPGGSLRLSCATSG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|AGINPKNGGTSHN|IGHV1-2|7|WMRQAPGKGLEWV|IGHV3-11|1
>ersodetug_VH|FTFSSYAMH|IGHV3-30/IGHV3-30-3/IGHV3-64|0|EVQLVETGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|2|AVISYDGSNKYYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|0|WVRQAPGKGLEWY|IGHV1-24|1
>erzotabart_VH|GTFSSYAIS|IGHV1-69/IGHV1-69D|0|QVQLVQSGAEVKKPGSSVKVSCKAFG|IGHV1-69/IGHV1-69D|1|GRIIRFLGIANYA|IGHV1-69/IGHV1-69D|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>etaracizumab_VH|FTFSSYDMS|IGHV3-13|1|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AKVSSGGGSTYYL|IGHV3-64|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>etesevimab_VH|FTVSSNYMS|IGHV3-53/IGHV3-66|0|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SVIYSGGSTFYA|IGHV3-53/IGHV3-66|1|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>etevritamab_VH|FTFRNYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|2|QVQLVESGGGVVQSGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|1|AVIWYDGSDKYYA|IGHV3-33|1|WVRQAPGKCLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>etevritamab_VH_1|FTFNKYAMN|IGHV3-21/IGHV3-48|3|EVQLVESGGGLVQPGGSLKLSCAASG|IGHV3-73|0|ARIRSKYNNYATYYA|IGHV3-73|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>etigilimab_VH|YSITSDYAWN|IGHV4-38-2|4|QVQLQESGPGLVKPSETLSLTCAVSG|IGHV4-38-2|0|GYISYSGSTSYN|IGHV4-28/IGHV4-30-4/IGHV4-31|2|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>etokimab_VH|YTFTSYWMH|IGHV1-3|1|QVQLMQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GTIYPRNSNTDYN|IGHV1-45|6|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>etrolizumab_VH|FFITNNYWG|IGHV3-53/IGHV3-66|6|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GYISYSGSTSYN|IGHV4-28/IGHV4-30-4/IGHV4-31|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>eurestobart_VH|YNLKDTFLH|IGHV1-24|6|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GRIDPAQGNIKYD|IGHV1-2|7|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>evalstotug_VH|FTFSHYTMH|IGHV3-13|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SFISYDGNNKYYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>evinacumab_VH|FTFDDYAMN|IGHV3-9|1|EVQLVESGGGVIQPGGSLRLSCAASG|IGHV3-53|1|SAISGDGGSTYYA|IGHV3-23/IGHV3-23D|1|WVRQGPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>evolocumab_VH|YTLTSYGIS|IGHV1-18|1|EVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GWVSFYNGNTNYA|IGHV1-18|2|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>evunzekibart_VH|FNFGYSYMS|IGHV3-11|4|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SSIGSTSSHTYYA|IGHV3-21|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>exbivirumab_VH|FVFRSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|2|QVQLVESGGGVVQPGGSLRLSCAPSG|IGHV3-NL1|1|SLIWHDGSNRFYA|IGHV3-33|5|WVRQTPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>exidavnemab_VH|FSLTSYGVH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|4|QVQLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|0|GVIWRGGSTDYS|IGHV3-53/IGHV3-66|5|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>exlinkibart_VH|YTFAGFEMH|IGHV1-2|3|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GAIDPKTGGTDYN|IGHV1-2|6|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>ezabenlimab_VH|FTFSKSAMS|IGHV3-23/IGHV3-23D|2|EVMLVESGGGLVQPGGSLRLSCTASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|2|AYISGGGGDTYYS|IGHV3-23/IGHV3-23D|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>falbikitug_VH|FTFSHAWMH|IGHV3-15|2|QVQLQESGGGLVKPGGSLRLSCAASG|IGHV3-11|1|GQIKAKSDDYATYYA|IGHV3-15|7|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>fanastomig_VH|FNIKDDYMH|IGHV1-69-2|5|EVQLVQSGAEVKKPGATVKLSCTASG|IGHV1-69-2|3|GWIVPENANTVYA|IGHV1-45|4|WVKQRPEQGLDWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|5
>fanastomig_VH_1|FTSSDYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SYISSGSYTIYYA|IGHV3-48|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>faricimab_VH|YDFTHYGMN|IGHV7-4-1|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GWINTYTGEPTYA|IGHV7-4-1|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>faricimab_VH_1|YTFTGYYMH|IGHV1-2|0|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWINPNSGGTNYA|IGHV1-2|1|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>farletuzumab_VH|FTFSGYGLS|IGHV3-11|3|EVQLVESGGGVVQPGRSLRLSCSASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|2|AMISSGGSYTYYA|IGHV3-NL1|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>fasinumab_VH|FTLTELSIH|IGHV1-24|2|QVQLVQSGAEVKKPGASVKVSCKVSG|IGHV1-24|0|GGFDPEDGETIYA|IGHV1-24|0|WVRQAPGKGLEWM|IGHV1-24|0
>favezelimab_VH|YTFTDYNVD|IGHV1-69-2|3|QMQLVQSGPEVKKPGTSVKVSCKASG|IGHV1-58|0|GDINPNDGGTIYA|IGHV1-2|3|WVRQARGQRLEWI|IGHV1-58|0
>fazpilodemab_VH|FSLTTYGVH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|5|EVQLVESGGGLVQPGGSLRLSCAASD|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|GVIWSGGSTDYN|IGHV3-53/IGHV3-66|4|WVRQAPGKGLEWL|IGHV1-24|1
>fazpilodemab_VH_1|FTFTSNYIS|IGHV1-18|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GEIDPYDGDTYYA|IGHV1-24|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>feladilimab_VH|YTFTDYAMH|IGHV1-3|1|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GLISIYSDHTNYN|IGHV1-18|6|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>felzartamab_VH|FTFSSYYMN|IGHV3-21/IGHV3-48|1|QVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-11|1|SGISGDPSNTYYA|IGHV3-23/IGHV3-23D|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>fepixnebart_VH|YTFTDAYIN|IGHV1-69-2|3|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GWIWPGPVITYYN|IGHV1-3|7|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>fezakinumab_VH|YTFTNYYMH|IGHV1-2|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWINPYTGSAFYA|IGHV1-46|5|WVRQAPGQGLEWV|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>fianlimab_VH|FTFSSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|0|QVQLVESGGGVVQPGRSLRLSCVASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|1|AIIWYDGSNKYYA|IGHV3-33|1|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>ficlatuzumab_VH|YTFTTYWMH|IGHV1-2|2|QVQLVQPGAEVKKPGTSVKLSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|3|GEINPTNGHTNYN|IGHV1-2|5|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>fidasimtamab_VH|FNIKDTYIH|IGHV1-69-2|6|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ARIYPTNGYTRYA|IGHV1-2|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>fidasimtamab_VH_1|FNIKDTYIH|IGHV1-69-2|6|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ARIYPTNGYTRYA|IGHV1-2|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>figitumumab_VH|FTFSSYAMN|IGHV3-21/IGHV3-48|1|EVQLLESGGGLVQPGGSLRLSCTASG|IGHV3-23/IGHV3-23D|1|SAISGSGGTTFYA|IGHV3-23/IGHV3-23D|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>finotonlimab_VH|FTFSSYGMS|IGHV3-23/IGHV3-23D|1|EVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|0|ATISGGGRDTYYS|IGHV3-23/IGHV3-23D|6|WVRQAPGKRLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>firastotug_VH|YSISSGYHWS|IGHV4-38-2|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ARIDWDDDKYYS|IGHV2-70|1|WIRQAPGKGLEWL|IGHV3-11|1
>firivumab_VH|VFFSSHAIS|IGHV1-69/IGHV1-69D|3|QVQLVQSGAEVKMPGSSVKVSCKTSG|IGHV1-69/IGHV1-69D|2|GGISPMFGTTHYA|IGHV1-69/IGHV1-69D|4|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>fiztasovimab_VH|GSFSGYYWG|IGHV4-34|1|QVQLQQWGAGLLKPSETLSLTCAVYG|IGHV4-34|0|GEINHSGSANSN|IGHV4-34|2|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>flanvotumab_VH|YTFTSYAMN|IGHV7-4-1|0|QVQLVQSGSELKKPGASVKISCKASG|IGHV7-4-1|1|GWINTNTGNPTYA|IGHV7-4-1|0|WVRQAPGQGLESM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>fletikumab_VH|YTFTNDIIH|IGHV1-18|4|QVQLVQSGAEVKRPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GWINAGYGNTQYS|IGHV1-3|2|WVRQAPGQRLEWM|IGHV1-3|0
>flotetuzumab_VH|YTFTDYYMK|IGHV1-69-2|1|EVQLVQSGAELKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|2|GDIIPSNGATFYN|IGHV1-45|6|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>flotetuzumab_VH_1|FTFSTYAMN|IGHV3-21/IGHV3-48|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GRIRSKYNNYATYYA|IGHV3-73|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>fontolizumab_VH|YIFTSSWIN|IGHV1-8|3|QVQLVQSGAELKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|1|GRIDPSDGEVHYN|IGHV5-10-1|5|WVKQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>foralumab_VH|FKFSGYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|2|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AVIWYDGSKKYYV|IGHV3-33|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>foravirumab_VH|FTFSSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|0|QVQLVESGGGAVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|1|AVILYDGSDKFYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>forimtamig_VH|YTFTDAYIN|IGHV1-69-2|3|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GWIWPGPVITYYN|IGHV1-3|7|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>forimtamig_VH_1|FQFSSYAMN|IGHV3-21/IGHV3-48|2|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SRIRSKYNNYATYYA|IGHV3-73|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>fremanezumab_VH|FTFSNYWIS|IGHV3-15|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AEIRSESDASATHYA|IGHV3-73|8|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>freneslerbart_VH|FTFRNYNIN|IGHV1-8|4|EVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|0|SLISGSSSYIYYA|IGHV3-21|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>fresolimumab_VH|YTFSSNVIS|IGHV1-18|3|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GGVIPIVDIANYA|IGHV1-69/IGHV1-69D|4|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>frexalimab_VH|DSITNGFWI|IGHV4-59|6|EVQLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|1|GYISYSGSTYYN|IGHV4-28/IGHV4-30-4/IGHV4-31|1|WIRKPPGNKLEYM|IGHV2-26/IGHV2-5/IGHV2-70|5
>frovocimab_VH|FPFSKLGMV|IGHV3-30-5/IGHV3-33/IGHV3-NL1|4|EVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|0|STISSGGGYTYYP|IGHV3-64|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>frunevetmab_VH|FSLTNNNVN|IGHV1-58|6|QVQLVESGAELVQPGESLRLTCAASG|IGHV3-11|5|GGVWAGGATDYN|IGHV4-28/IGHV4-30-4/IGHV4-31|7|WVRQAPGKGLEWM|IGHV1-24|0
>fulranumab_VH|FTLRSYSMN|IGHV3-21/IGHV3-48|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SYISRSSHTIFYA|IGHV3-48|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>futuximab_VH|YTFTSYWMH|IGHV1-3|1|EVQLQQPGSELVRPGASVKLSCKASG|IGHV7-4-1|6|GNIYPGSRSTNYD|IGHV1-2|6|WVKQRPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|3
>galcanezumab_VH|YTFGNYWMQ|IGHV1-2|4|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GAIYEGTGKTVYI|IGHV1-3|7|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>galegenimab_VH|YKFTDSEMH|IGHV1-69-2|3|EVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GGVDPETEGAAYN|IGHV1-24|7|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>galiximab_VH|GSISGGYGWG|IGHV4-38-2|3|QVQLQESGPGLVKPSETLSLTCAVSG|IGHV4-38-2|0|GSFYSSSGNTYYN|IGHV1-58|7|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>galvokimig1_VH|FTFSDYNMA|IGHV3-11|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ATITYEGRNTYYR|IGHV3-30/IGHV3-30-3/IGHV3-30-5|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>galvokimig1_VH_1|IDLSNYAIN|IGHV1-69/IGHV1-69D|5|EVQLLESGGGLVQPGGSLRLSCAVSG|IGHV3-23/IGHV3-23D|1|GIIWASGTTFYA|IGHV4-28/IGHV4-30-4/IGHV4-31|6|WVRQAPGKCLEWI|IGHV1-24|2
>galvokimig2_VH|YSFTSYYIH|IGHV1-46|2|EVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|1|GRIGPGSGDINYN|IGHV1-2|5|WVRQAPGQCLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>gancotamab_VH|FTFRSYAMS|IGHV3-23/IGHV3-23D|1|QVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-11|1|SAISGRGDNTYYA|IGHV3-23/IGHV3-23D|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>ganitumab_VH|GSISSSNWWS|IGHV4-4|0|QVQLQESGPGLVKPSGTLSLTCAVSG|IGHV4-28|1|GEIYHSGSTNYN|IGHV4-4|0|WVRQPPGKGLEWI|IGHV4-4|0
>gantenerumab_VH|FTFSSYAMS|IGHV3-23/IGHV3-23D|0|QVELVESGGGLVQPGGSLRLSCAASG|IGHV3-11|2|SAINASGTRTYYA|IGHV3-23/IGHV3-23D|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>garadacimab_VH|FTFSKYIMQ|IGHV3-11|3|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SGIDIPTKGTVYA|IGHV3-20|7|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>garetosmab_VH|GSFSSHFWS|IGHV4-34|3|QVQLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|0|GYILYTGGTSFN|IGHV4-28/IGHV4-30-4/IGHV4-31|5|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>garivulimab_VH|FSLTSYGVH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|4|EVQLVESGGGLVQPGGSLRLSCAVSG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|AVIWAGGSTNYA|IGHV3-53/IGHV3-66|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>gatipotuzumab_VH|FPFSNYWMN|IGHV3-15|3|EVQLVESGGGLVQPGGSMRLSCVASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|2|GEIRLKSNNYTTHYA|IGHV3-72|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>gatralimab_VH|FPFSNYWMN|IGHV3-15|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GQIRLKSNNYATHYA|IGHV3-73|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>gedivumab_VH|LTFSSYAVH|IGHV3-30/IGHV3-30-3/IGHV3-64|2|EVQLVESGGGVVQPGKSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|2|TLISYDGANQYYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>gefurulimab_VH|RPVSNYAAA|IGHV1-69/IGHV1-69D|6|EVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|0|SAINWQKTATYA|IGHV3-13|8|WFRQAPGKEREFV|IGHV3-49|3
>gefurulimab_VH_1|RAHSDYAMA|IGHV3-11|5|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AGIGWSGGDTLYA|IGHV3-20|5|WFRQAPGQEREFV|IGHV3-49|4
>gemtuzumab_VH|YTITDSNIH|IGHV1-69-2|4|EVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|1|GYIYPYNGGTDYN|IGHV1-18|6|WVRQAPGQSLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>geptanolimab_VH|YTFTNFGMN|IGHV7-4-1|3|QIQLVQSGSELKKPGASVKVSCKASG|IGHV7-4-1|1|GWISGYTREPTYA|IGHV7-4-1|5|WVRQAPGQGLKWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>gevokizumab_VH|FSLSTSGMGVG|IGHV2-5|1|QVQLQESGPGLVKPSQTLSLTCSFSG|IGHV4-30-4/IGHV4-31|2|AHIWWDGDESYN|IGHV2-70|6|WIRQPSGKGLEWL|IGHV2-26/IGHV2-5/IGHV2-70|2
>giloralimab_VH|YSITSNYYWN|IGHV4-38-2|3|EVQLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|1|GYIRYDGSNNYN|IGHV4-59/IGHV4-61|3|WIRQPPGKGLEWM|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|1
>gilvetmab_VH|FNIKNTYMH|IGHV1-2|6|EVQLVQSGGDLVKPGGSVRLSCVASG|IGHV3-15/IGHV3-21|4|GRIAPANVDTKYA|IGHV1-2|6|WVRQAPGKGLQWI|IGHV1-24|2
>gimsilumab_VH|FTFSRHWMH|IGHV3-74|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SRINGAGTSITYA|IGHV3-74|5|WLRQVPGKGPVWV|IGHV3-74|3
>ginisortamab_VH|YTFTDYYMH|IGHV1-69-2|0|QVQLVESGAEVKKPGATVKISCKVSG|IGHV1-69-2|2|GLVDPEDGETIYA|IGHV1-69-2|0|WVQQAPGKGLEWM|IGHV1-69-2|0
>girentuximab_VH|FTFSNYYMS|IGHV3-11|1|DVKLVESGGGLVKLGGSLKLSCAASG|IGHV3-11|4|AAINSDGGITYYL|IGHV3-64|5|WVRQTPEKRLELV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|4
>givastomig_VH|YTFTTYPIE|IGHV1-18|3|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GNFHPYNDDTKYN|IGHV1-18|8|WVRQAPGQRLEWM|IGHV1-3|0
>givastomig_VH_1|FTFSSYDMS|IGHV3-13|1|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SWISYSGGSIYYA|IGHV3-23/IGHV3-23D|3|WVRQAPGKCLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>glembatumumab_VH|GSISSFNYYWS|IGHV4-30-4|2|QVQLQESGPGLVKPSQTLSLTCTVSG|IGHV4-30-4/IGHV4-31|0|GYIYYSGSTYSN|IGHV4-28/IGHV4-30-4/IGHV4-31|1|WIRHHPGKGLEWI|IGHV4-31|1
>glenzocimab_VH|YTFTSYNMH|IGHV1-3|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GGIYPGNGDTSYN|IGHV5-51|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>glofitamab_VH|FTFSTYAMN|IGHV3-21/IGHV3-48|2|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SRIRSKYNNYATYYA|IGHV3-73|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>glofitamab_VH_1|YAFSYSWIN|IGHV1-8|5|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GRIFPGDGDTDYN|IGHV5-51|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>golimumab_VH|FIFSSYAMH|IGHV3-30/IGHV3-30-3/IGHV3-64|1|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AFMSYDGSNKKYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|3|WVRQAPGNGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>golocdacimab_VH|YTLTELSMH|IGHV1-24|0|QVQLVQSGAEVKKPGASVKVSCKVSG|IGHV1-24|0|GGFDPEDFKYHT|IGHV2-70|8|WVRQAPGKGLEWM|IGHV1-24|0
>gontivimab_VH|GSLSNYVLG|IGHV4-34|5|DVQLVESGGGLVQAGGSLSISCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|4|AAINWRGDITIGP|IGHV3-20|8|WFRQAPGKEREFV|IGHV3-49|3
>gontivimab_VH_1|GSLSNYVLG|IGHV4-34|5|EVQLVESGGGLVQAGGSLSISCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|3|AAINWRGDITIGP|IGHV3-20|8|WFRQAPGKEREFV|IGHV3-49|3
>gorivitug_VH|FTFSRYAMY|IGHV3-23/IGHV3-23D|2|EVQLVESGGGLVQPGGSLRLSCSASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|SAISSDGGSTYDA|IGHV3-64|2|WVRQAPGKGLEYV|IGHV3-64|0
>gosuranemab_VH|FSFSKYGMS|IGHV3-11|3|EVHLVESGGALVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|2|ATISSSGSRTYYP|IGHV3-11|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>gotistobart_VH|FSLTSYGLS|IGHV1-18|4|QVQLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|0|GYIWYDGNTNFH|IGHV4-59/IGHV4-61|5|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>gremubamab_VH|FTFSSYAMN|IGHV3-21/IGHV3-48|1|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SAITMSGITAYYT|IGHV3-11|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>gremubamab_VH_1|GSISPYYWT|IGHV4-59|2|QVQLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|0|GYIHSSGYTDYN|IGHV4-28/IGHV4-30-4/IGHV4-31|4|WIRQPPGKCLELI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|2
>gresonitamab_VH|YTFTGYYMH|IGHV1-2|0|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWINPNSGGTKYA|IGHV1-2|2|WVRQAPGQCLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>gresonitamab_VH_1|FTFNKYAMN|IGHV3-21/IGHV3-48|3|EVQLVESGGGLVQPGGSLKLSCAASG|IGHV3-73|0|ARIRSKYNNYATYYA|IGHV3-73|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>grisnilimab_VH|YTFTNYGMN|IGHV7-4-1|2|QIQLVQSGPELKKPGETVKISCKASG|IGHV1-58|5|GWINTYTGEPTYA|IGHV7-4-1|2|WVKQAPGKGLMWL|IGHV1-24|3
>gruticibart_VH|FSLTGYGIY|IGHV1-18|5|QVQLQESGPGLVKPSETLSITCTVSG|IGHV4-59/IGHV4-61|1|GMIWGDGRTDYN|IGHV4-28/IGHV4-30-4/IGHV4-31|6|WVRQPPGKGLEWL|IGHV4-4|1
>gulgafafusp_VH|FTLSSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|1|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AVIWYDGSNKYYA|IGHV3-33|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>gumokimab_VH|YSFTSDYAWS|IGHV4-38-2|5|DVQLQESGPGLVKPSQTLSLTCTVSS|IGHV4-30-4/IGHV4-31|2|GYITYSGVTSYN|IGHV4-28/IGHV4-30-4/IGHV4-31|3|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>guselkumab_VH|YSFSNYWIG|IGHV5-51|2|EVQLVQSGAEVKKPGESLKISCKGSG|IGHV5-51|0|GIIDPSNSYTRYS|IGHV5-10-1|3|WVRQMPGKGLEWM|IGHV5-10-1/IGHV5-51|0
>ianalumab_VH|DSVSSNSAAWG|IGHV6-1|1|QVQLQQSGPGLVKPSQTLSLTCAISG|IGHV6-1|0|GRIYYRSKWYNSYA|IGHV6-1|2|WIRQSPGRGLEWL|IGHV6-1|1
>ibalizumab_VH|YTFTSYVIH|IGHV1-18|2|QVQLQQSGPEVVKPGASVKMSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|4|GYINPYNDGTDYD|IGHV1-2|6|WVRQKPGQGLDWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|3
>ibentatug_VH|FTFSRYGMS|IGHV3-11|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ATISIGGTYTYYP|IGHV3-23/IGHV3-23D|7|WVRQAPGKRLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>ibritumomab_VH|YTFTSYNMH|IGHV1-3|1|QAYLQQSGAELVRPGASVKMSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|7|GAIYPGNGDTSYN|IGHV5-51|5|WVKQTPRQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|4
>icrucumab_VH|FAFSSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|1|QAQVVESGGGVVQSGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|3|AVIWYDGSNKYYA|IGHV3-33|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>idactamab_VH|GSFSGYYWS|IGHV4-34|0|QVQLQQWGAGLLKPSETLSLTCAVYG|IGHV4-34|0|GEIHHSGGANYN|IGHV4-34|3|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>idarucizumab_VH|FSLTSYIVD|IGHV1-58|5|QVQLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|0|GVIWAGGSTGYN|IGHV3-53/IGHV3-66|5|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>ieramilimab_VH|FTLTNYGMN|IGHV3-20|4|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWINTDTGEPTYA|IGHV7-4-1|2|WVRQARGQRLEWI|IGHV1-58|0
>ifabotuzumab_VH|YTFTGYWMN|IGHV1-2|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GDIYPGSGNTNYD|IGHV1-58|4|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>ifinatamab_VH|YTFTNYVMH|IGHV1-2|2|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GYINPYNDDVKYN|IGHV1-3|7|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>iladatuzumab_VH|YTFSSYWIE|IGHV1-18|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GEILPGGGDTNYN|IGHV1-2|6|WVRQAPGKGLEWI|IGHV1-24|1
>iluzanebart_VH|YSFTSYWIG|IGHV5-51|0|EVQLVQSGAEVKKPGESLKISCKGSG|IGHV5-51|0|GIIYPGDADARYS|IGHV5-51|2|WVRQMPGKGLEWM|IGHV5-10-1/IGHV5-51|0
>imalumab_VH|FTFSIYSMN|IGHV3-21/IGHV3-48|1|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SSIGSSGGTTYYA|IGHV3-11|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>imaprelimab_VH|FSLTSNAVS|IGHV1-58|4|QVTLKESGPVLVKPTETLTLTCTVSG|IGHV2-26|0|AAISSGGTTYYN|IGHV3-53/IGHV3-66|5|WVRQPPGKALEWI|IGHV4-4|1
>imgatuzumab_VH|FTFTDYKIH|IGHV1-69-2|3|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GYFNPNSGYSTYA|IGHV1-2|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>imsidolimab_VH|YTFTNYWMN|IGHV7-4-1|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GMFHPTGDVTRLN|IGHV1-24|9|WVRQAPRQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>imvotamab_VH|YTFISYTMH|IGHV1-3|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GYINPRSGYTHYN|IGHV1-2|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>imvotamab_VH_1|YSFTSYWIG|IGHV5-51|0|EVQLVQSGAEVKKPGESLKISCKGSG|IGHV5-51|0|GIIYPGDSDTRYS|IGHV5-51|0|WVRQMPGKGLEWM|IGHV5-10-1/IGHV5-51|0
>inclacumab_VH|FTFSNYDMH|IGHV3-13|1|EVQLVESGGGLVRPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|SAITAAGDIYYP|IGHV3-13|3|WVRQATGKGLEWV|IGHV3-13|0
>indatuximab_VH|YTFSNYWIE|IGHV1-18|4|QVQLQQSGSELMMPGASVKISCKATG|IGHV7-4-1|5|GEILPGTGRTIYN|IGHV1-2|7|WVKQRPGHGLEWI|IGHV4-4|3
>indusatumab_VH|GSFSGYYWS|IGHV4-34|0|QVQLQQWGAGLLKPSETLSLTCAVFG|IGHV4-34|1|GEINHRGNTNDN|IGHV4-34|3|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>inebilizumab_VH|FTFSSSWMN|IGHV3-21/IGHV3-48|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GRIYPGDGDTNYN|IGHV5-51|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>inezetamab_VH|FTFSRNAMS|IGHV3-23/IGHV3-23D|2|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SATGGSGISTYYA|IGHV3-23/IGHV3-23D|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>inezetamab_VH_1|FTFSDYYMS|IGHV3-11|0|QVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-11|0|SYISSSESIIYYV|IGHV3-11|3|WIRQAPGKCLEWI|IGHV3-11|2
>infliximab_VH|FIFSNHWMN|IGHV3-15|3|EVKLEESGGGLVQPGGSMKLSCVASG|IGHV3-73|4|AEIRSKSINSATHYA|IGHV3-73|7|WVRQSPEKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|2
>inotuzumab_VH|YRFTNYWIH|IGHV5-10-1|3|EVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GGINPGNNYATYR|IGHV1-3|7|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>intetumumab_VH|FTFSRYTMH|IGHV3-13|2|QVQLVESGGGVVQPGRSRRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|1|AVISFDGSNKYYV|IGHV3-30/IGHV3-30-3/IGHV3-30-5|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>iparomlimab_VH|YTFTNYWIH|IGHV1-18|3|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GEIDPYDSYTNYN|IGHV5-10-1|3|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>ipilimumab_VH|FTFSSYTMH|IGHV3-13|1|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|TFISYDGNNKYYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>iratumumab_VH|GSFSAYYWS|IGHV4-34|1|QVQLQQWGAGLLKPSETLSLTCAVYG|IGHV4-34|0|GDINHGGGTNYN|IGHV4-34|3|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>isatuximab_VH|YTFTDYWMQ|IGHV1-69-2|2|QVQLVQSGAEVAKPGTSVKLSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|3|GTIYPGDGDTGYA|IGHV5-51|4|WVKQRPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|3
>iscalimab_VH|FTFSSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|0|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AVISYEESNRYHA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>isecarosmab_VH|RTVSSYAMG|IGHV3-23/IGHV3-23D|3|DVQLVESGGGVVQPGGSLRLSCAASG|IGHV3-NL1|1|AGISRSAERTYYV|IGHV3-23/IGHV3-23D|7|WFRQAPGKEREFV|IGHV3-49|3
>isecarosmab_VH_1|FTFSSFGMS|IGHV3-23/IGHV3-23D|2|EVQLVESGGGVVQPGNSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|2|SSISGSGSDTLYA|IGHV3-23/IGHV3-23D|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>ispectamab_VH|FNISAPGIH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|5|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GFINPAGGYTDYA|IGHV1-46|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>istiratumab_VH|FMFSRYPMH|IGHV3-13|3|EVQLLQSGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|1|GSISGSGGATPYA|IGHV3-23/IGHV3-23D|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>istiratumab_VH_1|FTFDDYAMH|IGHV3-9|0|QVQLVQSGGGLVQPGGSLRLSCAASG|IGHV3-11|2|AGISWDSGSTGYA|IGHV3-9|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>itepekimab_VH|FTFSRSAMN|IGHV3-35|2|EVQLVESGGNLEQPGGSLRLSCTASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|3|SGISGSGGRTYYA|IGHV3-23/IGHV3-23D|2|WVRRAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>itolizumab_VH|FKFSRYAMS|IGHV3-23/IGHV3-23D|2|EVQLVESGGGLVKPGGSLKLSCAASG|IGHV3-15/IGHV3-21|1|ATISSGGSYIYYP|IGHV3-11|5|WVRQAPGKRLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>ivicentamab_VH|FSLSNYNMG|IGHV3-11|5|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SVIDASGTTYYA|IGHV3-53/IGHV3-66|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>ivicentamab_VH_1|FSLSYNAMN|IGHV3-21/IGHV3-48|5|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SIIFASGRTDYA|IGHV3-53/IGHV3-66|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>ivonescimab_VH|YTFTNYGMN|IGHV7-4-1|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GWINTYTGEPTYA|IGHV7-4-1|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>ivonescimab_VH_1|FAFSSYDMS|IGHV3-13|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ATISGGGRYTYYP|IGHV3-23/IGHV3-23D|6|WVRQAPGKGLDWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>ivuxolimab_VH|FTFSSYSMN|IGHV3-21/IGHV3-48|0|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SYISSSSSTIDYA|IGHV3-48|1|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>ixekizumab_VH|YSFTDYHIH|IGHV1-69-2|3|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GVINPMYGTTDYN|IGHV1-2|6|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>izalontamab_VH|FSLTNYGVH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|5|QVQLKQSGPGLVQPSQSLSITCTVSG|IGHV4-30-4/IGHV4-31|5|GVIWSGGNTDYN|IGHV3-53/IGHV3-66|5|WVRQSPGKGLEWL|IGHV1-24|2
>izalontamab_VH_1|FTFSSYWMS|IGHV3-7|0|QVQLQESGGGLVKPGGSLRLSCAASG|IGHV3-11|1|ANINRDGSASYYV|IGHV3-7|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>izastobart_VH|FTFSSYAMH|IGHV3-30/IGHV3-30-3/IGHV3-64|0|EVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|0|GRIKSKAQGGTTDYA|IGHV3-15|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>izeltabart_VH|FTFSSYWMH|IGHV3-74|0|EVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|0|GEIIPIFGHTNYN|IGHV1-69/IGHV1-69D|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>izenivetmab_VH|FTFSNYWMH|IGHV3-74|1|EVQLVESGGDLVKPGGSLRLSCVASG|IGHV3-15/IGHV3-21|2|ARIDPYGGGTKHN|IGHV1-2|7|WVRQAPGKGLQWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>izuralimab_VH|YTFTGYYMH|IGHV1-2|0|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWINPHSGGTNYA|IGHV1-2|2|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>izuralimab_VH_1|FTFSNYWMN|IGHV3-15|2|EVQLVESGGGLVKPGGSLRLSCVASG|IGHV3-15/IGHV3-21|1|AEIRLYSNNYATHYA|IGHV3-73|7|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>labetuzumab_VH|FDFTTYWMS|IGHV3-7|3|EVQLVESGGGVVQPGRSLRLSCSASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|2|GEIHPDSSTINYA|IGHV1-2|6|WVRQAPGKGLEWI|IGHV1-24|1
>lacnotuzumab_VH|YSITSDYAWN|IGHV4-38-2|4|QVQLQESGPGLVKPSQTLSLTCTVSD|IGHV4-30-4/IGHV4-31|1|GYISYSGSTSYN|IGHV4-28/IGHV4-30-4/IGHV4-31|2|WIRQFPGKGLEWM|IGHV1-24|2
>lacutamab_VH|YTFTTAGMQ|IGHV1-18|4|QIQLVQSGSELKKPGASVKVSCKASG|IGHV7-4-1|1|GWINSHSGVPKYA|IGHV7-4-1|5|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>ladiratuzumab_VH|LTIEDYYMH|IGHV1-69-2|3|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWIDPENGDTEYG|IGHV1-45|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>lafuvitug_VH|YNIRDYFIH|IGHV1-69-2|5|QVQLLQSGAAVTKPGASVRVSCEASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|5|GWINPKTGQPNNP|IGHV7-4-1|6|WWRQAPGQGLQWV|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|3
>lampalizumab_VH|YTFTNYGMN|IGHV7-4-1|2|EVQLVQSGPELKKPGASVKVSCKASG|IGHV7-4-1|2|GWINTYTGETTYA|IGHV7-4-1|3|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>lanadelumab_VH|FTFSHYIMM|IGHV3-11|3|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SGIYSSGGITVYA|IGHV3-20|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>lancastotug_VH|HSFTSDYAWS|IGHV4-38-2|6|DVQLQESGPGLVKPSQTLSLTCTVSG|IGHV4-30-4/IGHV4-31|1|GYISYSDSTNYN|IGHV4-59/IGHV4-61|2|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>landogrozumab_VH|LTFSRYPMS|IGHV3-11|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SAITSSGGSTYYS|IGHV3-23/IGHV3-23D|3|WVRQAPGKGLVWV|IGHV3-74|0
>laprituximab_VH|YTFTSYWMQ|IGHV1-3|2|QVQLVQSGAEVAKPGASVKLSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|2|GTIYPGDGDTTYT|IGHV5-51|4|WVKQRPGQGLECI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|4
>larcaviximab_VH|SSFTGFSMN|IGHV1-2|5|EVQLQESGPELEMPGASVKISCKASG|IGHV7-4-1|7|GNIDTYYGGTTYN|IGHV1-18|7|WVKQSNGKSLEWI|IGHV4-4|4
>latikafusp_VH|FTVDDYSMS|IGHV3-20|2|EVQLVESGGSVVRPGGSLRLSCAASG|IGHV3-20|1|SGINWNAGRTRYA|IGHV3-20|3|WVRQVPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>latozinemab_VH|YSISSGYYWG|IGHV4-38-2|0|QVQLQESGPGLVKPSETLSLTCAVSG|IGHV4-38-2|0|GTIYHSGSTYYN|IGHV4-30-2|1|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>lebrikizumab_VH|FSLSAYSVN|IGHV3-21/IGHV3-48|4|QVTLRESGPALVKPTQTLTLTCTVSG|IGHV2-70|1|AMIWGDGKIVYN|IGHV2-70|8|WIRQPPGKALEWL|IGHV2-26/IGHV2-5/IGHV2-70|0
>lecanemab_VH|FTFSSFGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|1|EVQLVESGGGLVQPGGSLRLSCSASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|AYISSGSSTIYYG|IGHV3-48|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>lemalesomab_VH|YTFRNYGMN|IGHV7-4-1|3|QVQLQESGPELKKPGETVKISCKASG|IGHV7-4-1|6|GWINTYTGEPTYA|IGHV7-4-1|2|WVKQAPGKGLKWM|IGHV1-24|2
>lemzoparlimab_VH|LTFERAWMN|IGHV3-15|4|EVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|0|GRIKRKTDGETTDYA|IGHV3-15|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>lenvervimab_VH|FSLTKYKMT|IGHV1-2|6|EVQLVESGGGLVKPGGSLRLSCSASG|IGHV3-15/IGHV3-21|1|SSISSTSRDIDYA|IGHV3-21|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>lenzilumab_VH|YSFTNYYIH|IGHV1-2|3|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWINAGNGNTKYS|IGHV1-3|0|WVRQAPGQRLEWM|IGHV1-3|0
>lepunafusp_VH|YSFMNYWLG|IGHV5-51|3|EVQLVQSGAEVKKPGESLKISCKGSG|IGHV5-51|0|GDIYPGGDYPTYS|IGHV5-51|6|WVRQMPGKGLEWM|IGHV5-10-1/IGHV5-51|0
>lerdelimumab_VH|FTFSSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|0|EVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|1|AVIWYDGSNKYYA|IGHV3-33|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>leronlimab_VH|YTFSNYWIG|IGHV5-51|3|EVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|0|GDIYPGGNYIRNN|IGHV5-51|7|WVRQAPGKGLEWI|IGHV1-24|1
>lesabelimab_VH|YSISSGYYWG|IGHV4-38-2|0|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GIIYPSGGGTNYA|IGHV1-46|3|WIRQAPGKGLEWI|IGHV3-11|1
>lesofavumab_VH|YSFTSQWIG|IGHV5-51|1|EVQLVQSGAEVKKPGESLKISCKVSG|IGHV5-51|1|GMMYPGESETIYS|IGHV5-51|5|WVRQMPGKGLEWI|IGHV4-4|1
>letaplimab_VH|GSISSYYWS|IGHV4-59|0|QVQLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|0|GYIYYSGSTNYN|IGHV4-59/IGHV4-61|0|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>letolizumab_VH|FTFNWELMG|IGHV3-11|5|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SGIEGPGDVTYYA|IGHV3-23/IGHV3-23D|5|WARQAPGKGLEWV|IGHV3-11|1
>levilimab_VH|FTFSSYYMS|IGHV3-11|1|QVQLVQSGGGLVQPGGSLRLSCAASG|IGHV3-11|2|SGIYSDGTTHYG|IGHV3-53/IGHV3-66|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>lexatumumab_VH|FTFDDYGMS|IGHV3-20|0|EVQLVQSGGGVERPGGSLRLSCAASG|IGHV3-20|2|SGINWNGGSTGYA|IGHV3-20|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>libivirumab_VH|FAFSDYSIN|IGHV3-21/IGHV3-48|3|QVQLVESGGGVVRPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|1|AIISYDGRITYYR|IGHV3-30/IGHV3-30-3/IGHV3-30-5|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>licaminlimab_VH|FTISRSYWIC|IGHV4-28|6|EVQLVESGGGSVQPGGSLRLSCTASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|2|GCIYGDNDITPLYA|IGHV6-1|10|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>lifastuzumab_VH|FSFSDFAMS|IGHV3-11|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ATIGRVAFHTYYP|IGHV3-23/IGHV3-23D|9|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>ligelizumab_VH|YTFSWYWLE|IGHV3-7|4|QVQLVQSGAEVMKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|1|GEIDPGTFTTNYN|IGHV5-10-1|6|WVRQAPGHGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>ligufalimab_VH|YTFTSYWMN|IGHV7-4-1|1|QVQLVQSGAEVVKPGASVKLSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|2|GMIDPSDSETHNA|IGHV5-10-1|5|WVRQRPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>lilotomab_VH|YSFTDYNMY|IGHV1-69-2|3|EIQLQQSGPELVKPGASVKVSCKASG|IGHV7-4-1|5|GYIDPYNGDTTYN|IGHV1-18|6|WVKQSHGKSLEWI|IGHV4-4|4
>linavonkibart_VH|FTFSSFSMD|IGHV3-21/IGHV3-48|2|EVQLVESGGGLVQPGGSLRLSCTASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|SYISPSADTIYYA|IGHV3-11|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>lintuzumab_VH|YTFTDYNMH|IGHV1-69-2|1|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GYIYPYNGGTGYN|IGHV1-18|6|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>linvoseltamab_VH|FTFSNFWMT|IGHV3-15|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ANMNQDGSEKYYV|IGHV3-7|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>linvoseltamab_VH_1|FTFDDYSMH|IGHV3-43|1|EVQLVESGGGLVQPGRSLRLSCAASG|IGHV3-9|0|SGISWNSGSKGYA|IGHV3-9|1|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>lipustobart_VH|YTFTSYYMY|IGHV1-46|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GGVNPSNGGTNFN|IGHV1-2|6|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>lirentelimab_VH|FSLTIYGAH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|5|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GVIWAGGSTNYN|IGHV4-34|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>lirilumab_VH|GTFSFYAIS|IGHV1-69/IGHV1-69D|1|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GGFIPIFGAANYA|IGHV1-69/IGHV1-69D|2|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>litifilimab_VH|FTFSTYTMS|IGHV3-11|2|DVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-11|1|ATISPGDSFGYYYP|IGHV6-1|13|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>livmoniplimab_VH|YRFTSYYID|IGHV1-18|3|QVQLVQPGAEVRKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|2|GRIDPEDAGTKYA|IGHV1-2|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>lixudebart_VH|FSFSSYGMN|IGHV3-21/IGHV3-48|2|EVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|0|SSISPSGSYFYYA|IGHV3-21|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>lodapolimab_VH|GTFSSYAIS|IGHV1-69/IGHV1-69D|0|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GGIIPIFGTANYA|IGHV1-69/IGHV1-69D|0|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>lodelcizumab_VH|YTFSTMYMS|IGHV3-11|3|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GRIDPANEHTNYA|IGHV1-2|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>lokivetmab_VH|FTFSNYGMS|IGHV3-11|2|EVQLVESGGDLVKPGGSLRLSCVASG|IGHV3-15/IGHV3-21|2|ATISYGGSYTYYP|IGHV3-30/IGHV3-30-3/IGHV3-30-5|5|WVRQAPGKGLQWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>lomtegovimab_VH|FTFRRYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|2|QVQLVESGGGVVQPGRSLRLSCAATG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|1|AGILFDGSNKYYV|IGHV3-30/IGHV3-30-3/IGHV3-30-5|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>lomvastomig_VH|FSFSSYTMS|IGHV3-23/IGHV3-23D|2|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|ATISGGGRDIYYP|IGHV3-11|7|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>lomvastomig_VH_1|FNIKTTYMH|IGHV1-2|6|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GRIDPADDNTKYA|IGHV5-10-1|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>loncastuximab_VH|YTFTSNWMH|IGHV1-3|2|QVQLVQPGAEVVKPGASVKLSCKTSG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|4|GEIDPSDSYTNYN|IGHV5-10-1|2|WVKQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>lonigutamab_VH|YTFTSYYIH|IGHV1-46|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWIWPGDGSTKYA|IGHV1-3|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>lorigerlimab_VH|YSFTSYWMN|IGHV5-10-1|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GVIHPSDSETWLD|IGHV5-10-1|6|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>lorigerlimab_VH_1|FTFSSYTMH|IGHV3-13|1|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|TFISYDGSNKHYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>lorukafusp_VH|SSFTGYNMN|IGHV1-2|4|EVQLVQSGAEVEKPGASVKISCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|3|GAIDPYYGGTSYN|IGHV1-2|6|WVRQNIGKSLEWI|IGHV4-4|3
>lorvotuzumab_VH|FTFSSFGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|1|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AYISSGSFTIYYA|IGHV3-48|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>losatuxizumab_VH|YSISRDFAWN|IGHV4-28|5|EVQLQESGPGLVKPSQTLSLTCTVSG|IGHV4-30-4/IGHV4-31|1|GYISYNGNTRYQ|IGHV4-28/IGHV4-30-4/IGHV4-31|5|WIRQPPGKGLEWM|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|1
>lucatumumab_VH|FTFSSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|0|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AVISYEESNRYHA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>lumiliximab_VH|FRFTFNNYYMD|IGHV4-30-4|9|EVQLVESGGGLAKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|1|SRISSSGDPTWYA|IGHV3-11|5|WVRQAPGQGLEWV|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>lumretuzumab_VH|YTFRSSYIS|IGHV1-18|3|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWIYAGTGSPSYN|IGHV1-3|6|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>lumrotatug_VH|FSLTSYGIH|IGHV1-18|4|QVQLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|0|GVIWRGGSTDYN|IGHV3-53/IGHV3-66|5|WLRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|1
>lunaxafusp_VH|YPFTNYGMN|IGHV7-4-1|3|QVQLQQSGPELKKPGETVKISCKASG|IGHV7-4-1|5|GWINTSTGESTFA|IGHV7-4-1|4|WVKQAPGQGLKWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>lunsekimig1_VH|RTFSSYRMG|IGHV3-13|3|DVQLVESGGGVVQPGGSLRLSCAASG|IGHV3-NL1|1|AALSGDGYSTYTA|IGHV3-23/IGHV3-23D|5|WFRQAPGKEREFV|IGHV3-49|3
>lunsekimig1_VH_1|FTFNNYAMK|IGHV3-23/IGHV3-23D|3|EVQLVESGGGVVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|SSITTGGGSTDYA|IGHV3-20|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>lunsekimig2_VH_1|FTFRSFGMS|IGHV3-20|3|EVQLVESGGGVVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|SSISGSGSDTLYA|IGHV3-23/IGHV3-23D|4|WVRQAPGKGPEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>lunsekimig3_VH|FTFADYDYDIG|IGHV2-5|9|EVQLVESGGGVVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|SCISNRDGSTYYA|IGHV3-23/IGHV3-23D|4|WFRQAPGKEREGV|IGHV3-49|3
>lupartumab_VH|FTFSNAWMS|IGHV3-15|0|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SYISSSGSTIYYA|IGHV3-11|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>lusvertikimab_VH|FTLSDYYMA|IGHV3-11|2|QVQLVESGGGLVKPGGSLRLSCAVSG|IGHV3-11|1|STISASGLRTYYP|IGHV3-23/IGHV3-23D|5|WIRQAPGKGLEWV|IGHV3-11|0
>lutikizumab_VH|FIFSRYDMS|IGHV3-11|3|EVQLVESGGGVVQPGRSLRLSCSASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|2|AYISHGGAGTYYP|IGHV3-11|7|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>lutikizumab_VH_1|FTFSMFGVH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|3|QVQLVESGGGVVQPGRSLRLSCTASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|1|AAVSYDGSNKYYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>luvagrobart_VH|FDLSGYDLN|IGHV3-13|5|QVQLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|0|GIVWGDGSSDYN|IGHV4-28/IGHV4-30-4/IGHV4-31|7|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>luveltamab_VH|FNIRTQSIH|IGHV1-24|7|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GDIFPIDGITDYA|IGHV1-2|6|WVRQAPGKGLEWI|IGHV1-24|1
>maftivimab_VH|FTSSSYAMN|IGHV3-21/IGHV3-48|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|STISGMGGSTYYA|IGHV3-23/IGHV3-23D|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>magrolimab_VH|YTFTNYNMH|IGHV1-2|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GTIYPGNDDTSYN|IGHV5-51|5|WVRQAPGQRLEWM|IGHV1-3|0
>manelimab_VH|FTFDDYAMS|IGHV3-20|1|EVQLVESGGGVVRPGGSLRLSCAASG|IGHV3-20|0|SDISWSGSNTNYA|IGHV3-11|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>manfidokimab_VH|YTFTEYTIH|IGHV1-18|3|QVQLVQSGAEVVKPGASVKVSCKTSG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|2|GGINPNNGGTVYN|IGHV1-2|4|WVRQAPGQSLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>margetuximab_VH|FNIKDTYIH|IGHV1-69-2|6|QVQLQQSGPELVKPGASLKLSCTASG|IGHV7-4-1|6|GRIYPTNGYTRYD|IGHV1-2|6|WVKQRPEQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|4
>maridebart_VH|FTFSNYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|1|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AAIWFDASDKYYA|IGHV3-33|4|WVRQAPGEGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>marstacimab_VH|FTFSSYAMS|IGHV3-23/IGHV3-23D|0|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SAISGSGGSTYYA|IGHV3-23/IGHV3-23D|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>masavibart_VH|FTFSNYAMY|IGHV3-23/IGHV3-23D|2|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AVISYDGSNKYYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>matuzumab_VH|YTFTSHWMH|IGHV1-3|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GEFNPSNGRTNYN|IGHV1-2|6|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>mavrilimumab_VH|YTLTELSIH|IGHV1-24|1|QVQLVQSGAEVKKPGASVKVSCKVSG|IGHV1-24|0|GGFDPEENEIVYA|IGHV1-24|4|WVRQAPGKGLEWM|IGHV1-24|0
>mazorelvimab_VH|FTFSGFAMS|IGHV3-23/IGHV3-23D|2|EVQLVESGGGLVQPGGSLILSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|ATISSGGTYTYS|IGHV2-26|7|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>mecbotamab_VH|YSFWGATMN|IGHV1-2|5|EVQLVQSGAEVKKPGATVKISCKVSG|IGHV1-69-2|0|GLIKPSNGGTSYN|IGHV1-46|5|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>melredableukin_VH|FTFSSYAMS|IGHV3-23/IGHV3-23D|0|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SAISGSGGSTYYA|IGHV3-23/IGHV3-23D|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>melrilimab_VH|FTFSIYDMI|IGHV3-13|2|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SSIRGEGGGTYYA|IGHV3-23/IGHV3-23D|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>mepolizumab_VH|FSLTSYSVH|IGHV1-24|5|QVTLRESGPALVKPTQTLTLTCTVSG|IGHV2-70|1|GVIWASGGTDYN|IGHV4-28/IGHV4-30-4/IGHV4-31|5|WVRQPPGKGLEWL|IGHV4-4|1
>metelimumab_VH|FTFSSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|0|EVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|1|AVISYDGSIKYYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|1|WVRQAPGKELEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>mevonlerbart_VH|FTFSSYAMS|IGHV3-23/IGHV3-23D|0|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SAISGRGYNADYA|IGHV3-23/IGHV3-23D|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>mezagitamab_VH|FTFDDYGMS|IGHV3-20|0|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SDISWNGGKTHYV|IGHV3-20|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>mibavademab_VH|FTFSTYAMY|IGHV3-23/IGHV3-23D|2|QVQLVESGGSVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|1|AVLYSDGSNKYYI|IGHV3-30/IGHV3-30-3/IGHV3-30-5|4|WVRQTPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>milatuzumab_VH|YTFTNYGVN|IGHV1-18|3|QVQLQQSGSELKKPGASVKVSCKASG|IGHV7-4-1|1|GWINPNTGEPTFD|IGHV7-4-1|4|WIKQAPGQGLQWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|3
>mipasetamab_VH|FTFSSYGMS|IGHV3-23/IGHV3-23D|1|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|ATISSGGSYTYYP|IGHV3-NL1|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>miptenalimab_VH|FSLSTSDMGVG|IGHV2-5|2|QVTLVESGGGVVQPGRSLRLSCAFSG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|2|AHIWWDDVKRYN|IGHV2-5|5|WIRQAPGKGLEWV|IGHV3-11|0
>mirikizumab_VH|YKFTRYVMH|IGHV1-2|3|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GYINPYNDGTNYN|IGHV1-2|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>miromavimab_VH|YAFTSSWMH|IGHV1-3|3|QVQLQQPGSVLVRPGASVKLSCKTSG|IGHV7-4-1|7|GQTHPNSGYTNYN|IGHV1-2|5|WAKQRPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|4
>mirvetuximab_VH|YTFTGYFMN|IGHV1-2|2|QVQLVQSGAEVVKPGASVKISCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|2|GRIHPYDGDTFYN|IGHV1-2|6|WVKQSPGQSLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|4
>mirzotamab_VH|YSITSGYSWH|IGHV4-38-2|3|EVQLQESGPGLVKPSETLSLTCAVTG|IGHV4-38-2|2|GYIHSSGSTNYN|IGHV4-59/IGHV4-61|2|WIRQFPGNGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|3
>mitazalimab_VH|FTFSTYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|1|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SYISGGSSYIFYA|IGHV3-21|4|WVRQAPGKGLEWL|IGHV1-24|1
>modakafusp_VH|YTFTDSVMN|IGHV1-69-2|3|EVQLVQSGAEVKKPGATVKISCKVSG|IGHV1-69-2|0|GWIDPEYGRTDVA|IGHV1-24|6|WVQQAPGKGLEWM|IGHV1-69-2|0
>modotuximab_VH|YTFTSHWMH|IGHV1-3|2|QVQLQQPGAELVEPGGSVKLSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|7|GEINPSSGRNNYN|IGHV1-2|5|WVKQRPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|3
>mogamulizumab_VH|FIFSNYGMS|IGHV3-11|3|EVQLVESGGDLVQPGRSLRLSCAASG|IGHV3-9|1|ATISSASTYSYYP|IGHV3-21|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>monalizumab_VH|YTFTSYWMN|IGHV7-4-1|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GRIDPYDSETHYA|IGHV5-10-1|4|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>mosunetuzumab_VH|YTFTNYYIH|IGHV1-2|2|EVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GWIYPGDGNTKYN|IGHV1-3|4|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>mosunetuzumab_VH_1|YTFTSYNMH|IGHV1-3|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GAIYPGNGDTSYN|IGHV5-51|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>motavizumab_VH|FSLSTAGMSVG|IGHV2-5|3|QVTLRESGPALVKPTQTLTLTCTFSG|IGHV2-70|0|ADIWWDDKKHYN|IGHV2-70|5|WIRQPPGKALEWL|IGHV2-26/IGHV2-5/IGHV2-70|0
>moxetumomab_VH|FAFSIYDMS|IGHV3-11|3|EVQLVESGGGLVKPGGSLKLSCAASG|IGHV3-15/IGHV3-21|1|AYISSGGGTTYYP|IGHV3-11|5|WVRQTPEKCLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|3
>mupadolimab_VH|YTFTSYWIT|IGHV1-18|2|QVQLVQSGAEVEKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GDIYPGSGNTNYN|IGHV1-58|4|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>murlentamab_VH|YTFTSYHIH|IGHV1-18|2|QVRLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GWIYPGDDSTKYS|IGHV5-51|4|WVRQAPGQRLEWM|IGHV1-3|0
>muromonab_VH|YTFTRYTMH|IGHV1-2|2|QVQLQQSGAELARPGASVKMSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|5|GYINPSRGYTNYN|IGHV1-2|5|WVKQRPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|3
>muzastotug_VH|YSISSGYHWS|IGHV4-38-2|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ARIDWDDDKYYS|IGHV2-70|1|WIRQAPGKGLEWL|IGHV3-11|1
>nadecnemab_VH|FTFSSYAMS|IGHV3-23/IGHV3-23D|0|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SVISGSGGSTYYA|IGHV3-23/IGHV3-23D|1|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>nadunolimab_VH|YAFTSSWMN|IGHV7-4-1|3|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GRIYPGDGNTHYA|IGHV1-2|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>namilumab_VH|YPFTDYLLH|IGHV1-69-2|3|QVQLVQSGAEVKKPGASVKVSCKAFG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GWLNPYSGDTNYA|IGHV1-2|4|WVRQAPGQGLEWV|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>naptumomab_VH|YSFTGYYMH|IGHV1-2|1|EVQLQQSGPDLVKPGASVKISCKASG|IGHV7-4-1|6|GRINPNNGVTLYN|IGHV1-2|4|WVKQSPGKGLEWI|IGHV4-4|2
>naratuximab_VH|FSLTTSGVS|IGHV1-58|5|QVQVQESGPGLVAPSQTLSITCTVSG|IGHV4-30-4/IGHV4-31|3|GVIWGDGSTNYH|IGHV4-34|5|WVRQPPGKGLEWL|IGHV4-4|1
>narlumosbart_VH|FTFSSYAMS|IGHV3-23/IGHV3-23D|0|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SGITGSGGSTYYA|IGHV3-23/IGHV3-23D|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>narnatumab_VH|FTFSSYLMT|IGHV3-13|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ANIKQDGSEKYYV|IGHV3-7|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>narsoplimab_VH|FSLSRGKMGVS|IGHV2-26|3|QVTLKESGPVLVKPTETLTLTCTVSG|IGHV2-26|0|AHIFSSDEKSYR|IGHV2-26|2|WIRQPPGKALEWL|IGHV2-26/IGHV2-5/IGHV2-70|0
>natalizumab_VH|FNIKDTYIH|IGHV1-69-2|6|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GRIDPANGYTKYD|IGHV5-10-1|5|WVRQAPGQRLEWM|IGHV1-3|0
>navicixizumab_VH|YSFTAYYIH|IGHV1-2|3|QVQLVQSGAEVKKPGASVKISCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GYISNYNRATNYN|IGHV1-18|5|WVKQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>navicixizumab_VH_1|YTFTNYWMH|IGHV1-2|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GDINPSNGRTSYK|IGHV1-46|4|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>navivumab_VH|YSFSTYGVS|IGHV1-18|4|QVQLVQSGAEVKKPGASVKVSCKTSG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GWISAYTGITDYA|IGHV1-18|3|WVRQAPGQGPEWV|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>naxitamab_VH|FSVTNYGVH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|5|QVQLVESGPGVVQPGRSLRISCAVSG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|3|GVIWAGGITNYN|IGHV4-34|5|WVRQPPGKGLEWL|IGHV4-4|1
>nebratamig1_VH|FTISSYHMQ|IGHV3-13|3|SRSLVESGGGLVQPGGSLRLSCTASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|4|GTISSGGNVYYA|IGHV3-53/IGHV3-66|5|WVRQAPGKGLEYI|IGHV3-64|1
>nebratamig1_VH_1|IDLNTYDMI|IGHV3-13|6|SQSVEESGGGLVQPGGSLRLSCTASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|6|GIITYSGSRYYA|IGHV4-28/IGHV4-30-4/IGHV4-31|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>nebratamig2_VH|FTISRYHMT|IGHV3-11|4|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|GHIYVNNDDTDYA|IGHV1-18|7|WVRQAPGKGLEWI|IGHV1-24|1
>nebratamig2_VH_1|FTISTNAMS|IGHV3-23/IGHV3-23D|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GVITGRDITYYA|IGHV3-53/IGHV3-66|6|WVRQAPGKGLEWI|IGHV1-24|1
>necitumumab_VH|GSISSGDYYWS|IGHV4-30-4|0|QVQLQESGPGLVKPSQTLSLTCTVSG|IGHV4-30-4/IGHV4-31|0|GYIYYSGSTDYN|IGHV4-28/IGHV4-30-4/IGHV4-31|1|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>negalstobart_VH|GSIYSESYYWG|IGHV4-39|2|QLQLQESGPGLVKPSETLSLTCTVSG|IGHV4-39|0|GSIVYSGYTYYN|IGHV4-39|2|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>nelistotug_VH|GTFVEYAIS|IGHV1-69/IGHV1-69D|2|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GGIIPAFGTAQYA|IGHV1-69/IGHV1-69D|2|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>nelmastobart_VH|YTFTHYNMD|IGHV1-2|3|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GYIYPSNGGTGYN|IGHV1-2|6|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>nemolizumab_VH|YTFTGYIMN|IGHV1-2|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GLINPYNGGTDYN|IGHV1-2|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>nepuvibart_VH|FTFSDYYMS|IGHV3-11|0|QVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-11|0|SYITYSGSTIYYA|IGHV3-11|2|WIRQAPGKGLEWV|IGHV3-11|0
>nesvacumab_VH|FTFSSYDIH|IGHV3-13|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SAIGPAGDTYYP|IGHV3-13|1|WVRQATGKGLEWV|IGHV3-13|0
>netakimab_VH|GTFATSPMG|IGHV3-35|5|QVQLVQSGGGLVQAGGSLRLSCAASG|IGHV3-11|3|AAISPSGGDRIYA|IGHV3-23/IGHV3-23D|5|WLRQAPGKGTEFV|IGHV3-11|3
>nezastomig_VH|FTFSSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|0|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AFMSYDGSNKFYS|IGHV3-30/IGHV3-30-3/IGHV3-30-5|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>nezastomig_VH_1|GSISSYYWS|IGHV4-59|0|QVQLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|0|GYIYYSGITHYN|IGHV4-28/IGHV4-30-4/IGHV4-31|2|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>nezutatug_VH|YSITSGYSWH|IGHV4-38-2|3|QVQLQESGPGLVKPSQTLSLTCTVSG|IGHV4-30-4/IGHV4-31|0|GSIRYSGGTDYN|IGHV4-39|3|WIRQHPGKGLEWI|IGHV4-31|0
>nimacimab_VH|YEFSYYWMN|IGHV3-21/IGHV3-48|4|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GQIYPGDGETKYA|IGHV1-24|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>nimotuzumab_VH|YTFTNYYIY|IGHV1-18|3|QVQLQQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|1|GGINPTSGGSNFN|IGHV1-2|5|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>nipocalimab_VH|FTFSTYAMG|IGHV3-23/IGHV3-23D|2|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SSIGASGSQTRYA|IGHV3-11|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>nirsevimab_VH|GLLEDYIIN|IGHV1-69/IGHV1-69D|6|QVQLVQSGAEVKKPGSSVMVSCQASG|IGHV1-69/IGHV1-69D|2|GGIIPVLGTVHYG|IGHV1-69/IGHV1-69D|5|WVRQAPGQGPEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>nisevokitug_VH|GTFSSYAIS|IGHV1-69/IGHV1-69D|0|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GGIIPIFGTANYA|IGHV1-69/IGHV1-69D|0|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>nivatrotamab_VH|FSVTNYGVH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|5|QVQLVESGPGVVQPGRSLRISCAVSG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|3|GVIWAGGITNYN|IGHV4-34|5|WVRQPPGKGLEWL|IGHV4-4|1
>nivatrotamab_VH_1|YTFTRYTMH|IGHV1-2|2|QVQLVQSGGGVVQPGRSLRLSCKASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|2|GYINPSRGYTNYN|IGHV1-2|5|WVRQAPGKCLEWI|IGHV1-24|2
>nivolumab_VH|ITFSNSGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|3|QVQLVESGGGVVQPGRSLRLDCKASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|2|AVIWYDGSKRYYA|IGHV3-33|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>nofazinlimab_VH|FTFTTYYIS|IGHV1-18|3|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GYINMGSGGTNYN|IGHV1-2|4|WVRQAPGQGLEYL|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>nolavetbart_VH|FSIKSSFIH|IGHV1-58|6|EVTLQESGPGLVKPSQTLSLTCVASG|IGHV4-30-4/IGHV4-31|4|GRIDPAFGATEYN|IGHV1-2|6|WLRQRPGRGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|3
>nurulimab_VH|FTFSSYTMH|IGHV3-13|1|EVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|1|TFISYDGNNKYYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>oberotatug_VH|FTYSNAWMS|IGHV3-15|1|EVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|0|GRIKSKTDGGTTDYA|IGHV3-15|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>obertamig_VH|DSVFNNNAAWS|IGHV6-1|4|QVQLQQSGPRLVRPSQTLSLTCAISG|IGHV6-1|2|GRTYYRSKWLYDYA|IGHV6-1|2|WIRQSPSRGLEWL|IGHV6-1|0
>obertamig_VH_1|DSVSSNSAAWN|IGHV6-1|0|QVQLQQSGPGLVKPSQTLSLTCAISG|IGHV6-1|0|GRTYYRSKWYNDYA|IGHV6-1|0|WIRQSPSRGLEWL|IGHV6-1|0
>obexelimab_VH|YTFTSYVMH|IGHV1-3|1|EVQLVESGGGLVKPGGSLKLSCAASG|IGHV3-15/IGHV3-21|1|GYINPYNDGTKYN|IGHV1-2|6|WVRQAPGKGLEWI|IGHV1-24|1
>obiltoxaximab_VH|YAFSSSWMN|IGHV3-21/IGHV3-48|4|QVQLQQSGPELKKPGASVKVSCKDSG|IGHV7-4-1|3|GRIYPGDGDTNYN|IGHV5-51|4|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>obinutuzumab_VH|YAFSYSWIN|IGHV1-8|5|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GRIFPGDGDTDYN|IGHV5-51|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>obrindatamab_VH|FTFSSFGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AYISSDSSAIYYA|IGHV3-48|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>obrindatamab_VH_1|FTFSTYAMN|IGHV3-21/IGHV3-48|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GRIRSKYNNYATYYA|IGHV3-73|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>ocaratuzumab_VH|RTFTSYNMH|IGHV1-3|2|EVQLVQSGAEVKKPGESLKISCKGSG|IGHV5-51|0|GAIYPLTGDTSYN|IGHV1-46|6|WVRQMPGKGLEWM|IGHV5-10-1/IGHV5-51|0
>ociperlimab_VH|FTFSDYYMY|IGHV3-11|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AYITKGGGSTYYP|IGHV3-23/IGHV3-23D|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>ocrelizumab_VH|YTFTSYNMH|IGHV1-3|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GAIYPGNGDTSYN|IGHV5-51|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>odesivimab_VH|FTFSSYDMH|IGHV3-13|0|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SAIGTAGDTYYP|IGHV3-13|0|WVRQATGKGLEWV|IGHV3-13|0
>odronextamab_VH|FTFNDYAMH|IGHV3-9|1|EVQLVESGGGLVQPGRSLRLSCVASG|IGHV3-49|1|SVISWNSDSIGYA|IGHV3-9|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>odronextamab_VH_1|FTFDDYTMH|IGHV3-43|0|EVQLVESGGGLVQPGRSLRLSCAASG|IGHV3-9|0|SGISWNSGSIGYA|IGHV3-9|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>ofatumumab_VH|FTFNDYAMH|IGHV3-9|1|EVQLVESGGGLVQPGRSLRLSCAASG|IGHV3-9|0|STISWNSGSIGYA|IGHV3-9|1|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>ogalvibart_VH|FTFSSYAMH|IGHV3-30/IGHV3-30-3/IGHV3-64|0|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AVIPFDGRNKYYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>olaratumab_VH|GSINSSSYYWG|IGHV4-39|1|QLQLQESGPGLVKPSETLSLTCTVSG|IGHV4-39|0|GSFFYTGSTYYN|IGHV4-39|3|WLRQSPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|2
>oleclumab_VH|FTFSSYAYS|IGHV3-23/IGHV3-23D|1|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SAISGSGGRTYYA|IGHV3-23/IGHV3-23D|1|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>olendalizumab_VH|YTFTDYSMD|IGHV1-69-2|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GAIHLNTGYTNYN|IGHV1-2|6|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>olinvacimab_VH|YTFSSYWMH|IGHV3-74|1|QMQLVQSGAEVKKPGASVKLSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|2|GEINPGNGHTNYN|IGHV1-2|5|WVRQAPGQRLEWM|IGHV1-3|0
>oloctinebart_VH|YSFTNYYMH|IGHV1-2|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWIYPGSGNTNYN|IGHV1-58|3|WVRQAPGQRLEWM|IGHV1-3|0
>olokizumab_VH|FNFNDYFMN|IGHV3-11|4|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AQMRNKNYQYGTYYA|IGHV3-72|8|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>omalizumab_VH|YSITSGYSWN|IGHV4-38-2|3|EVQLVESGGGLVQPGGSLRLSCAVSG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|ASITYDGSTNYN|IGHV4-39|4|WIRQAPGKGLEWV|IGHV3-11|0
>omburtamab_VH|YTFTNYDIN|IGHV1-8|1|QVQLQQSGAELVKPGASVKLSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|4|GWIFPGDGSTQYN|IGHV1-3|6|WVRQRPEQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|3
>omodenbamab_VH|FTFSTYGMS|IGHV3-11|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SSITGSGRSTFYA|IGHV3-23/IGHV3-23D|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>omoprubart_VH|HIFTDFYMQ|IGHV1-69-2|4|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GEILPGTGHTEYA|IGHV1-2|6|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>onartuzumab_VH|YTFTSYWLH|IGHV1-3|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GMIDPSNSDTRFN|IGHV5-10-1|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>onfekafusp_VH|FTFSSFSMS|IGHV3-21/IGHV3-48|2|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SSISGSSGTTYYA|IGHV3-23/IGHV3-23D|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>ongericimab_VH|FSISSYGIH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|3|QVQLQESGPGLVKPSQTLSLTCTVSG|IGHV4-30-4/IGHV4-31|0|GVIWRGGITDYN|IGHV3-53/IGHV3-66|6|WIRQSPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|1
>ontamalimab_VH|YTFTSYGIN|IGHV1-18|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWISVYSGNTNYA|IGHV1-18|2|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>ontuxizumab_VH|YTFTDYVIH|IGHV1-69-2|2|QVQLQESGPGLVRPSQTLSLTCTASG|IGHV4-30-4/IGHV4-31|2|GYINPYDDDTTYN|IGHV5-51|6|WVKQPPGRGLEWI|IGHV4-4|2
>onvatilimab_VH|GTFSSYAIS|IGHV1-69/IGHV1-69D|0|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GGIIPIFGTANYA|IGHV1-69/IGHV1-69D|0|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>opelkibart_VH|YSFTNYWIG|IGHV5-51|1|EVQLVQSGAEVKKPGESLKISCKGSG|IGHV5-51|0|AIINPRDSDTRYR|IGHV5-51|4|WVRQMPGKGLEWM|IGHV5-10-1/IGHV5-51|0
>opicinumab_VH|FTFSAYEMK|IGHV3-11|3|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SVIGPSGGFTFYA|IGHV1-46|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>oportuzumab_VH|YTFTNYGMN|IGHV7-4-1|2|EVQLVQSGPGLVQPGGSVRISCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|4|GWINTYTGESTYA|IGHV7-4-1|3|WVKQAPGKGLEWM|IGHV1-24|1
>opucolimab_VH|FTFSSYTMN|IGHV3-21/IGHV3-48|1|EVQLVQSGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|1|SSISSGSDYLYYA|IGHV3-21|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>ordesekimab_VH|YFFTTYWIG|IGHV5-51|2|EVQLVQSGAEVKKPGESLKISCKVSG|IGHV5-51|1|GIIYPGDSDTRYS|IGHV5-51|0|WVRQMPGKGLEYM|IGHV5-10-1/IGHV5-51|1
>orilanolimab_VH|YTFTSYGIS|IGHV1-18|0|QVQLVQSGAELKKPGASVKLSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|2|GEIYPRSGNTYYN|IGHV1-2|6|WVKQATGQGLEWI|IGHV1-8|2
>ormutivimab_VH|GTFNRYTVN|IGHV1-69/IGHV1-69D|5|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GGIIPIFGTANYA|IGHV1-69/IGHV1-69D|0|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>orticumab_VH|FTFSNAWMS|IGHV3-15|0|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SSISVGGHRTYYA|IGHV3-23/IGHV3-23D|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>osemitamab_VH|YTFTGYNMN|IGHV1-2|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GNIDPYYGGTSYN|IGHV1-2|6|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>osocimab_VH|FTFSQYGMD|IGHV3-30-5/IGHV3-33/IGHV3-NL1|2|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SGIGPSGGSTVYA|IGHV1-46|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>otelixizumab_VH|FTFSSFPMA|IGHV3-13|3|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|STISTSGGRTYYR|IGHV3-23/IGHV3-23D|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>otilimab_VH|FTFSSYWMN|IGHV3-21/IGHV3-48|1|QVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-11|1|SGIENKYAGGATYYA|IGHV3-15|8|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>otlertuzumab_VH|YSFTGYNMN|IGHV1-2|3|EVQLVQSGAEVKKPGESLKISCKGSG|IGHV5-51|0|GNIDPYYGGTTYN|IGHV1-2|6|WVRQMPGKGLEWM|IGHV5-10-1/IGHV5-51|0
>oxelumab_VH|FTFNSYAMS|IGHV3-23/IGHV3-23D|1|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SIISGSGGFTYYA|IGHV3-23/IGHV3-23D|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>ozanezumab_VH|YTFTSYWMH|IGHV1-3|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GNINPSNGGTNYN|IGHV1-2|4|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>ozekibart_VH|LTFPNYGMG|IGHV3-20|4|EVQLLESGGGEVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|1|SAIYWSGGTVYYA|IGHV3-23/IGHV3-23D|4|WFRQAPGKEREFV|IGHV3-49|3
>ozoralizumab_VH|FTFSDYWMY|IGHV3-11|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SEINTNGLITKYP|IGHV3-20|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>ozoralizumab_VH_1|FTFSSFGMS|IGHV3-23/IGHV3-23D|2|EVQLVESGGGLVQPGNSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|SSISGSGSDTLYA|IGHV3-23/IGHV3-23D|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>ozuriftamab_VH|YTFTEYTMH|IGHV1-2|2|EVQLVQSGAEVKKPGESLRISCKGSG|IGHV5-10-1|0|GGINTNNGGTGYN|IGHV1-2|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>pabinafusp_VH|YSFTNYWLG|IGHV5-51|2|EVQLVQSGAEVKKPGESLKISCKGSG|IGHV5-51|0|GDIYPGGDYPTYS|IGHV5-51|6|WVRQMPGKGLEWM|IGHV5-10-1/IGHV5-51|0
>pacanalotamab_VH|YTFTNHIIH|IGHV1-18|4|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GYINPYPGYHAYN|IGHV1-2|7|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>pacanalotamab_VH_1|FTFNKYAMN|IGHV3-21/IGHV3-48|3|EVQLVESGGGLVQPGGSLKLSCAASG|IGHV3-73|0|ARIRSKYNNYATYYA|IGHV3-73|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>pacmilimab_VH|FTFSSYAMS|IGHV3-23/IGHV3-23D|0|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SSIWRNGIVTVYA|IGHV3-20|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>palivizumab_VH|FSLSTSGMSVG|IGHV2-5|2|QVTLRESGPALVKPTQTLTLTCTFSG|IGHV2-70|0|ADIWWDDKKDYN|IGHV2-70|5|WIRQPPGKALEWL|IGHV2-26/IGHV2-5/IGHV2-70|0
>pamrevlumab_VH|FTFSSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|0|EGQLVQSGGGLVHPGGSLRLSCAGSG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|4|SGIGTGGGTYST|IGHV3-13|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>pamvatamig_VH|YTFTTYSMN|IGHV7-4-1|2|QVQLVQSGSELKKPGASVKVSCKASG|IGHV7-4-1|0|GWINTYTGDPTYA|IGHV7-4-1|2|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>pamvatamig_VH_1|YTFTSYGIS|IGHV1-18|0|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWISAYNANTNYA|IGHV1-18|1|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>panitumumab_VH|GSVSSGDYYWT|IGHV4-30-4|2|QVQLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|0|GHIYYSGNTNYN|IGHV4-59/IGHV4-61|2|WIRQSPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|1
>panobacumab_VH|FTFSPYWMH|IGHV3-74|1|EEQVVESGGGFVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|3|SRINSDGSTYYA|IGHV3-53/IGHV3-66|3|WVRQAPGKGLVWV|IGHV3-74|0
>paridiprubart_VH|YSITGGYSWH|IGHV4-38-2|4|QVQLQESGPGLVKPSDTLSLTCAVSG|IGHV4-28|0|GYIHYSGYTDFN|IGHV4-28/IGHV4-30-4/IGHV4-31|4|WIRQPPGKGLEWM|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|1
>parsatuzumab_VH|YTFIDYYMN|IGHV1-69-2|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GDINLDNSGTHYN|IGHV1-2|7|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>pasotuxizumab_VH|FTFSDYYMY|IGHV3-11|1|QVQLVESGGGLVKPGESLRLSCAASG|IGHV3-11|1|AIISDGGYYTYYS|IGHV3-23/IGHV3-23D|7|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>pasotuxizumab_VH_1|FTFNKYAMN|IGHV3-21/IGHV3-48|3|EVQLVESGGGLVQPGGSLKLSCAASG|IGHV3-73|0|ARIRSKYNNYATYYA|IGHV3-73|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>patecibart_VH|FSLTTSGLGVA|IGHV2-5|3|QVTLKESGPTLVKPTQTLTLTCTFSG|IGHV2-5|1|AHIWSDGDTRYY|IGHV2-26|7|WIRQPPGKALEWL|IGHV2-26/IGHV2-5/IGHV2-70|0
>pateclizumab_VH|YTFTSYVIH|IGHV1-18|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GYNNPYNAGTNYN|IGHV1-2|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>patritumab_VH|GSFSGYYWS|IGHV4-34|0|QVQLQQWGAGLLKPSETLSLTCAVYG|IGHV4-34|0|GEINHSGSTNYN|IGHV4-34|0|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>pavurutamab_VH|YTFTNHIIH|IGHV1-18|4|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GYINPYPGYHAYN|IGHV1-2|7|WVRQAPGQCLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>pavurutamab_VH_1|FTFNKYAMN|IGHV3-21/IGHV3-48|3|EVQLVESGGGLVQPGGSLKLSCAASG|IGHV3-73|0|ARIRSKYNNYATYYA|IGHV3-73|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>pelgifatamab_VH|FAFSRYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|2|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AVIWYDGSNKYYA|IGHV3-33|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>pembrolizumab_VH|YTFTNYYMY|IGHV1-2|2|QVQLVQSGVEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GGINPSNGGTNFN|IGHV1-2|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>pemivibart_VH|FTFGSYEMN|IGHV3-21/IGHV3-48|2|EVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|0|SSISEDGYSTYYP|IGHV3-43|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>penpulimab_VH|FAFSSYDMS|IGHV3-13|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ATISGGGRYTYYP|IGHV3-23/IGHV3-23D|6|WVRQAPGKGLDWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>pepinemab_VH|YSFSDYYMH|IGHV1-69-2|2|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GQINPTTGGASYN|IGHV1-2|6|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>perakizumab_VH|FTFSDYTML|IGHV3-11|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AIIKSGGSYSYYP|IGHV3-7|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>perenostobart_VH|GTFSSEGIS|IGHV1-69/IGHV1-69D|2|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GSILPIFGTANYA|IGHV1-69/IGHV1-69D|2|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>peresolimab_VH|YSLSKYDMS|IGHV3-11|5|QVQLVQSGAEVKKPGASVKVSCKVSG|IGHV1-24|0|GIIYTSGYTDYA|IGHV4-28/IGHV4-30-4/IGHV4-31|5|WVRQAPGKGLEWM|IGHV1-24|0
>pertuzumab_VH|FTFTDYTMD|IGHV3-43|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ADVNPNSGGSIYN|IGHV1-2|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>petosemtamab_VH|YDFTNYAMN|IGHV7-4-1|2|QVQLVQSGSELKKPGASVKISCKASG|IGHV7-4-1|1|GWINANTGDPTYA|IGHV7-4-1|2|WVRQAPGHGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>petosemtamab_VH_1|YTFTSYTMN|IGHV7-4-1|1|EVQLVQSGSKLKKPGASVKVSCKASG|IGHV7-4-1|2|GWINTDTGDPTYA|IGHV7-4-1|2|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>pexelizumab_VH|YIFSNYWIQ|IGHV5-10-1|4|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GEILPGSGSTEYT|IGHV1-2|6|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>picankibart_VH|YTFTSYLMH|IGHV1-3|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GYINPYNEGTNYA|IGHV1-2|4|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>pidilizumab_VH|YTFTNYGMN|IGHV7-4-1|2|QVQLVQSGSELKKPGASVKISCKASG|IGHV7-4-1|1|GWINTDSGESTYA|IGHV7-4-1|4|WVRQAPGQGLQWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>pimivalimab_VH|YTFPSYYMH|IGHV1-46|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GIINPEGGSTAYA|IGHV1-46|2|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>pimurutamab_VH|FSLTNYGVH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|5|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GVIWSGGNTDYG|IGHV3-53/IGHV3-66|5|WVRQAPGKGLEWL|IGHV1-24|1
>pinatuzumab_VH|YEFSRSWMN|IGHV3-35|4|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GRIYPGDGDTNYS|IGHV5-51|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>pivekimab_VH|YIFTSSIMH|IGHV1-3|3|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GYIKPYNDGTKYN|IGHV1-18|7|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>plamotamab_VH|YTFTSYNMH|IGHV1-3|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GAIYPGNGDTSYN|IGHV5-51|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>plamotamab_VH_1|FTFSTYAMN|IGHV3-21/IGHV3-48|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GRIRSKYNNYATYYA|IGHV3-73|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>plonmarlimab_VH|YTFTSHYLH|IGHV1-45|2|EVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GWIFPGDDKTKYN|IGHV1-3|6|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>plozalizumab_VH|FTFSAYAMN|IGHV3-21/IGHV3-48|2|EVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|0|GRIRTKNNNYATYYA|IGHV3-73|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>plutavimab_VH|FTVSSNYMS|IGHV3-53/IGHV3-66|0|EVQLVESGGGLIQPGGSLRLSCAASG|IGHV3-53|0|SIIYPGGSTEYA|IGHV3-53/IGHV3-66|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>polatuzumab_VH|YTFSSYWIE|IGHV1-18|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GEILPGGGDTNYN|IGHV1-2|6|WVRQAPGKGLEWI|IGHV1-24|1
>polzastobart_VH|FSLNTYAMGVS|IGHV2-26|4|QITLKESGPTLVKPTQTLTLTCTFSG|IGHV2-5|0|ASIWWNGNKYNN|IGHV2-5|7|WIRQPPGKALEWL|IGHV2-26/IGHV2-5/IGHV2-70|0
>ponezumab_VH|YYTEAYYIH|IGHV1-2|5|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GRIDPATGNTKYA|IGHV1-2|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>ponsegromab_VH|YTFSSYNID|IGHV1-18|3|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GGINPIFGTAFYN|IGHV1-69/IGHV1-69D|3|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>porgaviximab_VH|FTFSNYWMN|IGHV3-15|2|EVQLQESGGGLMQPGGSMKLSCVASG|IGHV3-73|4|AEIRLKSNNYATHYA|IGHV3-73|6|WVRQSPEKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|2
>porustobart_VH|FTVSKNYMS|IGHV3-53/IGHV3-66|1|EVQLVESGGGLIQPGGSLRLSCAVSG|IGHV3-53|1|SVVYSGGSKTYA|IGHV3-53/IGHV3-66|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>posdinemab_VH|FTFSSYAMS|IGHV3-23/IGHV3-23D|0|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|ASISKGGNTYYA|IGHV3-53/IGHV3-66|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>pozelimab_VH|DSVSSSYWT|IGHV4-59|4|QVQLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|0|GYIYYSGSSNYN|IGHV4-59/IGHV4-61|1|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>pradusinstobart_VH|FSLSTSGTCVS|IGHV2-70|1|QVTLKESGPALVKPTQTLTLTCTFSG|IGHV2-70|1|ATICWEDSKGYN|IGHV2-5|6|WIRQPPGKALEWL|IGHV2-26/IGHV2-5/IGHV2-70|0
>prafnosbart_VH|STFSNYGMK|IGHV3-30-5/IGHV3-33/IGHV3-NL1|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SSISRSSTYIYYA|IGHV3-21|2|WIRQAPGKGLEWV|IGHV3-11|0
>praluzatamab_VH|FSLSTYGMGVG|IGHV2-5|2|QITLKESGPTLVKPTQTLTLTCTFSG|IGHV2-5|0|ANIWWSEDKHYS|IGHV2-5|5|WIRQPPGKALEWL|IGHV2-26/IGHV2-5/IGHV2-70|0
>prasinezumab_VH|FTFSNYGMS|IGHV3-11|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ASISSGGGSTYYP|IGHV3-64|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>prezalumab_VH|FTFSSYWMS|IGHV3-7|0|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AYIKQDGNEKYYV|IGHV3-7|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>pritoxaximab_VH|YTFTSYNMH|IGHV1-3|1|QVQLQESGAELVRSGASVRMSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|8|GYIYPGNGGTNYI|IGHV1-2|5|WVKQTPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|3
>pritumumab_VH|FTFSNYAMS|IGHV3-23/IGHV3-23D|1|EVQLLESGGDLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|1|SAITPSGGSTNYA|IGHV3-23/IGHV3-23D|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>prolgolimab_VH|FTFSSYWMY|IGHV3-7|1|QVQLVQSGGGLVQPGGSLRLSCAASG|IGHV3-11|2|SAIDTGGGRTYYA|IGHV3-23/IGHV3-23D|4|WVRQVPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>pucotenlimab_VH|FTFSSYGMS|IGHV3-23/IGHV3-23D|1|EVQLVQSGGGLVQPGGSLKLSCAASG|IGHV3-73|1|ATISGGGRDTYYP|IGHV3-23/IGHV3-23D|6|WVRQAPGKGLDWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>pulocimab_VH|FTFSSYSMN|IGHV3-21/IGHV3-48|0|EVQLVQSGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|1|SSISSSSSYIYYA|IGHV3-21|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>puxitatug_VH|GSFSGYYWN|IGHV4-34|1|QVQLQQWGAGLLKPSETLSLACTVYG|IGHV4-34|2|GEINHSGSTSYN|IGHV4-34|1|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>quavonlimab_VH|FTFSDNWMN|IGHV3-11|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AQIRNKPYNYETYYS|IGHV3-49|9|WVRQAPGKGLEWL|IGHV1-24|1
>quetmolimab_VH|YTFTNYYIH|IGHV1-2|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWIYPGDGSPKFN|IGHV1-3|7|WVKQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>quilizumab_VH|FTFSDYGIA|IGHV3-11|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AFISDLAYTIYYA|IGHV3-11|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>quisovalimab_VH|GSFSGYNWH|IGHV4-34|2|QVQLQQWGAGLLKPSETLSLTCAVYG|IGHV4-34|0|GEITHSGSTNYN|IGHV4-34|1|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>racotumomab_VH|YTFTSYDIN|IGHV1-8|0|QVQLQQSGAELVKPGASVKLSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|4|GWIFPGDGSTKYN|IGHV1-3|5|WVRQRPEQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|3
>rademikibart_VH|FTFSRNAMF|IGHV3-23/IGHV3-23D|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SGIGTGGATSYA|IGHV3-13|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>radretumab_VH|FTFSSFSMS|IGHV3-21/IGHV3-48|2|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SSISGSSGTTYYA|IGHV3-23/IGHV3-23D|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>rafivirumab_VH|GTFNRYTVN|IGHV1-69/IGHV1-69D|5|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GGIIPIFGTANYA|IGHV1-69/IGHV1-69D|0|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>ragifilimab_VH|YTFTDYAMY|IGHV1-3|2|QVQLVQSGAEVKKPGASVKVSCKGSG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GVIRTYSGDVTYN|IGHV7-4-1|7|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>ragistomig_VH|FTFSSYDMS|IGHV3-13|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ATISDAGGYIYYR|IGHV3-11|7|WVRQAPGKSLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>ragistomig_VH_1|FTFSSYDMS|IGHV3-13|1|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SWISYSGGSIYYA|IGHV3-23/IGHV3-23D|3|WVRQAPGKCLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>ralpancizumab_VH|YTFTSYYMH|IGHV1-46|0|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GEIHPSGGRTNYN|IGHV1-46|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>raludotatug_VH|YTFTRNFMH|IGHV1-2|3|EVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GWIYPGDGETEYA|IGHV1-24|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>ralzapastotug_VH|YSITSGYSWH|IGHV4-38-2|3|QVQLQESGPGLVKPSGTLSLTCAVSG|IGHV4-28|1|GYVHYSGSTNYN|IGHV4-59/IGHV4-61|2|WVRQPPGKGLEWI|IGHV4-4|0
>ramucirumab_VH|FTFSSYSMN|IGHV3-21/IGHV3-48|0|EVQLVQSGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|1|SSISSSSSYIYYA|IGHV3-21|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>ranevetmab_VH|FSLTNNNVN|IGHV1-58|6|EVQLVESGGGLVQPGGSLRLSCVASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|GGVWAGGATDYN|IGHV4-28/IGHV4-30-4/IGHV4-31|7|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>ranibizumab_VH|YDFTHYGMN|IGHV7-4-1|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GWINTYTGEPTYA|IGHV7-4-1|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>ravagalimab_VH|FTFSDYGMN|IGHV3-11|2|EVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|0|AYISSGRGNIYYA|IGHV3-11|5|WVRQAPGKGLEWI|IGHV1-24|1
>ravulizumab_VH|HIFSNYWIQ|IGHV1-69/IGHV1-69D|5|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GEILPGSGHTEYT|IGHV1-2|6|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>recaticimab_VH|YTFTDYWMH|IGHV1-69-2|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GYINPSSGFTKYH|IGHV1-2|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>refanezumab_VH|YTFTNYGMN|IGHV7-4-1|2|QVQLVQSGSELKKPGASVKVSCKASG|IGHV7-4-1|0|GWINTYTGEPTYA|IGHV7-4-1|2|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>reflocibart_VH|YTFTGFWIH|IGHV1-2|3|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GHINPGNGGTNYN|IGHV1-2|4|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>regdanvimab_VH|FSLSTSGVGVG|IGHV2-5|0|QITLKESGPTLVKPTQTLTLTCSFSG|IGHV2-5|1|ALIDWDDNKYHT|IGHV2-70|3|WIRQPPGKALEWL|IGHV2-26/IGHV2-5/IGHV2-70|0
>relatlimab_VH|GSFSDYYWN|IGHV4-34|2|QVQLQQWGAGLLKPSETLSLTCAVYG|IGHV4-34|0|GEINHRGSTNSN|IGHV4-34|2|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>relfovetmab_VH|FTYSNYWMH|IGHV3-74|2|DVQLVESGGDLVKPGGSLRLTCVASG|IGHV3-11|4|ARIDPYGGGTKHN|IGHV1-2|7|WVRQAPGKGLQWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>remternetug_VH|FTFSSYPMS|IGHV3-23/IGHV3-23D|1|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SAISGSGGSTYYA|IGHV3-23/IGHV3-23D|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>remtolumab_VH|FTFDDYAMH|IGHV3-9|0|EVQLVESGGGLVQPGRSLRLSCAASG|IGHV3-9|0|SAITWNSGHIDYA|IGHV3-9|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>remtolumab_VH_1|GSFGGYGIG|IGHV4-34|4|EVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|1|GGITPFFGFADYA|IGHV1-69/IGHV1-69D|4|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>renvistobart_VH|GSVSSGIYYWS|IGHV4-61|1|QVHLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|1|GYIYYSGSTNYN|IGHV4-59/IGHV4-61|0|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>reozalimab_VH|GTFSSYAIS|IGHV1-69/IGHV1-69D|0|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GLIIPSFDTAGYA|IGHV1-69/IGHV1-69D|4|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>reozalimab_VH_1|GTFSSYAIS|IGHV1-69/IGHV1-69D|0|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GGIIPIFGTANYA|IGHV1-69/IGHV1-69D|0|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>reslizumab_VH|LSLTSNSVN|IGHV1-24|6|EVQLVESGGGLVQPGGSLRLSCAVSG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|GLIWSNGDTDYN|IGHV4-28/IGHV4-30-4/IGHV4-31|6|WIRQAPGKGLEWV|IGHV3-11|0
>resugosbart_VH|YTFTDYNLD|IGHV1-69-2|3|EVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GDIDPNDGDILYN|IGHV1-2|7|WLRQAPGEGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|3
>retifanlimab_VH|YSFTSYWMN|IGHV5-10-1|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GVIHPSDSETWLD|IGHV5-10-1|6|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>retlirafusp_VH|YTFTSYWMH|IGHV1-3|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GRIGPNSGFTSYN|IGHV1-2|4|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>revdofilimab_VH|FTFSRYGMS|IGHV3-11|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ATINSNGGRTYYP|IGHV3-64|5|WVRQAPGKGLELV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>rezetamig_VH|FTFHNYAMH|IGHV3-30/IGHV3-30-3/IGHV3-64|2|EVQLVESGGGLVQPGRSLRLSCAASG|IGHV3-9|0|SGISWNSGSIGYA|IGHV3-9|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>rezetamig_VH_1|DSISSGDYYWG|IGHV4-30-4|2|QLQLQESGPGLVKPSETLSLTCTVSG|IGHV4-39|0|GHIYYSGATYYN|IGHV4-28/IGHV4-30-4/IGHV4-31|2|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>rezorstobart_VH|FTFSPYAMS|IGHV3-23/IGHV3-23D|1|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SAISASGGTTYYA|IGHV3-23/IGHV3-23D|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>riliprubart_VH|FNIKDDYIH|IGHV1-69-2|6|QVQLVQSGAEVKKPGASVKLSCTASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|2|GRIDPADGHTKYA|IGHV1-2|5|WVKQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>rilotumumab_VH|GSISIYYWS|IGHV4-59|1|QVQLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|0|GYVYYSGSTNYN|IGHV4-59/IGHV4-61|1|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>riltovetbart_VH|FTFSNYGMS|IGHV3-11|2|EVQLVESGGDLVKPGGSLRLSCVASG|IGHV3-15/IGHV3-21|2|ATISYGGSYTYYP|IGHV3-30/IGHV3-30-3/IGHV3-30-5|5|WVRQAPGKGLQWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>rilvegostomig_VH|FTFSDYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AYISSGSYTIYSA|IGHV3-48|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>rilvegostomig_VH_1|FTFSSYAMH|IGHV3-30/IGHV3-30-3/IGHV3-64|0|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AVISYAGEVKYYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>rimteravimab_VH|RTFSEYAMG|IGHV3-23/IGHV3-23D|3|DVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|ATISWSGGATYYT|IGHV3-23/IGHV3-23D|5|WFRQAPGKEREFV|IGHV3-49|3
>rinucumab_VH|GSITSSSYYWG|IGHV4-39|1|QLQLQESGPGLVKPSETLSLTCTVSG|IGHV4-39|0|GSIYYRGSTNYN|IGHV4-39|2|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>ripertamab_VH|YTFTSYNMH|IGHV1-3|1|QVQLQQPGAELVKPGASVKMSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|5|GAIYPGNGDTSYN|IGHV5-51|5|WVKQTPGRGLEWI|IGHV4-4|3
>risankizumab_VH|YTFTDQTIH|IGHV1-69-2|3|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GYIYPRDDSPKYN|IGHV5-51|7|WMRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>rituximab_VH|YTFTSYNMH|IGHV1-3|1|QVQLQQPGAELVKPGASVKMSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|5|GAIYPGNGDTSYN|IGHV5-51|5|WVKQTPGRGLEWI|IGHV4-4|3
>rivabazumab_VH|FTFSNYPMH|IGHV3-13|2|EVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|1|AVISYDGSEKWYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>robatumumab_VH|FTFSSFAMH|IGHV3-30/IGHV3-30-3/IGHV3-64|1|EVQLVQSGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|1|SVIDTRGATYYA|IGHV3-53/IGHV3-66|4|WVRQAPGKGLEWI|IGHV1-24|1
>rocatinlimab_VH|FSLSTSGMGVG|IGHV2-5|1|QITLKESGPTLVKPKQTLTLTCTFSG|IGHV2-5|1|AVIYWDDHQLYS|IGHV2-5|5|WIRQPPGKALEWL|IGHV2-26/IGHV2-5/IGHV2-70|0
>roconkibart_VH|YIFTNYGMN|IGHV7-4-1|3|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWINDHTGEPTYA|IGHV7-4-1|3|WMRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>roledumab_VH|FTFKNYAMH|IGHV3-30/IGHV3-30-3/IGHV3-64|2|QVQLVESGGGVVQPGRSLRLSCTASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|1|ATISYDGRNIQYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|4|WVRQAPAKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>rolinsatamab_VH|YTFTTYWMH|IGHV1-2|2|EVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|1|GEIDPSDSYSNYN|IGHV5-10-1|3|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>rolistobart_VH|FTFSNYGMS|IGHV3-11|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ATISGGGDYTNYP|IGHV3-23/IGHV3-23D|7|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>romilkimab_VH|FSLTDSSIN|IGHV1-24|6|EVQLKESGPGLVAPGGSLSITCTVSG|IGHV4-30-4/IGHV4-31|7|GMIWGDGRIDYA|IGHV3-53/IGHV3-66|8|WVRQPPGKGLEWL|IGHV4-4|1
>romilkimab_VH_1|YSFTSYWIH|IGHV5-10-1|1|QVQLQQSGPELVKPGASVKISCKASG|IGHV7-4-1|4|GMIDPSDGETRLN|IGHV1-24|6|WIKQRPGQGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|3
>romlusevimab_VH|YTFTTYVMN|IGHV7-4-1|2|QVQLVQSGSELKKPGASVKVSCKASG|IGHV7-4-1|0|GWINTNTGNPTYA|IGHV7-4-1|0|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>romosozumab_VH|YTFTDYNMH|IGHV1-69-2|1|EVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GEINPNSGGAGYN|IGHV1-2|4|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>rontalizumab_VH|YTFTEYIIH|IGHV1-18|3|EVQLVESGGGLVQPGGSLRLSCATSG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|ASINPDYDITNYN|IGHV1-2|7|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>rosmantuzumab_VH|YTFTDYSIH|IGHV1-69-2|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GYIYPSNGDSGYN|IGHV1-45|7|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>rosnilimab_VH|YTFTDYSMH|IGHV1-69-2|1|QVQLVQSGSELKKPGASVKVSCKASN|IGHV7-4-1|1|GWINIETYYPTYA|IGHV7-4-1|4|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>rosopatamab_VH|YTFTEYTIH|IGHV1-18|3|EVQLVQSGPEVKKPGATVKISCKTSG|IGHV1-69-2|2|GNINPNNGGTTYN|IGHV1-2|4|WVKQAPGKGLEWI|IGHV1-24|2
>rovalpituzumab_VH|YTFTNYGMN|IGHV7-4-1|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWINTYTGEPTYA|IGHV7-4-1|2|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>rovelizumab_VH|YTFTNNWMQ|IGHV1-2|4|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GAIFPGDDETRYT|IGHV5-51|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>rozanolixizumab_VH|FTFSNYGMV|IGHV3-30-5/IGHV3-33/IGHV3-NL1|2|EVPLVESGGGLVQPGGSLRLSCAVSG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|2|AYIDSDGDNTYYR|IGHV3-30/IGHV3-30-3/IGHV3-30-5|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>rozibafusp_VH|FTFSSYWMS|IGHV3-7|0|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AYIKQDGNEKYYV|IGHV3-7|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>rulonilimab_VH|FTFSSYGMS|IGHV3-23/IGHV3-23D|1|EVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|0|ATISGGGRDTYYP|IGHV3-23/IGHV3-23D|6|WVRQTPEKRLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|3
>runimotamab_VH|FNIKDTYIH|IGHV1-69-2|6|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ARIYPTNGYTRYA|IGHV1-2|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>runimotamab_VH_1|YTFTNYYIH|IGHV1-2|2|EVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GWIYPGDGNTKYN|IGHV1-3|4|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>ruplizumab_VH|YIFTSYYMY|IGHV1-46|2|QVQLVQSGAEVVKPGASVKLSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|2|GEINPSNGDTNFN|IGHV1-2|6|WVKQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>sabatolimab_VH|YTFTSYNMH|IGHV1-3|1|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GDIYPGNGDTSYN|IGHV5-51|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>sabestomig_VH|FTFSDYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AYISSGSYTIYSA|IGHV3-48|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>sabestomig_VH_1|FTFSSYAMS|IGHV3-23/IGHV3-23D|0|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SAISGSGGSTYYA|IGHV3-23/IGHV3-23D|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>sabirnetug_VH|FTFSSFGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AYISRGSSTIYYA|IGHV3-48|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>sacituzumab_VH|YTFTNYGMN|IGHV7-4-1|2|QVQLQQSGSELKKPGASVKVSCKASG|IGHV7-4-1|1|GWINTYTGEPTYT|IGHV7-4-1|3|WVKQAPGQGLKWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>samalizumab_VH|YSFTDYIIL|IGHV5-10-1|3|QVQLQQSGSELKKPGASVKISCKASG|IGHV7-4-1|2|GHIDPYYGSSNYN|IGHV1-18|7|WVRQNPGKGLEWI|IGHV4-4|1
>samrotamab_VH|YKFSSYWIE|IGHV5-10-1|3|EVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GEILPGSDTTNYN|IGHV1-2|6|WVKQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>sarilumab_VH|FTFDDYAMH|IGHV3-9|0|EVQLVESGGGLVQPGRSLRLSCAASR|IGHV3-9|1|SGISWNSGRIGYA|IGHV3-9|1|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>sasanlimab_VH|YTFTSYWIN|IGHV1-8|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GNIYPGSSLTNYN|IGHV5-51|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>satralizumab_VH|HSISHDHAWS|IGHV4-4|5|QVQLQESGPGLVKPSETLSLTCAVSG|IGHV4-38-2|0|GFISYSGITNYN|IGHV4-59/IGHV4-61|3|WVRQPPGEGLEWI|IGHV4-4|1
>satumomab_VH|YTFTDHAIH|IGHV1-3|3|QVQLQQSDAELVKPGASVKISCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|5|GYISPGNDDIKYN|IGHV1-3|7|WAKQKPEQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|5
>secukinumab_VH|FTFSNYWMN|IGHV3-15|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AAINQDGSEKYYV|IGHV3-7|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>selicrelumab_VH|YTFTGYYMH|IGHV1-2|0|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWINPDSGGTNYA|IGHV1-2|2|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>semorinemab_VH|LIFRSYGMS|IGHV1-18|4|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ATINSGGTYTYYP|IGHV3-NL1|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>semzuvolimab_VH|YTFTDYVIH|IGHV1-69-2|2|QVQLVQSGPELKKPGASVKVSCKASG|IGHV7-4-1|1|GEIYPGSGSAYSN|IGHV1-2|8|WVKQATGQGLEWI|IGHV1-8|2
>seniprutug_VH|YTFTDYLVH|IGHV1-69-2|2|QVQLVQSGSELKKPGESVKVSCKASG|IGHV7-4-1|1|GWINTYTGTPTYA|IGHV7-4-1|2|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>serclutamab_VH|YSISRDFAWN|IGHV4-28|5|EVQLQESGPGLVKPSQTLSLTCTVSG|IGHV4-30-4/IGHV4-31|1|GYISYNGNTRYQ|IGHV4-28/IGHV4-30-4/IGHV4-31|5|WIRQPPGKGLEWM|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|1
>seribantumab_VH|FTFSHYVMA|IGHV3-11|3|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SSISSSGGWTLYA|IGHV3-23/IGHV3-23D|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>serplulimab_VH|FTFSNYGMS|IGHV3-11|2|QVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-11|0|STISGGGSNIYYA|IGHV3-11|4|WIRQAPGKGLEWV|IGHV3-11|0
>setoxaximab_VH|YSFTDYNMN|IGHV1-69-2|3|EVQLQQPGPELEKPGASVKLSCKASG|IGHV7-4-1|6|GKIDPYYGGPSYN|IGHV1-2|7|WVKQNNGESLEWI|IGHV1-58|5
>setrusumab_VH|FTFRSHWLS|IGHV3-7|3|QVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-11|1|SNINYDGSSTYYA|IGHV3-74|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>sibeprenlimab_VH|YTFTDYTIH|IGHV1-69-2|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWIYPLRGSINYA|IGHV1-45|5|WVRQATGQGLEWM|IGHV1-8|0
>sifalimumab_VH|YTFTSYSIS|IGHV1-18|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWISVYNGNTNYA|IGHV1-18|1|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>sigvotatug_VH|YSFTDYNVN|IGHV1-69-2|4|QFQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GVINPKYGTTRYN|IGHV1-2|6|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>silevimig_VH|FTFGSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|1|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|ATISYDGSIKDYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>silevimig_VH_1|GTYSGYTIN|IGHV1-69/IGHV1-69D|4|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GGIIPIFGTANYA|IGHV1-69/IGHV1-69D|0|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>siltuximab_VH|FTFSSFAMS|IGHV3-23/IGHV3-23D|1|EVQLVESGGKLLKPGGSLKLSCAASG|IGHV3-15/IGHV3-21|3|AEISSGGSYTYYP|IGHV3-NL1|5|WFRQSPEKRLEWV|IGHV3-49|3
>simaravibart_VH|GTFSSYTIS|IGHV1-69/IGHV1-69D|1|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GRIIPILDRVMYA|IGHV1-69/IGHV1-69D|6|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>simlukafusp_VH|FTFSSYAMS|IGHV3-23/IGHV3-23D|0|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SAIIGSGASTYYA|IGHV3-23/IGHV3-23D|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>simridarlimab_VH|GSIEHYYWS|IGHV4-59|2|QVQLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|0|GYIYYSGSTNYN|IGHV4-59/IGHV4-61|0|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>simridarlimab_VH_1|YTISRNSMG|IGHV1-24|5|QVQLQESGGGLVQPGGSLRLSCAASA|IGHV3-11|3|AAIESDGSTSYS|IGHV2-26|6|WFRQAPGKGLEGV|IGHV3-49|1
>simtuzumab_VH|YAFTYYLIE|IGHV1-18|4|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GVINPGSGGTNYN|IGHV1-2|3|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>sintilimab_VH|GTFSSYAIS|IGHV1-69/IGHV1-69D|0|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GLIIPMFDTAGYA|IGHV1-69/IGHV1-69D|4|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>sipavibart_VH|FPFDDYAIH|IGHV3-9|2|EVQLVESGGGLVQPGRSLRLSCAASG|IGHV3-9|0|SSISWDSGSIGYA|IGHV3-9|2|WVRLAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>sirexatamab_VH|FTFSSYTMS|IGHV3-23/IGHV3-23D|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ATISGGGFGTYYP|IGHV3-23/IGHV3-23D|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>sirtratumab_VH|FTFSSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|0|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AVIWYDGSNQYYA|IGHV3-33|1|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>sirukumab_VH|FTFSPFAMS|IGHV3-23/IGHV3-23D|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AKISPGGSWTYYS|IGHV3-30/IGHV3-30-3/IGHV3-30-5|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>socazolimab_VH|GTFSSYAIS|IGHV1-69/IGHV1-69D|0|EVQLVESGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|2|GGIIPIFGTANYA|IGHV1-69/IGHV1-69D|0|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>sofituzumab_VH|YSITNDYAWN|IGHV4-38-2|5|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GYISYSGYTTYN|IGHV4-28/IGHV4-30-4/IGHV4-31|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>solanezumab_VH|FTFSRYSMS|IGHV3-11|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AQINSVGNSTYYP|IGHV3-64|6|WVRQAPGKGLELV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>solitomab_VH|YAFTNYWLG|IGHV5-51|3|VQLLEQSGAELVRPGTSVKISCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|9|GDIFPGSGNIHYN|IGHV1-58|6|WVKQRPGHGLEWI|IGHV4-4|3
>solitomab_VH_1|YTFTRYTMH|IGHV1-2|2|DVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GYINPSRGYTNYA|IGHV1-2|4|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>solrikitug_VH|YIFTDYAMH|IGHV1-3|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GTFIPLLDTSDYA|IGHV1-69/IGHV1-69D|7|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>sonelokimab1_VH|RTFSSYVVG|IGHV1-69/IGHV1-69D|4|DVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|GAISGSGESIYYA|IGHV3-23/IGHV3-23D|3|WFRQAPGKEREFI|IGHV3-49|4
>sonelokimab1_VH_1|FTFSSFGMS|IGHV3-23/IGHV3-23D|2|EVQLVESGGGLVQPGNSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|SSISGSGSDTLYA|IGHV3-23/IGHV3-23D|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>sonelokimab2_VH|RTYDAMG|||EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AAISGSGDDTYYA|IGHV3-23/IGHV3-23D|3|WLRQAPGKEREFV|IGHV3-11|4
>sotevtamab_VH|FNIKDIYMH|IGHV1-69-2|5|QVQLVQSGAEVKKPGATVKISCKVSG|IGHV1-69-2|1|GRIDPAYGNTKYD|IGHV1-2|6|WVQQAPGKGLEWM|IGHV1-69-2|0
>sotiburafusp_VH|YAFTGYTIH|IGHV1-2|3|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWFYPGSGTLKYS|IGHV1-3|6|WVRQAPGQRLEWM|IGHV1-3|0
>sotigalimab_VH|FSFSSTYVC|IGHV1-58|5|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|ACIYTGDGTNYS|IGHV2-5|6|WVRQAPGKGLEWI|IGHV1-24|1
>sotrovimab_VH|YPFTSYGIS|IGHV1-18|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWISTYQGNTNYA|IGHV1-18|2|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>sovipostobart_VH|FTFSSYTMH|IGHV3-13|1|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|TFISYDGNNKYYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>spartalizumab_VH|YTFTTYWMH|IGHV1-2|2|EVQLVQSGAEVKKPGESLRISCKGSG|IGHV5-10-1|0|GNIYPGTGGSNFD|IGHV1-2|7|WVRQATGQGLEWM|IGHV1-8|0
>spesolimab_VH|YSFTSSWIH|IGHV5-10-1|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GEINPGNVRTNYN|IGHV1-2|6|WVKQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>stamulumab_VH|YTFTSYYMH|IGHV1-46|0|EVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GIINPSGGSTSYA|IGHV1-46|0|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>stapokibart_VH|FTFSRYAMS|IGHV3-23/IGHV3-23D|1|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|STISSGGSYTNYA|IGHV3-NL1|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>suciraslimab_VH|FAFSIYDMS|IGHV3-11|3|QVQLQESGGGLVKPGGSLKLSCAASG|IGHV3-11|2|AYISSGGGTTYYP|IGHV3-11|5|WVRQTPEKRLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|3
>sudubrilimab_VH|FTFSETWLH|IGHV3-74|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AWVSPFGGSTYYA|IGHV3-23/IGHV3-23D|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>sugemalimab_VH|FTFSSYAMS|IGHV3-23/IGHV3-23D|0|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SGISGSGGFTYYA|IGHV3-23/IGHV3-23D|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>suptavumab_VH|FTFDDYAMH|IGHV3-9|0|EVQLVESGGDLVQPGRSLRLSCVASG|IGHV3-49|2|SGVSWSGSTVGYA|IGHV3-35|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>surzebiclimab_VH|FTFSRYAMS|IGHV3-23/IGHV3-23D|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AAISSGGSLYYP|IGHV3-53/IGHV3-66|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>sutimlimab_VH|FTFSNYAMS|IGHV3-23/IGHV3-23D|1|EVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|0|ATISSGGSHTYYL|IGHV3-NL1|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>suvemcitug_VH|FSFSNNDVMC|IGHV4-28|8|EVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|0|GCIMTTDVVTEYA|IGHV1-18|8|WVRQAPGKGLEWI|IGHV1-24|1
>suvizumab_VH|YTFTNSWIG|IGHV5-51|3|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GDIYPGGGYTNYN|IGHV1-2|6|WFRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>suvratoxumab_VH|FTFSSHDMH|IGHV3-13|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SGIGTAGDTYYP|IGHV3-13|1|WVRQATGKGLEWV|IGHV3-13|0
>tabalumab_VH|GSFSGYYWS|IGHV4-34|0|QVQLQQWGAGLLKPSETLSLTCAVYG|IGHV4-34|0|GEINHSGSTNYN|IGHV4-34|0|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>tabituximab_VH|FNINDTYMH|IGHV1-69-2|5|EVQLQQSGAELVKPGASVKLSCTASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|6|GRIDPANGNTKYD|IGHV1-3|5|WVKQRPEQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|4
>tacatuzumab_VH|YAFTSYVIH|IGHV1-18|3|QVQLQQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|1|GYIHPYNGGTKYN|IGHV1-18|6|WVRQAPGQGLYWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>tadocizumab_VH|YAFTNYLIE|IGHV1-18|4|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GVIYPGSGGTNYN|IGHV1-2|4|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>tafasitamab_VH|YTFTSYVMH|IGHV1-3|1|EVQLVESGGGLVKPGGSLKLSCAASG|IGHV3-15/IGHV3-21|1|GYINPYNDGTKYN|IGHV1-2|6|WVRQAPGKGLEWI|IGHV1-24|1
>tafolecimab_VH|GSISSASYYWS|IGHV4-30-4|2|QLQLQESGPGLVKPSETLSLTCTVSG|IGHV4-39|0|GSINYRGSTYYN|IGHV4-39|2|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>tagitanlimab_VH|FSLSNYDIS|IGHV1-69/IGHV1-69D|5|QVQLQESGPGLVKPSETLSITCTVSG|IGHV4-59/IGHV4-61|1|GVIWTGGATNYN|IGHV4-34|5|WIRQPPGKGLEWL|IGHV2-26/IGHV2-5/IGHV2-70|1
>talacotuzumab_VH|YSFTDYYMK|IGHV1-69-2|2|EVQLVQSGAEVKKPGESLKISCKGSG|IGHV5-51|0|GDIIPSNGATFYN|IGHV1-45|6|WARQMPGKGLEWM|IGHV5-10-1/IGHV5-51|1
>talizumab_VH|YTFSMYWLE|IGHV3-7|4|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GEISPGTFTTNYN|IGHV1-18|7|WVRQAPGHGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>talquetamab_VH|YSFTGYTMN|IGHV1-2|3|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GLINPYNSDTNYA|IGHV1-18|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>talquetamab_VH_1|FTFNTYAMN|IGHV3-21/IGHV3-48|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ARIRSKYNNYATYYA|IGHV3-73|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>tamgiblimab_VH|YTFTEYYMH|IGHV1-2|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GIISPSAGSTKYA|IGHV1-46|3|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>tamrintamab_VH|GTFSSYWIE|IGHV1-69/IGHV1-69D|2|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GEILPGSGNTYYN|IGHV1-58|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>tamtuvetmab_VH|FTFTDFYMN|IGHV1-69-2|3|EVKLLESGGGLVQPGGSMRLSCAGSG|IGHV3-23/IGHV3-23D|3|GFIRDKAKGYTTEYN|IGHV3-49|4|WIRQPAGKAPEWL|IGHV2-26/IGHV2-5/IGHV2-70|2
>tanezumab_VH|FSLIGYDLN|IGHV1-8|6|QVQLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|0|GIIWGDGTTDYN|IGHV4-28/IGHV4-30-4/IGHV4-31|6|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>tarcocimab_VH|YDFTHYGMN|IGHV7-4-1|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GWINTYTGEPTYA|IGHV7-4-1|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>tarextumab_VH|FTFSSSGMS|IGHV3-23/IGHV3-23D|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SVIASSGSNTYYA|IGHV3-NL1|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>tarlatamab_VH|GSISSYYWS|IGHV4-59|0|QVQLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|0|GYVYYSGTTNYN|IGHV4-59/IGHV4-61|2|WIRQPPGKCLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|1
>tarlatamab_VH_1|FTFNKYAMN|IGHV3-21/IGHV3-48|3|EVQLVESGGGLVQPGGSLKLSCAASG|IGHV3-73|0|ARIRSKYNNYATYYA|IGHV3-73|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>tarperprumig_VH|RPVSNYAAA|IGHV1-69/IGHV1-69D|6|QVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-11|0|SAINWQKTATYA|IGHV3-13|8|WFRQAPGKEREFV|IGHV3-49|3
>tarperprumig_VH_1|RISSIIHMA|IGHV3-11|7|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SEISRVGTTVYA|IGHV3-53/IGHV3-66|6|WFRQAPGKERELV|IGHV3-49|3
>tavolimab_VH|GSFSSGYWN|IGHV4-34|3|QVQLQESGPGLVKPSQTLSLTCAVYG|IGHV4-28|2|GYISYNGITYHN|IGHV4-28/IGHV4-30-4/IGHV4-31|4|WIRKHPGKGLEYI|IGHV4-31|2
>tebentafusp_VH|YSFTGYTMN|IGHV1-2|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ALINPYKGVSTYN|IGHV1-2|8|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>tebotelimab_VH|YSFTSYWMN|IGHV5-10-1|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GVIHPSDSETWLD|IGHV5-10-1|6|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>tebotelimab_VH_1|YTFTDYNMD|IGHV1-69-2|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GDINPDNGVTIYN|IGHV1-2|6|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>tecaginlimab_VH|YTFTEYIMH|IGHV1-2|2|EVQLVQSGAEVKKPGASVKVSCKTSG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|2|GGIIPNNGGTSYN|IGHV1-2|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>tecaginlimab_VH_1|FSLNDYWMS|IGHV3-11|4|EVQLVESGGGLVQPGRSLRLSCTASG|IGHV3-49|0|GYIDVGGSLYYA|IGHV3-53/IGHV3-66|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>teclistamab_VH|GSISSGSYFWG|IGHV4-39|2|QLQLQESGPGLVKPSETLSLTCTVSG|IGHV4-39|0|GSIYYSGITYYN|IGHV4-39|1|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>teclistamab_VH_1|FTFNTYAMN|IGHV3-21/IGHV3-48|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ARIRSKYNNYATYYA|IGHV3-73|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>tegoprubart_VH|YIFTSYYMY|IGHV1-46|2|QVQLVQSGAEVVKPGASVKLSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|2|GEINPSNGDTNFN|IGHV1-2|6|WVKQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>telazorlimab_VH|FSLSTSGMGVG|IGHV2-5|1|QVTLKESGPALVKPTQTLTLTCSFSG|IGHV2-70|2|AHIWWDDDKYYN|IGHV2-70|3|WIRQPPGKALEWI|IGHV2-26/IGHV2-5/IGHV2-70|1
>telisotuzumab_VH|YIFTAYTMH|IGHV1-2|3|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWIKPNNGLANYA|IGHV1-45|4|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>temelimab_VH|YTFTDYEMH|IGHV1-69-2|1|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GAVAPETGGTAYN|IGHV1-69-2|6|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>temtokibart_VH|FTFSSYDMN|IGHV3-13|1|QVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-11|1|SSIYNDASNTAYS|IGHV3-74|7|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>tenatumomab_VH|YAFTSYNMY|IGHV1-3|3|EIQLQQSGPELVKPGASVKVSCKASG|IGHV7-4-1|5|GYIDPYNGVTSYN|IGHV1-18|6|WVKQSHGKSLEWI|IGHV4-4|4
>teneliximab_VH|YAFTTTGMQ|IGHV1-18|5|QIQLVQSGPELKKPGETVRISCKASG|IGHV1-58|6|GWINTHSGVPKYV|IGHV7-4-1|5|WVQEMPGKGLKWI|IGHV1-69-2|4
>teplizumab_VH|YTFTRYTMH|IGHV1-2|2|QVQLVQSGGGVVQPGRSLRLSCKASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|2|GYINPSRGYTNYN|IGHV1-2|5|WVRQAPGKGLEWI|IGHV1-24|1
>tepoditamab_VH|YTFTSYYMH|IGHV1-46|0|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GIINPSGGSTSYA|IGHV1-46|0|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>tepoditamab_VH_1|FTFSSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|0|QVQLVQSGGGVVQPGRSLRLSCVASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|2|AAIWYNARKQDYA|IGHV3-33|7|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>teprotumumab_VH|FTFSSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|0|QVELVESGGGVVQPGRSQRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|2|AIIWFDGSSTYYA|IGHV3-33|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>teropavimab_VH|YNIRDYFIH|IGHV1-69-2|5|QVQLLQSGAAVTKPGASVRVSCEASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|5|GWINPKTGQPNNP|IGHV7-4-1|6|WWRQAPGQGLQWV|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|3
>tesidolumab_VH|GTFSSYAIS|IGHV1-69/IGHV1-69D|0|EVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|1|GGIGPFFGTANYA|IGHV1-69/IGHV1-69D|2|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>tesnatilimab_VH|DSISSYYWS|IGHV4-59|1|QVHLQESGPGLVKPSETLSLTCTVSD|IGHV4-59/IGHV4-61|2|GHISYSGSANYN|IGHV4-59/IGHV4-61|3|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>tezepelumab_VH|FTFRTYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|2|QMQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|1|AVIWYDGSNKHYA|IGHV3-33|1|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>tibulizumab_VH|GSFSGYYWS|IGHV4-34|0|QVQLQQWGAGLLKPSETLSLTCAVYG|IGHV4-34|0|GEINHSGSTNYN|IGHV4-34|0|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>tibulizumab_VH_1|YKFTDYHIH|IGHV1-69-2|3|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GVINPTYGTTDYN|IGHV1-2|6|WVRQAPGQCLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>tidutamab_VH|FTFSDYGMA|IGHV3-11|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SFISNLGYSIYYA|IGHV3-11|5|WFRQAPGKGLEWV|IGHV3-49|0
>tidutamab_VH_1|FTFSTYAMN|IGHV3-21/IGHV3-48|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GRIRSKYNNYATYYA|IGHV3-73|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>tifcemalimab_VH|YNFKHTYAH|IGHV1-2|5|QVQLVQSGAEVKKPGASVKLSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GRIDPANGNTKYD|IGHV1-3|5|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>tigatuzumab_VH|FTFSSYVMS|IGHV3-23/IGHV3-23D|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ATISSGGSYTYYP|IGHV3-NL1|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>tilavonemab_VH|FTFSNYWVN|IGHV3-15|3|EVKVVESGGGLVQPGGSMKLSCVVSG|IGHV3-73|5|AQIRLKSDNYATHYE|IGHV3-73|8|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>tildrakizumab_VH|YIFITYWMT|IGHV1-2|5|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GQIFPASGSADYN|IGHV1-2|7|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>tilogotamab_VH|FNIKDTHMH|IGHV3-43|5|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GRIDPANGNTEYD|IGHV1-45|5|WVRQAPGQRLEWI|IGHV1-3|1
>tilvestamab_VH|YSFTDFYIN|IGHV1-69-2|4|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ARIFPGGDNTYYN|IGHV3-30/IGHV3-30-3/IGHV3-30-5|7|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>timcevibart_VH|LTVSSNYMS|IGHV3-53/IGHV3-66|1|QVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-11|1|SVIYSGGSTYYA|IGHV3-53/IGHV3-66|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>timigutuzumab_VH|FNIKDTYIH|IGHV1-69-2|6|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ARIYPTNGYTRYA|IGHV1-2|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>timolumab_VH|FTFFSYAMH|IGHV3-30/IGHV3-30-3/IGHV3-64|1|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AVIWFDGSNENYV|IGHV3-33|4|WVRQTPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>tinurilimab_VH|FSLSTYGIGVG|IGHV2-5|2|QVTLRESGPALVKPTQTLTLTCTFSG|IGHV2-70|0|AHIWWNDNKYYS|IGHV2-26|4|WIRQPPGKALEWL|IGHV2-26/IGHV2-5/IGHV2-70|0
>tiragolumab_VH|DSVSSNSAAWN|IGHV6-1|0|EVQLQQSGPGLVKPSQTLSLTCAISG|IGHV6-1|1|GKTYYRFKWYSDYA|IGHV6-1|3|WIRQSPSRGLEWL|IGHV6-1|0
>tirnovetmab_VH|DSITSGYWN|IGHV4-59|4|EVQLVESGPSLVKPGGSLRLTCSVTG|IGHV3-15/IGHV3-21|6|GYISYSGITDYN|IGHV4-28/IGHV4-30-4/IGHV4-31|3|WIRKFPGNKLEYM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|6
>tislelizumab_VH|FSLTSYGVH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|4|QVQLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|0|GVIYADGSTNYN|IGHV4-4|3|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>tisotumab_VH|FTFSNYAMS|IGHV3-23/IGHV3-23D|1|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SSISGSGDYTYYT|IGHV3-23/IGHV3-23D|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>tixagevimab_VH|FTFMSSAVQ|IGHV1-58|1|QMQLVQSGPEVKKPGTSVKVSCKASG|IGHV1-58|0|GWIVIGSGNTNYA|IGHV1-58|1|WVRQARGQRLEWI|IGHV1-58|0
>tobemstomig_VH|FSFSSYTMS|IGHV3-23/IGHV3-23D|2|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|ATISGGGRDIYYP|IGHV3-11|7|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>tobemstomig_VH_1|FIFDDYTMN|IGHV3-43|2|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|AVISWDGGGTYYT|IGHV3-43|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>tobevibart_VH|RIFRSFYMS|IGHV1-46|5|ELQLVESGGGWVQPGGSQRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|3|ATINQDGSEKLYV|IGHV3-7|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>tocilizumab_VH|YSITSDHAWS|IGHV4-28|5|QVQLQESGPGLVRPSQTLSLTCTVSG|IGHV4-30-4/IGHV4-31|1|GYISYSGITTYN|IGHV4-28/IGHV4-30-4/IGHV4-31|3|WVRQPPGRGLEWI|IGHV4-4|1
>tomaralimab_VH|FTFTTYGIN|IGHV1-18|3|EVQLVQSGSELKKPGASVKLSCKASG|IGHV7-4-1|2|GWIYPRDGSTNFN|IGHV1-45|6|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>tomuzotuximab_VH|FSLTNYGVH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|5|QVQLKQSGPGLVQPSQSLSITCTVSG|IGHV4-30-4/IGHV4-31|5|GVIWSGGNTDYN|IGHV3-53/IGHV3-66|5|WVRQSPGKGLEWL|IGHV1-24|2
>toripalimab_VH|YTFTDYEMH|IGHV1-69-2|1|QGQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GVIESETGGTAYN|IGHV1-2|7|WVRQAPIHGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|3
>torudokimab_VH|FTFSFYAMS|IGHV3-23/IGHV3-23D|1|EVQLVETGGGLIQPGGSLRLSCAASG|IGHV3-53|1|SAISGSGGSTYYA|IGHV3-23/IGHV3-23D|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>tosatoxumab_VH|YKFGTHWIG|IGHV5-51|4|EVQMVQSGAEVKKPGEPLKISCKGSG|IGHV5-51|2|GIIHPADSETKYS|IGHV5-51|4|WVRQRPGKGLEWM|IGHV1-24|1
>tovetumab_VH|FTFSDYYMN|IGHV3-11|1|QVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-11|0|SYISSSGSIIYYA|IGHV3-11|1|WIRQAPGKGLEWV|IGHV3-11|0
>tozorakimab_VH|FTFSSYAMS|IGHV3-23/IGHV3-23D|0|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SGISAIDQSTYYA|IGHV3-23/IGHV3-23D|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>trabikibart_VH|FTFPWYRVH|IGHV3-13|4|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SSIRSSGGFPYYN|IGHV3-11|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>tralokinumab_VH|YTFTNYGLS|IGHV1-18|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWISANNGDTNYG|IGHV1-18|3|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>trastuzumab_VH|FNIKDTYIH|IGHV1-69-2|6|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ARIYPTNGYTRYA|IGHV1-2|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>traxivitug_VH|FTFNNYWMT|IGHV3-15|3|QVQLVESGGTLVQPGGSLRLSCAASG|IGHV3-11|2|ANIKKDGSEKYYV|IGHV3-7|1|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>tregalizumab_VH|FSFSDCRMY|IGHV3-11|4|EEQLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|1|GVISVKSENYGANYA|IGHV3-73|9|WLRQAPGKGLEWI|IGHV1-24|2
>tremelimumab_VH|FTFSSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|0|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AVIWYDGSNKYYA|IGHV3-33|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>trevogrumab_VH|FTFSAYAMT|IGHV3-23/IGHV3-23D|2|EVQVLESGGDLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|2|SAISGSGGSAYYA|IGHV3-23/IGHV3-23D|1|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>trinbelimab_VH|GIFRTYAIS|IGHV1-69/IGHV1-69D|3|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GGIIPMFGTVNYA|IGHV1-69/IGHV1-69D|2|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>trontinemab_VH|FTFSSYAMS|IGHV3-23/IGHV3-23D|0|QVELVESGGGLVQPGGSLRLSCAASG|IGHV3-11|2|SAINASGTRTYYA|IGHV3-23/IGHV3-23D|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>trontinemab_VH_1|FSLSSYAMS|IGHV3-23/IGHV3-23D|2|QSMQESGPGLVKPSQTLSLTCTVSG|||GYIWSGGSTDYA|IGHV3-53/IGHV3-66|4|WIRQHPGKGLEWI|IGHV4-31|0
>tucotuzumab_VH|YTFTNYGMN|IGHV7-4-1|2|EIQLVQSGAEVKKPGETVKISCKASG|IGHV1-69-2|3|GWINTYTGEPTYA|IGHV7-4-1|2|WVKQTPGKGLKWM|IGHV1-24|3
>tulisokibart_VH|FDIQDTYMH|IGHV1-69-2|5|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GRIDPASGHTKYD|IGHV1-2|5|WVKQRPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>tuparstobart_VH|FNIKDTYIH|IGHV1-69-2|6|QVQMVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GEIDPANDNTKYD|IGHV1-3|6|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>tusamitamab_VH|FVFSSYDMS|IGHV3-13|2|EVQLQESGPGLVKPGGSLSLSCAASG|IGHV3-15/IGHV3-21|3|AYISSGGGITYA|IGHV3-53/IGHV3-66|6|WVRQTPERGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|3
>tuvonralimab_VH|FTFSSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|0|QVQLVESGGGVVEPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|1|AVIWYKPSEKDYA|IGHV3-33|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>ubamatamab_VH|FTFSNYYMS|IGHV3-11|1|QVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-11|0|SYISGRGSTIFYA|IGHV3-11|3|WVRQAPGKGLEWI|IGHV1-24|1
>ubamatamab_VH_1|FTFDDYSMH|IGHV3-43|1|EVQLVESGGGLVQPGRSLRLSCAASG|IGHV3-9|0|SGISWNSGSKGYA|IGHV3-9|1|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>ublituximab_VH|YTFTSYNMH|IGHV1-3|1|QAYLQQSGAELVRPGASVKMSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|7|GGIYPGNGDTSYN|IGHV5-51|5|WVKQTPRQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|4
>ucenprubart_VH|FSFSSGYYMA|IGHV4-38-2|4|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GLIGVGSGSLWYA|IGHV1-58|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>ulenistamab_VH|FNIKDYYMH|IGHV1-69-2|4|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWIDPENGNTNYA|IGHV1-45|2|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>uliledlimab_VH|YSITSGYYWN|IGHV4-38-2|2|EVQLQESGPGLVKPSETLSLTCAVSG|IGHV4-38-2|1|GYINYGGSNGYN|IGHV4-28/IGHV4-30-4/IGHV4-31|4|WIRQPPGKKLEWM|IGHV2-26/IGHV2-5/IGHV2-70|2
>ulocuplumab_VH|FTFSSYSMN|IGHV3-21/IGHV3-48|0|EVQLVESGGGLVQPGGSLRLSCAAAG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|SYISSRSRTIYYA|IGHV3-48|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>ulviprubart_VH|YTFTDHNMH|IGHV1-69-2|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GFINPNTGVTRYN|IGHV1-2|5|WVKQATGQGLEWF|IGHV1-8|2
>umesolerbart_VH|FTFSSYEMN|IGHV3-21/IGHV3-48|1|EVQLVESGGDLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|SFISDSSSNIYYA|IGHV3-21|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>umizortamig1_VH|FTISTNAMS|IGHV3-23/IGHV3-23D|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GVITGRDITYYA|IGHV3-53/IGHV3-66|6|WVRQAPGKGLEWI|IGHV1-24|1
>umizortamig1_VH_1|YSITSDFAWN|IGHV4-28|5|DVQLQESGPSLVKPSQSLSLTCTVTG|IGHV4-30-4/IGHV4-31|4|GYISYSGNTRYN|IGHV4-28/IGHV4-30-4/IGHV4-31|3|WIRQFPGNKLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|4
>umizortamig2_VH|FSFSSGYDMC|IGHV4-38-2|5|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|ACIAAGSAGITYDA|IGHV6-1|12|WVRQAPGKGLEWI|IGHV1-24|1
>umizortamig2_VH_1|FSFSSNYWIC|IGHV4-28|6|SQSLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|3|ACIYVGSSGDTYYA|IGHV6-1|10|WVRQAPGKGLEWI|IGHV1-24|1
>unasnemab_VH|FTFSDAWMD|IGHV3-15|2|EVQLVESGGGLVQPGRSLRLSCTASG|IGHV3-49|0|AEIRSKANNHATYYA|IGHV3-73|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>upanovimab_VH|FTFSNYGMS|IGHV3-11|2|EVKLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|1|AEISSGGSYTYYP|IGHV3-NL1|5|WVRQAPGKRLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>upinitatug_VH|YTFTGYNIH|IGHV1-2|2|QVQLVQSGAEVVKPGASVKMSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|2|GAIYPGNGDTSYK|IGHV5-51|5|WVKQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>uprevstobart_VH|YTFTSYGLS|IGHV1-18|1|EVQLVQSGAEVKKPGESLKISCKGSG|IGHV5-51|0|GEIYPGSGNTYYN|IGHV1-58|5|WVRQMPGKGLEWM|IGHV5-10-1/IGHV5-51|0
>urabrelimab_VH|VSIRSINWWN|IGHV4-28|4|QVQLQESGPGLVKPSGTLSLTCAVSG|IGHV4-28|1|GEIYHSGSTNYN|IGHV4-4|0|WVRQPPGKGLEWI|IGHV4-4|0
>urelumab_VH|GSFSGYYWS|IGHV4-34|0|QVQLQQWGAGLLKPSETLSLTCAVYG|IGHV4-34|0|GEINHGGYVTYN|IGHV4-34|4|WIRQSPEKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|2
>urtoxazumab_VH|FTFSSYGMS|IGHV3-23/IGHV3-23D|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ATISTGGSYTYYP|IGHV3-30/IGHV3-30-3/IGHV3-30-5|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>usilnetug_VH|FSLSTSGMGVS|IGHV2-70|1|EVQLQESGPGLVKPSQTLSLTCTFSG|IGHV4-30-4/IGHV4-31|2|AHIYWDDDKRYN|IGHV2-5|3|WIRQPPGKGLEWL|IGHV2-26/IGHV2-5/IGHV2-70|1
>ustekinumab_VH|YSFTTYWLG|IGHV5-51|2|EVQLVQSGAEVKKPGESLKISCKGSG|IGHV5-51|0|GIMSPVDSDIRYS|IGHV5-51|4|WVRQMPGKGLDWI|IGHV4-4|2
>utomilumab_VH|YSFSTYWIS|IGHV5-10-1|2|EVQLVQSGAEVKKPGESLRISCKGSG|IGHV5-10-1|0|GKIYPGDSYTNYS|IGHV5-10-1|3|WVRQMPGKGLEWM|IGHV5-10-1/IGHV5-51|0
>vadastuximab_VH|YTFTNYDIN|IGHV1-8|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWIYPGDGSTKYN|IGHV1-3|5|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>valanafusp_VH|YTFTNYDIH|IGHV1-8|2|QVQLQQSGPELVKPGALVKISCKASG|IGHV7-4-1|5|GWIYPGDGSTKYN|IGHV1-3|5|WVKQRPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|3
>vamikibart_VH|YVLPNYLIE|IGHV1-18|6|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GVTTPGGGTINYA|IGHV1-45|6|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>vandortuzumab_VH|YSITSDYAWN|IGHV4-38-2|4|EVQLVESGGGLVQPGGSLRLSCAVSG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|GYISNSGSTSYN|IGHV4-28/IGHV4-30-4/IGHV4-31|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>vantictumab_VH|FTFSHYTLS|IGHV3-11|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SVISGDGSYTYYA|IGHV3-23/IGHV3-23D|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>vanucizumab_VH|YTFTGYYMH|IGHV1-2|0|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWINPNSGGTNYA|IGHV1-2|1|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>vanucizumab_VH_1|YTFTNYGMN|IGHV7-4-1|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GWINTYTGEPTYA|IGHV7-4-1|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>varisacumab_VH|GTFSSYAIS|IGHV1-69/IGHV1-69D|0|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GGFDPEDGETIYA|IGHV1-24|0|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>varlilumab_VH|FTFSSYDMH|IGHV3-13|0|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AVIWYDGSNKYYA|IGHV3-33|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>varokibart_VH|GSISNGGYYWS|IGHV4-31|1|QVQLQESGPGLVKPSQTLSLTCTVSG|IGHV4-30-4/IGHV4-31|0|GYIYYSGSTYYN|IGHV4-28/IGHV4-30-4/IGHV4-31|0|WIRQHPGKGLEWI|IGHV4-31|0
>vatelizumab_VH|FSLTNYGIH|IGHV1-18|5|QVQLQESGPGLVKPSETLSLTCTVSG|IGHV4-59/IGHV4-61|0|GVIWARGFTNYN|IGHV4-34|5|WIRQPPGKGLEWL|IGHV2-26/IGHV2-5/IGHV2-70|1
>vedolizumab_VH|YTFTSYWMH|IGHV1-3|1|QVQLVQSGAEVKKPGASVKVSCKGSG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GEIDPSESNTNYN|IGHV5-10-1|4|WVRQAPGQRLEWI|IGHV1-3|1
>veligrotug_VH|YTFTSYWMH|IGHV1-3|1|QVQLVQSGAEVVKPGASVKLSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|2|GEINPSNGRTNYN|IGHV1-2|5|WVKQRPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|3
>veltuzumab_VH|YTFTSYNMH|IGHV1-3|1|QVQLQQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|1|GAIYPGMGDTSYN|IGHV5-51|5|WVKQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>venanprubart_VH|FSLSSYGVS|IGHV3-23/IGHV3-23D|4|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GAISYDGITYYA|IGHV4-28/IGHV4-30-4/IGHV4-31|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>vensobafusp_VH|YTITDYHFD|IGHV1-69-2|4|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GDISMNYGYHIYN|IGHV1-18|8|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>vepsitamab_VH|GSFSGYYWS|IGHV4-34|0|QVQLQQWGAGLLKPSETLSLTCAVYG|IGHV4-34|0|GDIDASGSTKYN|IGHV4-28/IGHV4-30-4/IGHV4-31|4|WIRQPPGKCLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|1
>vepsitamab_VH_1|FTFNKYAMN|IGHV3-21/IGHV3-48|3|EVQLVESGGGLVQPGGSLKLSCAASG|IGHV3-73|0|ARIRSKYNNYATYYA|IGHV3-73|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>verekitug_VH|FTFRSSAMH|IGHV3-30/IGHV3-30-3/IGHV3-64|2|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SSVSGSGAGTYYA|IGHV3-23/IGHV3-23D|4|WVRQAPGKGLKWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>verzistobart_VH|FTFRQNAWS|IGHV3-23/IGHV3-23D|4|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SAISGSGGSTYYA|IGHV3-23/IGHV3-23D|0|WVRRAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>vesencumab_VH|FTFSSYAMS|IGHV3-23/IGHV3-23D|0|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SQISPAGGYTNYA|IGHV3-23/IGHV3-23D|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>vibecotamab_VH|YTFTDYYMK|IGHV1-69-2|1|QVQLQQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GDIIPSNGATFYN|IGHV1-45|6|WVKQSHGKSLEWM|IGHV1-24|4
>vibecotamab_VH_1|FTFSTYAMN|IGHV3-21/IGHV3-48|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GRIRSKYNNYATYYA|IGHV3-73|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>vibostolimab_VH|YTFSSYVMH|IGHV1-3|2|EVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|1|GYIDPYNDGAKYA|IGHV1-18|7|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>vilamakitug_VH|GRFTNYAIL|IGHV1-69/IGHV1-69D|4|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GGIIPIFDETDHA|IGHV1-69/IGHV1-69D|5|WVRQAPGQGLQWL|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|2
>vilastobart_VH|YTFTNYFMN|IGHV7-4-1|2|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GRVDPEQGRADYA|IGHV1-69-2|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>vilobelimab_VH|YSFTTFWMD|IGHV5-10-1|4|QVQLQQSGPQLVRPGTSVKISCKASG|IGHV1-58|7|GRIDPSDSESRLD|IGHV5-10-1|5|WVKQRPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|3
>vipalanebart_VH|FTFSSYYMS|IGHV3-11|1|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SAISLSGGSTYYA|IGHV3-23/IGHV3-23D|1|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>visilizumab_VH|YTFISYTMH|IGHV1-3|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GYINPRSGYTHYN|IGHV1-2|5|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>visugromab_VH|FSLSTSGMGVS|IGHV2-70|1|QITLKESGPTLVKPTQTLTLTCTFSG|IGHV2-5|0|AHIYWDDDKRYN|IGHV2-5|3|WIRQPPGKGLEWL|IGHV2-26/IGHV2-5/IGHV2-70|1
>vixarelimab_VH|YTFTSYEIN|IGHV1-8|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWMNPNSGYTGYA|IGHV1-8|1|WVRQATGQGLEWM|IGHV1-8|0
>vixtimotamab_VL|YTFTSYDIN|IGHV1-8|0|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWMNPNSGNTGFA|IGHV1-8|1|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>vixtimotamab_VL_1|FTFSTYAMN|IGHV3-21/IGHV3-48|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GRIRSKYNNYATYYA|IGHV3-73|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>vobarilizumab_VH|SVFKINVMA|IGHV1-2|7|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AGIISGGSTSYA|IGHV3-53/IGHV3-66|4|WYRQAPGKGRELV|IGHV3-11|3
>vobarilizumab_VH_1|FTFSSFGMS|IGHV3-23/IGHV3-23D|2|EVQLVESGGGLVQPGNSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|1|SSISGSGSDTLYA|IGHV3-23/IGHV3-23D|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>vobramitamab_VH|FTFSSYGMS|IGHV3-23/IGHV3-23D|1|EVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|0|ATINSGGSNTYYP|IGHV3-NL1|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>vofatamab_VH|FTFTSTGIS|IGHV1-18|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GRIYPTSGSTNYA|IGHV1-2|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>volagidemab_VH|FTFSSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|0|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AVMWYDGSNKDYV|IGHV3-33|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>volociximab_VH|FSLTDYGVH|IGHV1-69-2|5|QVQLKESGPGLVAPSQSLSITCTISG|IGHV4-30-4/IGHV4-31|5|VVIWSDGSSTYN|IGHV3-53/IGHV3-66|6|WVRQPPGKGLEWL|IGHV4-4|1
>volrustomig_VH|FTFSSYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|0|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AVIWYDGSNKYYA|IGHV3-33|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>volrustomig_VH_1|FTFSDYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|1|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AYISSGSYTIYSA|IGHV3-48|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>vonlerolizumab_VH|YTFTDSYMS|IGHV1-69-2|2|EVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GDMYPDNGDSSYN|IGHV1-45|8|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>vonsetamig_VH|FTFSNFWMT|IGHV3-15|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ANMNQDGSEKYYV|IGHV3-7|2|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>vonsetamig_VH_1|FTFDDYSMH|IGHV3-43|1|EVQLVESGGGLVQPGRSLRLSCAASG|IGHV3-9|0|SGISWNSGSIGYA|IGHV3-9|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>vopikitug_VH|GTFSSLAIS|IGHV1-69/IGHV1-69D|1|QVQLVQSGAEVKKPGSSVKVSCKASG|IGHV1-69/IGHV1-69D|0|GGIIPIFGTANYA|IGHV1-69/IGHV1-69D|0|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>vopratelimab_VH|FTFSDYWMD|IGHV3-11|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SNIDEDGSITEYS|IGHV3-74|6|WVRQAPGKGLVWV|IGHV3-74|0
>vorsetuzumab_VH|YTFTNYGMN|IGHV7-4-1|2|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWINTYTGEPTYA|IGHV7-4-1|2|WVRQAPGQGLKWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>voxalatamab_VH|FTFKSDAMH|IGHV3-30/IGHV3-30-3/IGHV3-64|2|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SEISGSGGYTNYA|IGHV3-23/IGHV3-23D|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>voxalatamab_VH_1|FTFNTYAMN|IGHV3-21/IGHV3-48|3|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ARIRSKYNNYATYYA|IGHV3-73|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>vudalimab_VH|FTFSSYTMH|IGHV3-13|1|EVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|0|SFISYDGNNKYYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>vudalimab_VH_1|FTFSNYWMN|IGHV3-15|2|EVQLVESGGGLVKPGGSLRLSCVASG|IGHV3-15/IGHV3-21|1|AEIRLYSNNYATHYA|IGHV3-73|7|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>vulinacimab_VH|FSFSTYAMS|IGHV3-23/IGHV3-23D|2|QVQLVQSGGGLVQPGGSLRLSCAASG|IGHV3-11|2|SGISGSGGTTHYA|IGHV3-23/IGHV3-23D|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>vunakizumab_VH|YTFTDYEVH|IGHV1-69-2|2|EVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GVIDPGTGGVAYN|IGHV1-2|7|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>xaluritamig_VH|YTFSTYWIE|IGHV1-18|4|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GEILPGSGQTDFN|IGHV1-2|7|WVRQAPGQRLEWM|IGHV1-3|0
>xaluritamig_VH_1|FTFSTYAMN|IGHV3-21/IGHV3-48|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GRIRSKYNNYATYYA|IGHV3-73|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>xeligekimab_VH|MSMSDYWMN|IGHV3-11|5|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|AAINQDGDEKYYV|IGHV3-7|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>xentuzumab_VH|FTFTSYWMS|IGHV3-7|1|QVELVESGGGLVQPGGSLRLSCAASG|IGHV3-11|2|SSITSYGSFTYYA|IGHV3-NL1|4|WVRQAPGKGLELV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|1
>xirestomig_VH|GPFSTYAIS|IGHV1-69/IGHV1-69D|2|QVQLVQSGAEVKKPGSSVKVSCKASR|IGHV1-69/IGHV1-69D|1|GRIIPILGIANYA|IGHV1-69/IGHV1-69D|3|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>xirestomig_VH_1|FTFSSYAMS|IGHV3-23/IGHV3-23D|0|QVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-11|1|SAISGSGGSTYYA|IGHV3-23/IGHV3-23D|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>zagotenemab_VH|YTFSNYWIE|IGHV1-18|4|EVQLVQSGAEVKKPGESLKISCKGSG|IGHV5-51|0|GEILPGSDSIKYE|IGHV1-2|8|WVRQMPGKGLEWM|IGHV5-10-1/IGHV5-51|0
>zalifrelimab_VH|FTFSSYSMN|IGHV3-21/IGHV3-48|0|EVQLVESGGGLVKPGGSLRLSCAASG|IGHV3-15/IGHV3-21|0|SSISSSSSYIYYA|IGHV3-21|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>zalutumumab_VH|FTFSTYGMH|IGHV3-30-5/IGHV3-33/IGHV3-NL1|1|QVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|0|AVIWDDGSYKYYG|IGHV3-33|3|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>zamerovimab_VH|YSFTDYIML|IGHV1-69-2|3|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GDIYPYYGSTSYN|IGHV1-46|5|WVRQAPGQRLEWI|IGHV1-3|1
>zampilimab_VH|FTLSTHAMS|IGHV3-23/IGHV3-23D|3|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|ATISSGGRSTYYP|IGHV3-64|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>zanidatamab_VH|FTFADYTMD|IGHV3-43|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|GDVNPNSGGSIYN|IGHV1-2|5|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>zanidatamab_VH_1|FNIKDTYIH|IGHV1-69-2|6|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|ARIYPTNGYTRYA|IGHV1-2|6|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>zanolimumab_VH|GSFSGYYWS|IGHV4-34|0|QVQLQQWGAGLLKPSETLSLTCAVYG|IGHV4-34|0|GEINHSGSTNYN|IGHV4-34|0|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>zansecimab_VH|YSFTDYNMV|IGHV1-69-2|3|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GYIDPYNGGTGYN|IGHV1-18|6|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>zeleciment_VH|YSITSGYYWN|IGHV4-38-2|2|QVQLQESGPGLVKPSQTLSLTCTVTG|IGHV4-30-4/IGHV4-31|1|GYITFDGANNYN|IGHV4-59/IGHV4-61|5|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>zelminemab_VH|FTFSRFAMH|IGHV3-30/IGHV3-30-3/IGHV3-64|2|QVQLVESGAEVVKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|2|GVISYDGGNKYYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|2|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>zeluvalimab_VH|FTFSSYDMS|IGHV3-13|1|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SLISGGGSQTYYA|IGHV3-23/IGHV3-23D|4|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>zenocutuzumab_VH|YTFTGYYMH|IGHV1-2|0|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GWINPNSGGTNYA|IGHV1-2|1|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>zenocutuzumab_VH_1|YTFTAYYIN|IGHV1-8|2|QVQLVQSGAEVKKPGASVKLSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|1|GRIYPGSGYTSYA|IGHV1-2|4|WVRQAPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|1
>zeripatamig_VH|FTFSSYAMS|IGHV3-23/IGHV3-23D|0|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SAISGSGGSTYYA|IGHV3-23/IGHV3-23D|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>zeripatamig_VH_1|FTFSSYAMS|IGHV3-23/IGHV3-23D|0|EVQLLESGGGLVQPGGSLRLSCAASG|IGHV3-23/IGHV3-23D|0|SAISGSGGSTYYA|IGHV3-23/IGHV3-23D|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>zifibancimig_VH|FFEYDDMS|||SEHLVESGGGLVKPGGSLRLSCATAD|IGHV3-11|6|GSISPKGDHKYLN|IGHV3-30/IGHV3-30-3/IGHV3-30-5|8|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>zifibancimig_VH_1|FFEYDDMS|||SEHLVESGGGLVKPGGSLRLSCATAD|IGHV3-11|6|GSISPKGDHKYLN|IGHV3-30/IGHV3-30-3/IGHV3-30-5|8|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>zigakibart_VH|YTFTSYVMH|IGHV1-3|1|QVQLVQSGAEVKKPGASVKVSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|0|GYINPYNDAPKYN|IGHV1-3|7|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>zilovertamab_VH|YAFTAYNIH|IGHV1-18|4|QVQLQESGPGLVKPSQTLSLTCTVSG|IGHV4-30-4/IGHV4-31|0|GSFDPYDGGSSYN|IGHV1-24|6|WVRQAPGQGLEWM|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|0
>ziltivekimab_VH|FTISSNYMI|IGHV3-53/IGHV3-66|2|EVQLVESGGGLVQPGGSLRLSCAASG|IGHV3-13/IGHV3-35/IGHV3-48/IGHV3-64/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-74|0|SDLYYYAGDTYYA|IGHV3-23/IGHV3-23D|7|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>zimberelimab_VH|DSISSTTYYWV|IGHV4-30-4|4|QLQLQESGPGLVKPSETLTLTCTVSA|IGHV4-39|2|GSISYSGSTYYN|IGHV4-39|1|WIRQPPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|0
>zinlirvimab_VH|DSMNNYYWT|IGHV4-34|5|QVQLQESGPGLVKPSETLSVTCSVSG|IGHV4-38-2|2|GYISDRESATYN|IGHV4-28/IGHV4-30-4/IGHV4-31|6|WIRQSPGKGLEWI|IGHV4-28/IGHV4-30-2/IGHV4-30-4/IGHV4-34/IGHV4-38-2/IGHV4-39/IGHV4-59/IGHV4-61|1
>zolbetuximab_VH|YTFTSYWIN|IGHV1-8|1|QVQLQQPGAELVRPGASVKLSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|6|GNIYPSDSYTNYN|IGHV5-10-1|3|WVKQRPGQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|3
>zovostotug_VH|FTFSSYAMH|IGHV3-30/IGHV3-30-3/IGHV3-64|0|EVQLVESGGGVVQPGRSLRLSCAASG|IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33|1|AVISYDGSNKYYA|IGHV3-30/IGHV3-30-3/IGHV3-30-5|0|WVRQAPGKGLEWV|IGHV3-15/IGHV3-20/IGHV3-21/IGHV3-23/IGHV3-23D/IGHV3-30/IGHV3-30-3/IGHV3-30-5/IGHV3-33/IGHV3-43/IGHV3-48/IGHV3-53/IGHV3-66/IGHV3-7/IGHV3-72/IGHV3-9/IGHV3-NL1|0
>zuberitamab_VH|YTFTSYNMH|IGHV1-3|1|EVQLQQSGAELVRPGASVKMSCKASG|IGHV1-18/IGHV1-2/IGHV1-3/IGHV1-46/IGHV1-8|6|GAIYPGNGDTSYN|IGHV5-51|5|WVKQTPRQGLEWI|IGHV1-18/IGHV1-2/IGHV1-46/IGHV1-69/IGHV1-69D/IGHV7-4-1|4
(1052 rows)
